U.S. patent application number 15/013706 was filed with the patent office on 2016-09-01 for anti-garp protein and uses thereof.
The applicant listed for this patent is ARGEN-X N.V., UNIVERSITE CATHOLIQUE DE LOUVAIN. Invention is credited to Pierre Coulie, Gitte De Boeck, Hans De Haard, Sophie Lucas, Michael Saunders, Sebastian Van De Woning.
Application Number | 20160251438 15/013706 |
Document ID | / |
Family ID | 52431038 |
Filed Date | 2016-09-01 |
United States Patent
Application |
20160251438 |
Kind Code |
A1 |
Lucas; Sophie ; et
al. |
September 1, 2016 |
ANTI-GARP PROTEIN AND USES THEREOF
Abstract
The present invention relates to a protein binding to GARP in
the presence of TGF-.beta. and uses thereof.
Inventors: |
Lucas; Sophie; (Tervuren,
BE) ; Van De Woning; Sebastian; (Bachte-Maria-Leerne,
BE) ; Saunders; Michael; (Brussels, BE) ; De
Haard; Hans; (Oudelande, NL) ; De Boeck; Gitte;
(Malderen, BE) ; Coulie; Pierre; (Kraainem,
BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ARGEN-X N.V.
UNIVERSITE CATHOLIQUE DE LOUVAIN |
Breda
Louvain-la-Neuve |
|
NL
BE |
|
|
Family ID: |
52431038 |
Appl. No.: |
15/013706 |
Filed: |
February 2, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14908368 |
Jan 28, 2016 |
|
|
|
PCT/EP2014/066650 |
Aug 1, 2014 |
|
|
|
15013706 |
|
|
|
|
62111429 |
Feb 3, 2015 |
|
|
|
61861008 |
Aug 1, 2013 |
|
|
|
Current U.S.
Class: |
424/139.1 |
Current CPC
Class: |
C07K 2317/24 20130101;
C07K 2317/31 20130101; C07K 2317/565 20130101; C07K 2317/92
20130101; C07K 2317/54 20130101; C07K 2317/569 20130101; A61P 25/00
20180101; C07K 2317/622 20130101; C07K 2317/32 20130101; C07K
2317/33 20130101; C07K 2317/624 20130101; A61P 9/00 20180101; C07K
2317/626 20130101; C07K 2317/55 20130101; A61P 31/00 20180101; C07K
16/30 20130101; A61P 35/00 20180101; C07K 2317/515 20130101; C07K
2317/76 20130101; A61P 9/10 20180101; C07K 2317/41 20130101; A61K
45/06 20130101; C07K 2317/34 20130101; A61K 2039/505 20130101; C07K
16/28 20130101; C07K 16/2875 20130101; C07K 2317/22 20130101; C07K
16/2863 20130101; A61P 29/00 20180101; A61P 37/04 20180101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; A61K 39/395 20060101 A61K039/395; A61K 45/06 20060101
A61K045/06; C07K 16/22 20060101 C07K016/22 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 1, 2013 |
EP |
13178958.8 |
May 7, 2014 |
EP |
14167425.9 |
Claims
1. An antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta., said epitope comprising at least one of the
residues 137, 138, or 139 of GARP (SEQ ID NO: 1) and at least one
residue of TGF-.beta. (SEQ ID NO: 53).
2. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
at least one of the residues 137, 138, or 139 of GARP (SEQ ID NO:
1) and at least one residue from the Latency associated peptide
(LAP) of TGF-.beta. (SEQ ID NO: 54) and at least one residue from
mature TGF-.beta. (SEQ ID NO: 55).
3. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue of TGF-.beta. (SEQ ID NO: 53).
4. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue from the Latency associated peptide (LAP) of TGF-.beta.
(SEQ ID NO: 54) and at least one residue from mature TGF-.beta.
(SEQ ID NO: 55).
5. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
at least one of residues 137, 138 or 139 of GARP (SEQ ID NO: 1) and
at least one residue from the Latency associated peptide (LAP) of
TGF-.beta. selected from the group of residues 58, 100, 146, 269,
270, 271, 272, and 273 of TGF-.beta. (SEQ ID NO: 53) and at least
one residue from mature TGF-.beta. (SEQ ID NO: 55).
6. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
at least one of residues 137, 138 or 139 of GARP (SEQ ID NO: 1) and
at least one residue from the Latency associated peptide (LAP) of
TGF-.beta. (SEQ ID NO: 54) and at least one residue from mature
TGF-.beta. selected from the group of residues 284, 336, 337, 338,
341, and 345 of TGF: 13 (SEQ ID NO: 53).
7. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
at least one of residues 137, 138 or 139 of GARP (SEQ ID NO: 1) and
at least one residue from the Latency associated peptide (LAP) of
TGF-.beta. selected from the group of residues 58, 100, 146, 269,
270, 271, 272, and 273 of TGF-.beta. (SEQ ID NO: 53) and at least
one residue from mature TGF-.beta. selected from the group of
residues 284, 336, 337, 338, 341, and 345 of TGF: 13 (SEQ ID NO:
53).
8. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue from the Latency associated peptide (LAP) of TGF-.beta.
selected from the group of residues 58, 100, 146, 269, 270, 271,
272, and 273 of TGF-.beta. (SEQ ID NO: 53) and at least one residue
from mature TGF-.beta. selected from the group of residues 284,
336, 337, 338, 341, and 345 of TGF: 13 (SEQ ID NO: 53).
9. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
at least one of residues 137, 138 or 139 of GARP (SEQ ID NO: 1) and
at least one residue from TGF-.beta. selected from the group of
residues 58, 100, 146, 269, 270, 271, 272, 273, 284, 336, 337, 338,
341, and 345 of TGF-.beta. (SEQ ID NO: 53).
10. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue selected from the group of residues 113, 114, 116, 117,
118, 119, 140, 142, 143, 144, 145, 146, 162, 163, 165, 166, 167,
170 and 189 of GARP (SEQ ID NO: 1) and at least one residue from
the Latency associated peptide (LAP) of TGF-.beta. (SEQ ID NO: 54)
and at least one residue from mature TGF-.beta. (SEQ ID NO:
55).
11. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue selected from the group of residues 113, 114, 116, 117,
118, 119, 140, 142, 143, 144, 145, 146, 162, 163, 165, 166, 167,
170 and 189 of GARP (SEQ ID NO: 1) and at least one residue from
the Latency associated peptide (LAP) of TGF-.beta. selected from
the group of residues 58, 100, 146, 269, 270, 271, 272, and 273 of
TGF-.beta. (SEQ ID NO: 53) and at least one residue from mature
TGF-.beta. (SEQ ID NO: 55).
12. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue selected from the group of residues 113, 114, 116, 117,
118, 119, 140, 142, 143, 144, 145, 146, 162, 163, 165, 166, 167,
170 and 189 of GARP (SEQ ID NO: 1) and at least one residue from
the Latency associated peptide (LAP) of TGF-.beta. (SEQ ID NO: 54)
and at least one residue from mature TGF-.beta. selected from the
group of residues 284, 336, 337, 338, 341, and 345 of TGF: 13 (SEQ
ID NO: 53).
13. The antibody binding to an epitope of a complex formed by human
GARP and TGF-.beta. according to claim 1, said epitope comprising
residues 137, 138 and 139 of GARP (SEQ ID NO: 1) and at least one
residue selected from the group of residues 113, 114, 116, 117,
118, 119, 140, 142, 143, 144, 145, 146, 162, 163, 165, 166, 167,
170 and 189 of GARP (SEQ ID NO: 1) and at least one amino acid from
the Latency associated peptide (LAP) of TGF-.beta. selected from
the group of residues 58, 100, 146, 269, 270, 271, 272, and 273 of
TGF-.beta. (SEQ ID NO: 53) and at least one residue from mature
TGF-.beta. selected from the group of residues 284, 336, 337, 338,
341, and 345 of TGF: 13 (SEQ ID NO: 53).
14. The antibody of claim 1, wherein the antibody is selected from
the group consisting of a whole antibody, a humanized antibody, a
single chain antibody, a dimeric single chain antibody, a Fv, a
Fab, a F(ab)'2, a defucosylated antibody, a bi-specific antibody, a
diabody, a triabody, a tetrabody; or an antibody fragment selected
from the group consisting of a unibody, a domain antibody, and a
nanobody; or an antibody mimetic selected from the group consisting
of an affibody, an affilin, an affitin, an adnectin, an atrimer, an
evasin, a DARPin, an anticalin, an avimer, a fynomer, a versabody
and a duocalin.
15. The antibody of claim 1, wherein the antibody inhibits
TGF-.beta. signaling.
16. The antibody of claim 1, wherein the antibody prevents the
release of active TGF-.beta. from GARP/TGF-.beta..
17. A method for inhibiting TGF-.beta. signaling comprising
administering an antibody according to claim 1.
18. A method for treating a TGF-.beta. related disorder in a
subject in need thereof, comprising administering to the subject a
therapeutically effective amount of the antibody according to claim
1.
19. The method according to claim 18, wherein the TGF-.beta.
related disorder is selected from the group consisting of
inflammatory diseases, chronic infection, cancer, fibrosis,
cardiovascular diseases, cerebrovascular disease, and
neurodegenerative diseases.
20. A method for treating cancer in a subject in need thereof,
comprising administering to the subject a therapeutically effective
amount of the antibody according to claim 1 in combination with
another treatment for cancer or another immunotherapeutic
agent.
21. The method according to claim 20, wherein the immunotherapeutic
agent is a tumor vaccine or an immunostimulatory antibody.
22. The method according to claim 20, wherein the method reduces
immunosuppression in the tumor environment.
23. A method for boosting the immune system in a subject in need
thereof, comprising administering to the subject a therapeutically
effective amount of the antibody according to claim 1 in
combination with another treatment for cancer or another
immunotherapeutic agent.
24. A method for inhibiting the immune suppressive function of
human Tregs in a subject in need thereof, comprising administering
to the subject a therapeutically effective amount of the antibody
according to claim 1 in combination with another treatment for
cancer or another immunotherapeutic agent.
Description
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional
Application No. 62/111,429, filed on Feb. 3, 2015, the contents of
which are hereby incorporated herein by reference in their
entirety. This application is also a continuation-in-part of U.S.
Non-Provisional application Ser. No. 14/908,368, filed on Jan. 28,
2016, which is a 371 of International Patent Application No.
PCT/EP2014/066650, filed Aug. 1, 2014, which claims priority to EP
Patent Application No. 14167425.9 filed May 7, 2014, EP Patent
Application No. 13178958.8 filed Aug. 1, 2013 and U.S. Provisional
Patent Application No. 61/861,008 filed Aug. 1, 2013. The contents
of each of these related applications are hereby incorporated by
reference in their entireties.
FIELD OF INVENTION
[0002] The present invention relates to human anti-GARP protein
that inhibits TGF-.beta. signaling. The present invention also
relates to the treatment of immune disorders and diseases such as
cancer.
BACKGROUND OF INVENTION
[0003] Since the molecular identification of the first human tumor
antigens in the early 1990's, several clinical trials were
completed to evaluate the effects of therapeutic vaccination of
cancer patients with shared tumor-specific antigens (Boon, T. et
al. Annu. Rev. Immunol. 2006, 24:175-208). Evidence of tumor
regression was observed in about 20% of the patients, with
objective clinical responses in 5-10%. Therefore, vaccination with
tumor-specific antigens represents a new promising therapy for
treating cancer. Strategies are needed to improve the proportion of
patients that respond to vaccination. The main limiting factor to
clinical efficacy of current therapeutic cancer vaccines does not
appear to be the vaccine itself, but local factors controlling the
tumor microenvironment in which the anti-tumor T cells have to
work.
[0004] Regulatory T cells, or Tregs, are a subset of CD4+ T
lymphocytes specialized in the inhibition of immune responses.
Insufficient Treg function results in autoimmune pathology, while
excessive Treg function may inhibit anti-tumor immune responses in
cancer patients. The exact mechanisms by which Tregs inhibit immune
responses are not fully understood.
[0005] Due to their immunosuppressive functions, Tregs represent
potential inhibitors of spontaneous or vaccine-induced anti-tumor
immune responses. In murine models, the depletion of Tregs can
improve immune responses against experimental tumors (Colombo et
al. Nat. Rev. Cancer 2007, 7:880-887). Thus, targeting Tregs in
humans could improve the efficacy of immunotherapy against
cancer.
[0006] It has been demonstrated that active TGF-.beta. is produced
by human Tregs, but not other types of human T lymphocytes
(Stockis, J. et al. Eur. J. Immunol. 2009, 39:869-882), TGF-.beta.
could be a target of interest.
[0007] However, antibodies against hTGF-.beta. were not found
promising. Phase 1 clinical trials have been conducted in focal
segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis
(IPF) and advanced malignant melanoma or renal cell carcinoma (RCC)
(Lonning S et al. Current Pharmaceutical Biotechnology 2011,
12:2176-2189). Depending on the trial, adverse events were observed
in some patients. The main adverse reactions reported consisted in
the development of keratoacanthoma (KA) and squamous cell carcinoma
(SCC) in melanoma patients. It is possible that the KA or SCC
lesions in melanoma patients evolved from pre-cancerous cells whose
proliferation was being inhibited by endogenous TGF-.beta. (Lonning
S et al. Current Pharmaceutical Biotechnology 2011, 12:2176-2189).
Therefore, a major concern regarding the use of anti-TGF-.beta.
antibodies in the context of cancer is that they may favor the
appearance of new neoplastic lesions, due to the inhibition of the
tumor-suppressive effect exerted by endogenous TGF-.beta. on
pre-cancerous cells.
[0008] One object of the invention is to provide a new strategy for
improving cancer treatment by targeting Tregs via their production
of TGF-.beta..
[0009] It was previously shown that the production of TGF-.beta. is
tightly regulated by a multi-step process. The precursor
pro-TGF-.beta.1 homodimerizes prior to cleavage by pro-protein
convertase FURIN. The resulting product is called latent
TGF-.beta.1, in which the C-terminal fragment, or mature
TGF-.beta.1, remains non-covalently bound to the N-terminal
fragment known as the Latency Associated Peptide, or LAP. This
latent complex is inactive because LAP prevents mature TGF-.beta.1
from binding to its receptor.
[0010] In the present application, the inventors show that latent
TGF-.beta. is shown to bind to the surface of Tregs through the
transmembrane protein GARP (glycoprotein A repetitions
predominant).
[0011] The present invention therefore provides a new strategy for
targeting Treg based on an anti-GARP protein inhibiting TGF-.beta.
signaling.
SUMMARY
[0012] One object of the invention is a protein binding to
Glycoprotein A repetitions predominant (GARP) in the presence of
TGF-.beta.. In an embodiment, said protein binds to GARP only in
the presence of TGF-.beta.. In another embodiment, said protein
binds to GARP when GARP is complexed to TGF-.beta.. In another
embodiment, said protein binds to a complex of GARP and
TGF-.beta..
[0013] In an embodiment of the invention, said protein is an
antibody molecule selected from the group consisting of a whole
antibody, a humanized antibody, a single chain antibody, a dimeric
single chain antibody, a Fv, a Fab, a F(ab)'2, a defucosylated
antibody, a bi-specific antibody, a diabody, a triabody, a
tetrabody.
[0014] In another embodiment, said protein is an antibody fragment
selected from the group consisting of a unibody, a domain antibody,
and a nanobody.
[0015] In another embodiment, said protein is an antibody mimetic
selected from the group consisting of an affibody, an affilin, an
affitin, an adnectin, an atrimer, an evasin, a DARPin, an
anticalin, an avimer, a fynomer, a versabody and a duocalin.
[0016] Another object of the invention is a protein as described
here above or a protein binding GARP and inhibiting TGF-.beta.
signaling.
[0017] In an embodiment, said protein is an antibody or antigen
binding fragment thereof that binds to a conformational epitope
comprising one or more amino acids of GARP or an epitope of GARP
modified as a result of GARP being complexed with latent
TGF-.beta..
[0018] In another embodiment, said antibody or antigen binding
fragment thereof further binds one or more amino acids of latent
TGF-.beta.. In another embodiment, said antibody or antigen binding
fragment thereof binds an epitope comprising one or more residues
from residues 101 to 141 of GARP as set forth in SEQ ID NO: 1.
[0019] Another object of the invention is a protein having the
variable region of the heavy chain comprising at least one of the
following CDRs:
TABLE-US-00001 VH-CDR1: (SEQ ID NO: 2) GFSLTGYGIN or (SEQ ID NO:
52) GYGIN; VH-CDR2: (SEQ ID NO: 3) MIWSDGSTDYNSVLTS; and VH-CDR3:
(SEQ ID NO: 4) DRNYYDYDGAMDY,
[0020] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 2-4 or 52, [0021] or having the
variable region of the light chain comprising at least one of the
following CDRs:
TABLE-US-00002 [0021] VL-CDR1: (SEQ ID NO: 5) KASDHIKNWLA; VL-CDR2:
(SEQ ID NO: 6) GATSLEA; and VL-CDR3: (SEQ ID NO: 7) QQYWSTPWT,
[0022] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 5-7; or the variable region of
the heavy chain comprises at least one of the following CDRs:
TABLE-US-00003 [0022] VH-CDR1: (SEQ ID NO: 13) SYYID; VH-CDR2: (SEQ
ID NO: 14) RIDPEDGGTKYAQKFQG; or VH-CDR3: (SEQ ID NO: 15)
NEWETVVVGDLMYEYEY,
[0023] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 13-15; [0024] or wherein the
variable region of the light chain comprises at least one of the
following CDRs:
TABLE-US-00004 [0024] VL-CDR1: SEQ ID NO: 16)
QASQX.sub.1IX.sub.2SX.sub.3LA,
wherein X.sub.1 is S or T, X.sub.2 is S or V, X.sub.3 is Y or
F;
TABLE-US-00005 VL-CDR2: (SEQ ID NO: 17)
X.sub.1X.sub.2SX.sub.3X.sub.4X.sub.5T,
wherein X.sub.1 is G or R; X.sub.2 is A or T; X.sub.3 is R or I;
X.sub.4 is L or P; X.sub.5 is Q or K;
TABLE-US-00006 VL-CDR3: QQYX.sub.1SX.sub.2PX.sub.3T,
wherein X.sub.1 is D, A, Y or V; X.sub.2 is A, L or V; X.sub.3 is V
or P (SEQ ID NO: 18); [0025] or any CDR having an amino acid
sequence that shares at least 60% identity with SEQ ID NO:
16-18.
[0026] In an embodiment, the variable region of the heavy chain
comprises at least one of the following CDRs:
TABLE-US-00007 VH-CDR1: (SEQ ID NO: 2) GFSLTGYGIN or (SEQ ID NO:
52) GYGIN; VH-CDR2: (SEQ ID NO: 3) MIWSDGSTDYNSVLTS; and VH-CDR3:
(SEQ ID NO: 4) DRNYYDYDGAMDY,
[0027] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 2-4 or 52, [0028] and the
variable region of the light chain comprises at least one of the
following CDRs:
TABLE-US-00008 [0028] VL-CDR1: (SEQ ID NO: 5) KASDHIKNWLA; VL-CDR2:
(SEQ ID NO: 6) GATSLEA; and VL-CDR3: (SEQ ID NO: 7) QQYWSTPWT,
[0029] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 5-7; or the variable region of
the heavy chain comprises at least one of the following CDRs:
TABLE-US-00009 [0029] VH-CDR1: (SEQ ID NO: 13) SYYID; VH-CDR2: (SEQ
ID NO: 14) RIDPEDGGTKYAQKFQG; or VH-CDR3: (SEQ ID NO: 15)
NEWETVVVGDLMYEYEY;
[0030] or any CDR having an amino acid sequence that shares at
least 60% identity with SEQ ID NO: 13-15, [0031] and the variable
region of the light chain comprises at least one of the following
CDRs:
TABLE-US-00010 [0031] VL-CDR1: (SEQ ID NO: 16) QASQX1IX2SX3LA,
wherein X.sub.1 is S or T, X.sub.2 is S or V, X.sub.3 is Y or
F;
TABLE-US-00011 VL-CDR2: (SEQ ID NO: 17)
X.sub.1X.sub.2SX.sub.3X.sub.4X.sub.5T,
wherein X.sub.1 is G or R; X.sub.2 is A or T; X.sub.3 is R or I;
X.sub.4 is L or P; X.sub.5 is Q or K;
TABLE-US-00012 VL-CDR3: QQYX.sub.1SX.sub.2PX.sub.3T,
wherein X.sub.1 is D, A, Y or V; X.sub.2 is A, L or V; X.sub.3 is V
or P (SEQ ID NO: 18); [0032] or any CDR having an amino acid
sequence that shares at least 60% identity with SEQ ID NO:
16-18.
[0033] In another embodiment, the variable region of the heavy
chain comprises the following CDRs: GFSLTGYGIN (SEQ ID NO: 2),
MIWSDGSTDYNSVLTS (SEQ ID NO: 3), DRNYYDYDGAMDY (SEQ ID NO: 4) and
the variable region of the light chain comprises the following
CDRs: KASDHIKNWLA (SEQ ID NO: 5), GATSLEA (SEQ ID NO: 6), QQYWSTPWT
(SEQ ID NO: 7) or any CDR having an amino acid sequence that shares
at least 60% identity with said SEQ ID NO: 2-7;
or the variable region of the heavy chain comprises the following
CDRs: GYGIN (SEQ ID NO: 52), MIWSDGSTDYNSVLTS (SEQ ID NO: 3),
DRNYYDYDGAMDY (SEQ ID NO: 4) and the variable region of the light
chain comprises the following CDRs: KASDHIKNWLA (SEQ ID NO: 5),
GATSLEA (SEQ ID NO: 6), QQYWSTPWT (SEQ ID NO: 7) or any CDR having
an amino acid sequence that shares at least 60% identity with said
SEQ ID NO: 52 and 3-7; or wherein the variable region of the heavy
chain comprises the following CDRs: SYYID (SEQ ID NO: 13),
RIDPEDGGTKYAQKFQG (SEQ ID NO: 14), or NEWETVVVGDLMYEYEY (SEQ ID NO:
15); and the variable region of the light chain comprises the
following CDRs: QASQX.sub.1I X.sub.2S X.sub.3LA (SEQ ID NO: 16),
wherein X.sub.1 is S or T, X.sub.2 is S or V, X.sub.3 is Y or F;
X.sub.1X.sub.2SX.sub.3X.sub.4X.sub.5T (SEQ ID NO: 17), wherein
X.sub.1 is G or R; X.sub.2 is A or T; X.sub.3 is R or I; X.sub.4 is
L or P; X.sub.5 is Q or K; QQYX.sub.1SX.sub.2PX.sub.3T, wherein
X.sub.1 is D, A, Y or V; X.sub.2 is A, L or V; X.sub.3 is V or P
(SEQ ID NO: 18); or any CDR having an amino acid sequence that
shares at least 60% identity with said SEQ ID NO: 16-18.
[0034] In another embodiment, the amino acid sequence of the heavy
chain variable region is SEQ ID NO: 8 or SEQ ID NO: 50 and the
amino acid sequence of the light chain variable region is SEQ ID
NO: 9 or SEQ ID NO: 51, or the amino acid sequence of the heavy
chain variable region is SEQ ID NO: 34 and the amino acid sequence
of the light chain variable region is one of SEQ ID NO: 35-39 or
any sequence having an amino acid sequence that shares at least 60%
identity with said SEQ ID NO: 8-9, 50-51 or 34-39.
[0035] Another object of the invention is a protein as defined here
above binding to an epitope on the polypeptide having the amino
acid sequence SEQ ID NO: 1 recognized by an antibody comprising a
heavy chain variable region as set forth in SEQ ID NO: 8 or in SEQ
ID NO: 50 and a light chain variable region as set forth in SEQ ID
NO: 9 or in SEQ ID NO: 51, or by an antibody comprising a heavy
chain variable region as set forth in SEQ ID NO: 34 and one of the
light chain variable region as set forth in SEQ ID NO: 35-39.
[0036] Another object of the invention is an antibody or antigen
binding fragment produced by a hybridoma registered under the
accession number LMBP 10246CB on May 30, 2013.
[0037] Another object of the invention is a polynucleotide sequence
encoding the antibody or antigen binding fragment as described here
above.
[0038] Another object of the invention is an expression vector
comprising the polynucleotide according to claim as described here
above.
[0039] Another object of the invention is a hybridoma cell line
producing an antibody against GARP registered under the accession
number LMBP 10246CB on May 30, 2013.
[0040] Another object of the invention is a pharmaceutical
composition comprising the protein as described here above and a
pharmaceutically acceptable excipient.
[0041] Another object of the invention is a pharmaceutical
composition as described here above for treating a TGF-.beta.
related disorder in a subject in need thereof. In an embodiment,
the TGF-.beta. related disorder is selected from the group
consisting of inflammatory diseases, chronic infection, cancer,
fibrosis, cardiovascular diseases, cerebrovascular disease (e.g.
ischemic stroke), and neurodegenerative diseases.
[0042] In another embodiment, the pharmaceutical composition as
described here above is to be administered in combination with
another treatment for cancer or another immunotherapeutic agent
such as a tumor vaccine or an immunostimulatory antibody. In
another embodiment, the pharmaceutical composition as described
here above is to be administered as an immunostimulatory antibody
for treatment of cancer patients.
BRIEF DESCRIPTION OF THE DRAWINGS
[0043] FIG. 1. New monoclonal antibodies that recognize human GARP
on the cell surface. Murine BW5147 T cells, transfected or not with
human GARP (hGARP) were stained with biotinylated in-house
anti-hGARP antibodies (MHGARP1 to 9) and streptavidin-PE (SA-PE,
top panels), or with a commercial anti-hGARP antibody (clone
Plato-1) and secondary anti-mouse IgG2b coupled to AlexaFluor 488
(AF488, bottom panels).
[0044] FIG. 2. MHGARP8 inhibits active TGF-.beta. production by a
human Treg clone. Clone Treg A1 was stimulated during 24 hours with
>CD3/CD28 antibodies, alone or in the presence of the indicated
anti-hGARP mAbs (20 .mu.g/ml). (A) Cell lysates were analyzed by WB
with anti-pSMAD2 and anti-.beta.-ACTIN antibodies. (B)
Quantification of ECL signals from WB shown in A.
[0045] FIG. 3. (A) Regions in the hGARP protein required for
binding by anti-hGARP antibodies. Murine BW5147 T cells expressing
the HA-tagged proteins schematized on the left were stained with
anti-hGARP (MHGARP1 to 9, as indicated on top of the figure) or
anti-HA antibodies, and analyzed by flow cytometry. Histograms are
gated on live cells. Based on the FACS results, regions required
for binding by the various MHGARP mAbs were identified and are
indicated by horizontal bars above the representations of the
HA-tagged chimeras.
[0046] (B) Abundance of the epitope recognized by MHGARP-8
increases upon overexpression of TGF-.beta.1. Parental BW5147 T
cells (BW untransfected) or clones stably transfected with hGARP
alone (BW+hGARP) or with hTGFB1 (BW+hGARP+hTGF-b1) were stained as
in A, or with anti-mLAP-AF647 or anti-hLAP-APC antibodies, and
analyzed by flow cytometry.
[0047] (C) MHGARP-1, -2, -3, -4 and -5 recognize free hGARP, but
not hGARP bound to TGF-.beta.1. Cell lysates from parental BW5147 T
cells or a clone stably transfected with hGARP and hTGFB1 were
imunoprecipitated with anti-hGARP mAbs (MHGARP1 to 9, as indicated
on top of the figure). Cell lysates (30% input) or IP products were
analyzed by Western blot with a commercial anti-hGARP mAb (clone
Plato-1, top panels) and with an antibody directed against a
C-terminal epitope of TGF-.beta.1, which detects pro-TGF-.beta.1 as
a 50 kDa band and mature TGF-.beta.1 as a 13 kDa band (bottom
panels). * A specific product detected in untransfected cells.
[0048] (D) Overexpression of hTGFB1 in hGARP-transfected 293T cells
decreases binding of MHGARP-1, -2, -3, -4, and -5, but increases
binding of MHGARP-8. 293T cells were co-transfected with a
hGARP-encoding plasmid (0.25 .mu.g), the indicated amounts of a
hTGFB1-encoding plasmid, and an empty plasmid to bring the total
amount of transfected DNA to 2.5 .mu.g in all conditions.
Transfected cells were stained with anti-hGARP mAbs (MHGARP1 to 9,
as indicated on top of the figure), and analyzed by flow
cytometry.
[0049] (E) Silencing of hTGFB1 in hGARP-transduced JURKAT cells
decreases binding of MHGARP-8. JURKAT cells, transduced or not with
hGARP, were transfected with siRNA specific for the TGFB1 mRNA
(siTGFB1) or a scramble siRNA control. Transfected cells were
stained with anti-hGARP mAbs (MHGARP1 to 9, as indicated on top of
the figure) or with an anti-hLAP antibody, and analyzed by flow
cytometry.
[0050] FIG. 4. Presentation of hTGF-.beta.1 on the cell surface is
not sufficient for binding by MHGARP8. 293T cells were transfected
as indicated below, stained with anti-hLAP antibodies or with
MGARP8, then analyzed by flow cytometry.
[0051] (A) Transfection with constructs encoding the HA-tagged
proteins schematized on the left, without a hTGFB1 construct.
[0052] (B) Co-transfection with constructs encoding the HA-tagged
proteins schematized on the left, with a hTGFB1 construct.
[0053] FIG. 5. Binding of MHGARP-2, -3 and -8 requires amino-acids
137-138-139 of hGARP. Parental BW5147 T cells (BW untransfected) or
clones stably transfected with plasmids encoding HA-tagged forms of
hGARP were stained with the indicated anti-hGARP or anti-HA
antibodies, and analyzed by flow cytometry. The HA-tagged forms of
hGARP tested here comprised aa 20-662 of hGARP (wild type, WT), or
aa 20-662 of hGARP in which groups of 3 amino-acids located in
region 101-141 were replaced by the amino-acids found in the
corresponding region of mGARP (Mut I, Mut II and Mut III)
Amino-acid sequences of region 101-141 of hGARP-WT, -Mut I, -Mut
II, -Mut III and mGARP are indicated on the left. Amino-acids that
differ between human and mouse GARP are highlighted by grey
vertical boxes, and amino-acids mutated in Mut I, Mut II and Mut
III are indicated by black horizontal boxes.
[0054] FIG. 6. MHGARP8 inhibits Treg function in vivo. On day 0,
the indicated groups of NSG mice received i.v. injections of human
PBMCs, in combination or not with human Tregs. Mice from groups III
and IV were treated with the MHGARP8 antibody, injected i.p. once a
week, starting on day -1. Objective signs of GvHD development in
the recipient mice were monitored bi-weekly. A GvHD score was
established based on weight loss (0: <10%; 1: 10%-20%; 2:
>20%; 3: >30%), anemia (0: red or pink tail; 1: white tail),
posture (0: normal; 1: hump), general activity (0: normal; 1:
limited), hair loss (0: no hair loss; 1: hair loss) and icterus (0:
white or red tail; 1: yellow tail). Maximum disease severity or
death corresponded to a score of 7. (A) Experiment 1. Values
represent mean scores. (B) Experiment 2. Values represent mean
scores+SEM.
[0055] FIG. 7. New anti-hGARP mAbs. (A) Schematic representation of
the experimental strategies used to derive anti-hGARP mAbs. (B)
Flow cytometry analyses of clone ThA2 (human CD4+ Th cells which do
not express hGARP), or ThA2 cells transduced with hGARP, after
staining with biotinylated MHG-1 to -14 mAbs and streptavidin
coupled to PE (SA-PE), with LHG-1 to -17 mAbs and a secondary
anti-hIgG1 antibody coupled to PE, or with a commercially available
mouse anti-hGARP mAb (clone Plato-1) and a secondary anti-mIgG2b
antibody coupled to AF647.
[0056] FIG. 8. Immune responses from immunized llamas. (A) shows
immune responses from DNA immunized llamas. (B) shows immune
responses from llamas immunized with BW cells expressing
hGARP/hTGF.beta..
[0057] FIG. 9. Cross-reactivity to cynomolgus GARP-TGF.beta.
measured on cells by FACS. 293E cells were transfected with
human/cyno GARP and human/cyno TGFB. LHG-10-D and the affinity
optimized variants are cross-reactive with cynomolgus
GARP-TGFB.
[0058] FIG. 10. Sequences of LHG-10 antibodies and its shuffle
variants.
[0059] FIG. 11. MHGARP8 and LHG-10 inhibit production of active
TGF-.beta. by human Tregs. After a short in vitro amplification,
human CD4+CD25hiCD127lo cells (Tregs) were re-stimulated with
anti-CD3/CD28 coated beads during 24 hours, in the presence or
absence of the indicated mAbs (10 .mu.g/ml). Cells lysates were
analyzed by Western Blot with antibodies against phosphorylated
SMAD2 (pSMAD2), as a read-out for active TGF-.beta. production, or
13-ACTIN (loading control).
[0060] FIG. 12. MHGARP8 and LHG-10 inhibit the suppressive activity
of human Tregs in vitro. (A) Freshly isolated human
CD4+CD25-CD127hi cells (Th; 2.times.10.sup.4 per microwell) were
seeded alone or with clone Treg A1 (Stockis, J. et al. Eur. J.
Immunol. 2009, 39:869-882) at a 1/1 Treg to Th ratio. Cells were
stimulated with coated anti-CD3 and soluble anti-CD28, in the
presence or absence of the indicated anti-hGARP mAbs (10 .mu.g/ml).
3H-Thymidine (3H-Thy) was added during the last 16 hours of a 4-day
culture and incorporation was measured in a scintillation counter
as a read-out for proliferation. Bar histograms indicate kcpm
(means of triplicates+SD). Clone Treg A1 did not proliferate in the
absence of Th cells (Treg alone: 0.5.+-.0.04 kcpm). Suppression of
Th proliferation in the presence of Tregs is indicated above each
black bar, and is calculated as follows: % suppression=1-(kcpm (Th
alone)/kcpm (Th+Treg). (B) Clone ThA2 cells (Th; 1.times.10.sup.4
per microwell) were seeded with clone Treg A1 at the indicated Treg
to Th ratios, in the presence or absence of MHGARP8 (MHG-8),
anti-hTGF-131 mAb (clone 1D11) or an isotype control (mIgG1).
Stimulation, measure of proliferation and calculation of
suppression were performed as in A.
[0061] FIG. 13. Forms and regions of GARP bound by anti-GARP mAbs.
(A) Schematic representations of GARP and GARP/TGF-.beta.
complexes. Protein GARP is represented by a thick curved grey line.
Numbers indicate amino-acid positions. TGF-.beta. is represented
with the Latency Associated Peptide (LAP) as thick black lines, and
the mature TGF-.beta.1 peptide as thick straight grey lines. Thin
black lines represent inter-chain disulfide bonds. (B)
Classification of anti-hGARP mAbs based on their binding
requirements.
[0062] FIG. 14. Three groups of anti-hGARP mAbs bind free GARP
only, free GARP and GARP/TGF-.beta.1 complexes, or GARP/TGF-.beta.1
complexes only, respectively.
[0063] (A) Cell lysates of BW cells transfected with hGARP and
hTGFB1 were immunoprecipitated with the indicated anti-hGARP mAbs.
Total lysates (BW+hGARP+hTGFB1 or untransfected controls) and IP
products were analysed by Western Blot with antibodies against
hGARP (clone Plato-1), LAP or the mature TGF-.beta. peptide. (B)
Flow cytometry analyses of 293T cells, untransfected or transfected
with hGARP, hTGFB1 or both, and stained as indicated with
anti-LAP-APC, biotinylated MHG mAbs and streptavidin-PE, clone
Plato-1 and anti-mIgG2b-AF647, or LHG mAbs and anti-hIgG1-PE.
[0064] FIG. 15. Amino-acids of hGARP required for binding by MHG
and LHG mAbs.
[0065] (A) Flow cytometry analyses of 293T cells transfected with
plasmids encoding the HA-tagged mGARP/hGARP chimeras schematized on
the left (numbers represent amino-acid positions in hGARP). Cells
were stained with biotinylated MHG mAbs and strepatvidin-PE, LHG
mAbs and anti-hIgG1-PE, or anti-HA and anti-mIgG1-AF647. hTGFB1 was
co-transfected with mGARP/hGARP chimeras for the analyses of mAbs
that bind hGARP/hTGF-.beta.1 complexes only (LHG-3, MHGARP8
(MHG-8), LHG-10). (B) As above, except that 293T cells were
transfected with plasmids encoding mutated forms of full-length
HA-tagged hGARP. In each mutant, 3 amino-acids of hGARP were
replaced by the 3 amino-acids found in mGARP, as illustrated in the
alignment on the left (numbers represent amino-acid positions in
hGARP).
[0066] FIG. 16. Inhibition of human Treg function by anti-hGARP in
vivo. (A) shows the protocol on day 0, the indicated groups of NSG
mice received i.v. injections of human PBMCs, in combination or not
with human Tregs. (B) shows the results of 4 independent
experiments (I to IV), performed with cells from donors A, B or C,
with the indicated numbers of mice per group (n). Disease onset is
the day when mean disease score becomes .gtoreq.1, and is indicated
for 3 experimental groups in which mice were grafted with PBMCs
only (group a), PBMCs and Tregs (group b), or PBMCs and Tregs and
treated with MHGARP8 (MHG-8) (group c). (C) Detailed results from
experiment IV, showing the evolution of mean disease score (left)
and survival curves (right) in the indicated groups of mice.
Statistical significance of differences between groups b
(PBMCs+Tregs) and c (PBMCs+Tregs+MHG-8) were calculated using 2-way
Anova analysis for progression of disease scores (p=0.0001), and a
Log-rank (Mantel-Cox) test for survival (p=0.0027).
[0067] FIG. 17. Anti-hGARP mAbs that block TGF-.beta. production
inhibit suppression by human Tregs in vivo. Experiment performed
according to protocol shown in FIG. 16, part A. Top graph shows
progression of disease scores (means per group+sem), bottom graph
shows survival.
[0068] FIG. 18. Inhibition of human Tregs by MHG-8 increases
cytokine production and T cell proliferation in vivo.
[0069] NSG mice injected as in FIG. 16, part A were sacrificed 20
days after cell transfer. (A) Serum levels of human cytokines were
measured in a multiplex bead assay. (B-C) Numbers and proportions
of the indicated human cells in the spleens were evaluated by flow
cytometry. Squares and triangles represent individual mice (N=4-5
mice per group). Circles represent numbers or proportions of the
corresponding human cells injected per mouse on day 0. Statistical
significance between groups was determined with a Student's t-test.
P values are indicated above brackets. Data from one experiment
representative of two.
[0070] FIG. 19. Impact of mutations in GARP or TGF-.beta.1 on the
binding of anti-GARP or anti-LAP antibodies to GARP/TGF-.beta.1
complexes.
[0071] (A) Mean percent residual binding of MHG-8 to
GARP/TGF-.beta.1 complexes containing the mutations indicated below
the bar graphs. (B) Mean percent residual binding of LHG-10 to
GARP/TGF-.beta.1 complexes containing the mutations indicated below
the bar graphs. (C) Mean percent residual binding of MHG-6 to
GARP/TGF-.beta.1 complexes containing the mutations indicated below
the bar graphs. Ratios of EC50 were not measured for MHG-6. (D)
Mean percent residual binding of an anti-LAP antibody. Ratios of
EC50 were not measured for anti-LAP to GARP/TGF-.beta.1 complexes
containing the mutations indicated below the bar graphs. n: number
of independent experiments. The number indicated below each
mutation corresponds to the ratio between the EC50 of MHG-8 binding
to the mutant and the EC50 of MHG-8 binding to the WT. Mutations
with a ratio >2 are considered to decrease the avidity for
binding by MHG-8. NE: non evaluable (residual binding <10%); nt:
not tested.
[0072] FIG. 20. Impact of mutations in GARP or TGF-.beta.1 on the
inhibitory activity of MHG-8 and LHG-10.
[0073] (A) Residual inhibitory activity of MHG-8 on the indicated
mutated forms of GARP or TGF-.beta.1 (means of triplicates).
Mutations that are underlined induced complete loss of binding by
MHG-8, as illustrated in FIG. 19, part A. (B) Residual inhibitory
activity of LHG-10 on the indicated mutated forms of GARP or
TGF-.beta.1 (means of triplicates). Mutations that are underlined
induced complete loss of binding by LHG-10, as illustrated in FIG.
19, part B. (C) Residual inhibitory activity of the control
anti-TGF-.beta.1 neutralizing antibody on the indicated mutated
forms of GARP or TGF-.beta.1 (means of triplicates). Error bars
correspond to standard deviation. Negative values were brought to
zero.
DETAILED DESCRIPTION
Definitions
[0074] In the present invention, the following terms have the
following meanings:
[0075] "Antibody" or "Immunoglobulin"--As used herein, the term
"immunoglobulin" includes a polypeptide having a combination of two
heavy and two light chains whether or not it possesses any relevant
specific immunoreactivity. "Antibodies" refers to such assemblies
which have significant known specific immunoreactive activity to an
antigen of interest (e.g. human GARP). The term "GARP antibodies"
is used herein to refer to antibodies which exhibit immunological
specificity for human GARP protein. As explained elsewhere herein,
"specificity" for human GARP does not exclude cross-reaction with
species homologues of GARP. In addition, it also does not exclude
antibodies recognising an epitope spanning GARP protein residues
and TGF-.beta. protein residue. Antibodies and immunoglobulins
comprise light and heavy chains, with or without an interchain
covalent linkage between them. Basic immunoglobulin structures in
vertebrate systems are relatively well understood. The generic term
"immunoglobulin" comprises five distinct classes of antibody that
can be distinguished biochemically. All five classes of antibodies
are within the scope of the present invention, the following
discussion will generally be directed to the IgG class of
immunoglobulin molecules. With regard to IgG, immunoglobulins
comprise two identical light polypeptide chains of molecular weight
approximately 23,000 Daltons, and two identical heavy chains of
molecular weight 53,000-70,000 Daltons. The four chains are joined
by disulfide bonds in a "Y" configuration wherein the light chains
bracket the heavy chains starting at the mouth of the "Y" and
continuing through the variable region. The light chains of an
antibody are classified as either kappa or lambda ([.kappa.],
[.lamda.]). Each heavy chain class may be bonded with either a
kappa or lambda light chain. In general, the light and heavy chains
are covalently bonded to each other, and the "tail" regions of the
two heavy chains are bonded to each other by covalent disulfide
linkages or non-covalent linkages when the immunoglobulins are
generated either by hybridomas, B cells or genetically engineered
host cells. In the heavy chain, the amino acid sequences run from
an N-terminus at the forked ends of the Y configuration to the
C-terminus at the bottom of each chain. Those skilled in the art
will appreciate that heavy chains are classified as gamma, mu,
alpha, delta, or epsilon (.gamma., .mu., .alpha., .delta.,
.epsilon.) with some subclasses among them (e.g.,
.gamma.1-.gamma.4). It is the nature of this chain that determines
the "class" of the antibody as IgG, IgM, IgA IgG, or IgE,
respectively. The immunoglobulin subclasses (isotypes) e.g., IgG1,
IgG2, IgG3, IgG4, IgA1, etc. are well characterized and are known
to confer functional specialization. Modified versions of each of
these classes and isotypes are readily discernable to the skilled
artisan in view of the instant disclosure and, accordingly, are
within the scope of the instant invention. As indicated above, the
variable region of an antibody allows the antibody to selectively
recognize and specifically bind epitopes on antigens. That is, the
VL domain and VH domain of an antibody combine to form the variable
region that defines a three dimensional antigen binding site. This
quaternary antibody structure forms the antigen binding site
present at the end of each arm of the Y. More specifically, the
antigen binding site is defined by three complementarity
determining regions (CDRs) on each of the VH and VL chains.
[0076] "An isolated antibody"--As used herein, an "isolated
antibody" is one that has been separated and/or recovered from a
component of its natural environment. Contaminant components of its
natural environment are materials that would interfere with
diagnostic or therapeutic uses of the antibody, and may include
enzymes, hormones, and other proteinaceous or non proteinaceous
components. In preferred embodiments, the antibody is purified: (1)
to greater than 95% by weight of antibody as determined by the
Lowry method, and most preferably more than 99% by weight; (2) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator;
or (3) to homogeneity as shown by SDS-PAGE under reducing or
non-reducing conditions and using Coomassie blue or, preferably,
silver staining. An isolated antibody includes the antibody in situ
within recombinant cells since at least one component of the
antibody's natural environment will not be present. Ordinarily,
however, an isolated antibody will be prepared by at least one
purification step.
[0077] "Affinity variants"--As used herein, the term "affinity
variant" refers to a variant antibody which exhibits one or more
changes in amino acid sequence compared to a reference GARP
antibody, wherein the affinity variant exhibits an altered affinity
for the human GARP protein or GARP/TGF-.beta. complex in comparison
to the reference antibody. Typically, affinity variants will
exhibit an improved affinity for human GARP or human
GARP/TGF-.beta. complex, as compared to the reference GARP
antibody. The improvement may be a lower KD for human GARP, a
faster off-rate for human GARP, or an alteration in the pattern of
cross-reactivity with non-human GARP homologues. Affinity variants
typically exhibit one or more changes in amino acid sequence in the
CDRs, as compared to the reference GARP antibody. Such
substitutions may result in replacement of the original amino acid
present at a given position in the CDRs with a different amino acid
residue, which may be a naturally occurring amino acid residue or a
non-naturally occurring amino acid residue. The amino acid
substitutions may be conservative or non-conservative.
[0078] "Binding Site"--As used herein, the term "binding site"
comprises a region of a polypeptide which is responsible for
selectively binding to a target antigen of interest (e.g. human
GARP). Binding domains or binding regions comprise at least one
binding site. Exemplary binding domains include an antibody
variable domain. The antibody molecules of the invention may
comprise a single antigen binding site or multiple (e.g., two,
three or four) antigen binding sites.
[0079] "Conservative amino acid substitution"--As used herein, a
"conservative amino acid substitution" is one in which the amino
acid residue is replaced with an amino acid residue having a
similar side chain Families of amino acid residues having similar
side chains have been defined in the art, including basic side
chains (e.g., lysine, arginine, histidine), acidic side chains
(e.g., aspartic acid, glutamic acid), uncharged polar side chains
(e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine,
cysteine), nonpolar side chains (e.g., alanine, valine, leucine,
isoleucine, proline, phenylalanine, methionine, tryptophan),
beta-branched side chains (e.g., threonine, valine, isoleucine) and
aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,
histidine). Thus, a nonessential amino acid residue in an
immunoglobulin polypeptide may be replaced with another amino acid
residue from the same side chain family. In another embodiment, a
string of amino acids can be replaced with a structurally similar
string that differs in order and/or composition of side chain
family members.
[0080] "Chimeric"--As used herein, a "chimeric" protein comprises a
first amino acid sequence linked to a second amino acid sequence
with which it is not naturally linked in nature. The amino acid
sequences may normally exist in separate proteins that are brought
together in the fusion polypeptide or they may normally exist in
the same protein but are placed in a new arrangement in the fusion
polypeptide. A chimeric protein may be created, for example, by
chemical synthesis, or by creating and translating a polynucleotide
in which the peptide regions are encoded in the desired
relationship. Exemplary chimeric GARP antibodies include fusion
proteins comprising camelid-derived VH and VL domains, or humanised
variants thereof, fused to the constant domains of a human
antibody, e.g. human IgG1, IgG2, IgG3 or IgG4.
[0081] "CDR"--As used herein, the term "CDR" or "complementarity
determining region" means the non-contiguous antigen combining
sites found within the variable region of both heavy and light
chain polypeptides. These particular regions have been described by
Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et
al., Sequences of protein of immunological interest. (1991), by
Chothia et al., J. Mol. Biol. 196:901-917 (1987), and by MacCallum
et al., J. Mol. Biol. 262:732-745 (1996) where the definitions
include overlapping or subsets of amino acid residues when compared
against each other. The amino acid residues which encompass the
CDRs as defined by each of the above cited references are set forth
for comparison. Preferably, the term "CDR" is a CDR as defined by
Kabat based on sequence comparisons.
TABLE-US-00013 TABLE 1 CDR definitions CDR definitions Kabat (1)
Chothia (2) MacCallum (3) VH CDR1 31-35 26-32 30-35 VH CDR2 50-65
53-55 47-58 VH CDR3 95-102 96-101 93-101 VL CDR1 24-34 26-32 30-36
VL CDR2 50-56 50-52 46-55 VL CDR3 89-97 91-96 89-96 (1) Residue
numbering follows the nomenclature of Kabat et al., supra (2)
Residue numbering follows the nomenclature of Chothia et al., supra
(3) Residue numbering follows the nomenclature of MacCallum et al.,
supra
[0082] "CH2 domain"--As used herein the term "CH2 domain" includes
the region of a heavy chain molecule that extends, e.g., from about
residue 244 to residue 360 of an antibody using conventional
numbering schemes (residues 244 to 360, Kabat numbering system; and
residues 231-340, EU numbering system, Kabat E A et al. Sequences
of Proteins of Immunological Interest. Bethesda, US Department of
Health and Human Services, NIH. 1991). The CH2 domain is unique in
that it is not closely paired with another domain. Rather, two
N-linked branched carbohydrate chains are interposed between the
two CH2 domains of an intact native IgG molecule. It is also well
documented that the CH3 domain extends from the CH2 domain to the
C-terminal of the IgG molecule and comprises approximately 108
residues.
[0083] "Camelid-Derived"--In certain preferred embodiments, the
GARP antibody molecules of the invention comprise framework amino
acid sequences and/or CDR amino acid sequences derived from a
camelid conventional antibody raised by active immunization of a
camelid with GARP antigen. However, GARP antibodies comprising
camelid-derived amino acid sequences may be engineered to comprise
framework and/or constant region sequences derived from a human
amino acid sequence or other non-camelid mammalian species. For
example, a human or non-human primate framework region, heavy chain
region, and/or hinge region may be included in the subject GARP
antibodies. In an embodiment, one or more non-camelid amino acids
may be present in the framework region of a "camelid-derived" GARP
antibody, e.g., a camelid framework amino acid sequence may
comprise one or more amino acid mutations in which the
corresponding human or non-human primate amino acid residue is
present. Moreover, camelid-derived VH and VL domains, or humanized
variants thereof, may be linked to the constant domains of human
antibodies to produce a chimeric molecule, as extensively described
elsewhere herein.
[0084] "Derived From"--As used herein the term "derived from" a
designated protein (e.g. a GARP antibody or antigen-binding
fragment thereof) refers to the origin of the polypeptide. In an
embodiment, the polypeptide or amino acid sequence which is derived
from a particular starting polypeptide is a CDR sequence or
sequence related thereto. In an embodiment, the amino acid sequence
which is derived from a particular starting polypeptide is not
contiguous. For example, in an embodiment, one, two, three, four,
five, or six CDRs are derived from a starting antibody. In an
embodiment, the polypeptide or amino acid sequence which is derived
from a particular starting polypeptide or amino acid sequence has
an amino acid sequence that is essentially identical to that of the
starting sequence, or a region thereof wherein the region consists
of at least of at least 3-5 amino acids, 5-10 amino acids, at least
10-20 amino acids, at least 20-30 amino acids, or at least 30-50
amino acids, or which is otherwise identifiable to one of ordinary
skill in the art as having its origin in the starting sequence. In
an embodiment, the one or more CDR sequences derived from the
starting antibody are altered to produce variant CDR sequences,
e.g. affinity variants, wherein the variant CDR sequences maintain
GARP binding activity.
[0085] "Diabodies"--As used herein, the term "diabodies" refers to
small antibody fragments prepared by constructing sFv fragments
(see sFv paragraph) with short linkers (about 5-10 residues)
between the VH and VL domains such that inter-chain but not
intra-chain pairing of the V domains is achieved, resulting in a
bivalent fragment, i.e., fragment having two antigen-binding sites.
Bispecific diabodies are heterodimers of two "crossover" sFv
fragments in which the VH and VL domains of the two antibodies are
present on different polypeptide chains Diabodies are described
more fully in, for example, EP 404,097; WO 93/11161; and Holliger
et al., Proc. Natl. Acad. Sci., 90:6444-6448 (1993).
[0086] "Engineered"--As used herein the term "engineered" includes
manipulation of nucleic acid or polypeptide molecules by synthetic
means (e.g. by recombinant techniques, in vitro peptide synthesis,
by enzymatic or chemical coupling of peptides or some combination
of these techniques). Preferably, the antibodies of the invention
are engineered, including for example, humanized and/or chimeric
antibodies, and antibodies which have been engineered to improve
one or more properties, such as antigen binding,
stability/half-life or effector function.
[0087] "Epitope"--As used herein, the term "epitope" refers to a
specific arrangement of amino acids located on a peptide or protein
or proteins to which an antibody binds. Epitopes often consist of a
chemically active surface grouping of molecules such as amino acids
or sugar side chains, and have specific three dimensional
structural characteristics as well as specific charge
characteristics. Epitopes can be linear or conformational, i.e.,
involving two or more sequences of amino acids in various regions
of the antigen that may not necessarily be contiguous.
[0088] "Framework region"--The term "framework region" or "FR
region" as used herein, includes the amino acid residues that are
part of the variable region, but are not part of the CDRs (e.g.,
using the Kabat definition of CDRs). Therefore, a variable region
framework is between about 100-120 amino acids in length but
includes only those amino acids outside of the CDRs. For the
specific example of a heavy chain variable region and for the CDRs
as defined by Kabat et al., framework region 1 corresponds to the
domain of the variable region encompassing amino acids 1-30;
framework region 2 corresponds to the domain of the variable region
encompassing amino acids 36-49; framework region 3 corresponds to
the domain of the variable region encompassing amino acids 66-94,
and framework region 4 corresponds to the domain of the variable
region from amino acids 103 to the end of the variable region. The
framework regions for the light chain are similarly separated by
each of the light claim variable region CDRs. Similarly, using the
definition of CDRs by Chothia et al. or McCallum et al. the
framework region boundaries are separated by the respective CDR
termini as described above. In preferred embodiments the CDRs are
as defined by Kabat. In naturally occurring antibodies, the six
CDRs present on each monomeric antibody are short, non-contiguous
sequences of amino acids that are specifically positioned to form
the antigen binding site as the antibody assumes its three
dimensional configuration in an aqueous environment. The remainder
of the heavy and light variable domains show less inter-molecular
variability in amino acid sequence and are termed the framework
regions. The framework regions largely adopt a [beta]-sheet
conformation and the CDRs form loops which connect, and in some
cases form part of, the [beta]-sheet structure. Thus, these
framework regions act to form a scaffold that provides for
positioning the six CDRs in correct orientation by inter-chain,
non-covalent interactions. The antigen binding site formed by the
positioned CDRs defines a surface complementary to the epitope on
the immunoreactive antigen. This complementary surface promotes the
non-covalent binding of the antibody to the immunoreactive antigen
epitope. The position of CDRs can be readily identified by one of
ordinary skill in the art.
[0089] "Fragment"--As used herein, the term "fragment" refers to a
part or region of an antibody or antibody chain comprising fewer
amino acid residues than an intact or complete antibody or antibody
chain. The term "antigen-binding fragment" refers to a polypeptide
fragment of an immunoglobulin or antibody that binds antigen or
competes with intact antibody (i.e., with the intact antibody from
which they were derived) for antigen binding (i.e., specific
binding to human GARP). As used herein, the term "fragment" of an
antibody molecule includes antigen-binding fragments of antibodies,
for example, an antibody light chain variable domain (VL), an
antibody heavy chain variable domain (VH), a single chain antibody
(scFv), a F(ab')2 fragment, a Fab fragment, an Fd fragment, an Fv
fragment, a single domain antibody fragment (DAb), a one-armed
(monovalent) antibody, diabodies or any antigen-binding molecule
formed by combination, assembly or conjugation of such antigen
binding fragments. Fragments can be obtained, e.g., via chemical or
enzymatic treatment of an intact or complete antibody or antibody
chain or by recombinant means.
[0090] "Fv"--As used herein, the term "Fv" is the minimum antibody
fragment that contains a complete antigen-recognition and -binding
site. This fragment consists of a dimer of one heavy- and one
light-chain variable region domain in tight, non-covalent
association. From the folding of these two domains emanate six
hypervariable loops (three loops each from the H and L chain) that
contribute the amino acid residues for antigen binding and confer
antigen binding specificity to the antibody. However, even a single
variable domain (or half of an Fv comprising only three CDRs
specific for an antigen) has the ability to recognize and bind
antigen, although at a lower affinity than the entire binding
site.
[0091] "Heavy chain region"--As used herein, the term "heavy chain
region" includes amino acid sequences derived from the constant
domains of an immunoglobulin heavy chain. A polypeptide comprising
a heavy chain region comprises at least one of: a CH1 domain, a
hinge (e.g., upper, middle, and/or lower hinge region) domain, a
CH2 domain, a CH3 domain, or a variant or fragment thereof. In an
embodiment, a binding molecule of the invention may comprise the Fc
region of an immunoglobulin heavy chain (e.g., a hinge portion, a
CH2 domain, and a CH3 domain) In another embodiment, a binding
molecule of the invention lacks at least a region of a constant
domain (e.g., all or part of a CH2 domain). In certain embodiments,
at least one, and preferably all, of the constant domains are
derived from a human immunoglobulin heavy chain. For example, in
one preferred embodiment, the heavy chain region comprises a fully
human hinge domain. In other preferred embodiments, the heavy chain
region comprising a fully human Fc region (e.g., hinge, CH2 and CH3
domain sequences from a human immunoglobulin). In certain
embodiments, the constituent constant domains of the heavy chain
region are from different immunoglobulin molecules. For example, a
heavy chain region of a polypeptide may comprise a CH2 domain
derived from an IgG1 molecule and a hinge region derived from an
IgG3 or IgG4 molecule. In other embodiments, the constant domains
are chimeric domains comprising regions of different immunoglobulin
molecules. For example, a hinge may comprise a first region from an
IgG1 molecule and a second region from an IgG3 or IgG4 molecule. As
set forth above, it will be understood by one of ordinary skill in
the art that the constant domains of the heavy chain region may be
modified such that they vary in amino acid sequence from the
naturally occurring (wild-type) immunoglobulin molecule. That is,
the polypeptides of the invention disclosed herein may comprise
alterations or modifications to one or more of the heavy chain
constant domains (CH1, hinge, CH2 or CH3) and/or to the light chain
constant domain (CL). Exemplary modifications include additions,
deletions or substitutions of one or more amino acids in one or
more domains
[0092] "Hinge region"--As used herein, the term "hinge region"
includes the region of a heavy chain molecule that joins the CH1
domain to the CH2 domain. This hinge region comprises approximately
25 residues and is flexible, thus allowing the two N-terminal
antigen binding regions to move independently. Hinge regions can be
subdivided into three distinct domains: upper, middle, and lower
hinge domains (Roux et al. J. Immunol. 1998 161:4083).
[0093] The terms "hypervariable loop" and "complementarity
determining region" are not strictly synonymous, since the
hypervariable loops (HVs) are defined on the basis of structure,
whereas complementarity determining regions (CDRs) are defined
based on sequence variability (Kabat et al., Sequences of Proteins
of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md., 1983) and the limits of the
HVs and the CDRs may be different in some VH and VL domains. The
CDRs of the VL and VH domains can typically be defined as
comprising the following amino acids: residues 24-34 (CDRL1), 50-56
(CDRL2) and 89-97 (CDRL3) in the light chain variable domain, and
residues 31-35 or 31-35b (CDRH1), 50-65 (CDRH2) and 95-102 (CDRH3)
in the heavy chain variable domain; (Kabat et al., Sequences of
Proteins of Immunological Interest, 5th Ed. Public Health Service,
National Institutes of Health, Bethesda, Md. (1991)). Thus, the HVs
may be comprised within the corresponding CDRs and references
herein to the "hypervariable loops" of VH and VL domains should be
interpreted as also encompassing the corresponding CDRs, and vice
versa, unless otherwise indicated. The more highly conserved
regions of variable domains are called the framework region (FR),
as defined below. The variable domains of native heavy and light
chains each comprise four FRs (FR1, FR2, FR3 and FR4,
respectively), largely adopting a [beta]-sheet configuration,
connected by the three hypervariable loops. The hypervariable loops
in each chain are held together in close proximity by the FRs and,
with the hypervariable loops from the other chain, contribute to
the formation of the antigen-binding site of antibodies. Structural
analysis of antibodies revealed the relationship between the
sequence and the shape of the binding site formed by the
complementarity determining regions (Chothia et al., J. Mol. Biol.
227: 799-817 (1992)); Tramontano et al., J. Mol. Biol, 215: 175-182
(1990)). Despite their high sequence variability, five of the six
loops adopt just a small repertoire of main-chain conformations,
called "canonical structures". These conformations are first of all
determined by the length of the loops and secondly by the presence
of key residues at certain positions in the loops and in the
framework regions that determine the conformation through their
packing, hydrogen bonding or the ability to assume unusual
main-chain conformations.
[0094] "Humanising substitutions"--As used herein, the term
"humanising substitutions" refers to amino acid substitutions in
which the amino acid residue present at a particular position in
the VH or VL domain antibody GARP antibody (for example a
camelid-derived GARP antibody) is replaced with an amino acid
residue which occurs at an equivalent position in a reference human
VH or VL domain. The reference human VH or VL domain may be a VH or
VL domain encoded by the human germline, in which case the
substituted residues may be referred to as "germlining
substitutions". Humanising/germlining substitutions may be made in
the framework regions and/or the CDRs of a GARP antibody, defined
herein.
[0095] "High human homology"--An antibody comprising a heavy chain
variable domain (VH) and a light chain variable domain (VL) will be
considered as having high human homology if the VH domains and the
VL domains, taken together, exhibit at least 90% amino acid
sequence identity to the closest matching human germline VH and VL
sequences. Antibodies having high human homology may include
antibodies comprising VH and VL domains of native non-human
antibodies which exhibit sufficiently high % sequence identity
human germline sequences, including for example antibodies
comprising VH and VL domains of camelid conventional antibodies, as
well as engineered, especially humanized, variants of such
antibodies and also "fully human" antibodies. In an embodiment the
VH domain of the antibody with high human homology may exhibit an
amino acid sequence identity or sequence homology of 80% or greater
with one or more human VH domains across the framework regions FR1,
FR2, FR3 and FR4. In other embodiments the amino acid sequence
identity or sequence homology between the VH domain of the
polypeptide of the invention and the closest matching human
germline VH domain sequence may be 85% or greater, 90% or greater,
95% or greater, 97% or greater, or up to 99% or even 100%. In an
embodiment the VH domain of the antibody with high human homology
may contain one or more (e.g. 1 to 10) amino acid sequence
mis-matches across the framework regions FR1, FR2, FR3 and FR4, in
comparison to the closest matched human VH sequence. In another
embodiment the VL domain of the antibody with high human homology
may exhibit a sequence identity or sequence homology of 80% or
greater with one or more human VL domains across the framework
regions FR1, FR2, FR3 and FR4. In other embodiments the amino acid
sequence identity or sequence homology between the VL domain of the
polypeptide of the invention and the closest matching human
germline VL domain sequence may be 85% or greater 90% or greater,
95% or greater, 97% or greater, or up to 99% or even 100%.
[0096] In an embodiment the VL domain of the antibody with high
human homology may contain one or more (e.g. 1 to 10) amino acid
sequence mis-matches across the framework regions FR1, FR2, FR3 and
FR4, in comparison to the closest matched human VL sequence. Before
analyzing the percentage sequence identity between the antibody
with high human homology and human germline VH and VL, the
canonical folds may be determined, which allow the identification
of the family of human germline segments with the identical
combination of canonical folds for H1 and H2 or L1 and L2 (and L3).
Subsequently the human germline family member that has the highest
degree of sequence homology with the variable region of the
antibody of interest is chosen for scoring the sequence homology.
The determination of Chothia canonical classes of hypervariable
loops L1, L2, L3, H1 and H2 can be performed with the
bioinformatics tools publicly available on webpage
www.bioinf.org.uk/abs/chothia.html.page. The output of the program
shows the key residue requirements in a data file. In these data
files, the key residue positions are shown with the allowed amino
acids at each position. The sequence of the variable region of the
antibody of interest is given as input and is first aligned with a
consensus antibody sequence to assign the Kabat numbering scheme.
The analysis of the canonical folds uses a set of key residue
templates derived by an automated method developed by Martin and
Thornton (Martin et al., J. Mol. Biol. 263:800-815 (1996)). With
the particular human germline V segment known, which uses the same
combination of canonical folds for H1 and H2 or L1 and L2 (and L3),
the best matching family member in terms of sequence homology can
be determined With bioinformatics tools the percentage sequence
identity between the VH and VL domain framework amino acid
sequences of the antibody of interest and corresponding sequences
encoded by the human germline can be determined, but actually
manual alignment of the sequences can be applied as well. Human
immunoglobulin sequences can be identified from several protein
data bases, such as VBase (http://vbase.mrc-cpe.cam.ac.uk/) or the
Pluckthun/Honegger database
(http://www.bioc.unizh.ch/antibody/Sequences/Germlines). To compare
the human sequences to the V regions of VH or VL domains in an
antibody of interest a sequence alignment algorithm such as
available via websites like www.expasy.ch/tools/#align can be used,
but also manual alignment with the limited set of sequences can be
performed. Human germline light and heavy chain sequences of the
families with the same combinations of canonical folds and with the
highest degree of homology with the framework regions 1, 2, and 3
of each chain are selected and compared with the variable region of
interest; also the FR4 is checked against the human germline JH and
JK or JL regions. Note that in the calculation of overall percent
sequence homology the residues of FR1, FR2 and FR3 are evaluated
using the closest match sequence from the human germline family
with the identical combination of canonical folds. Only residues
different from the closest match or other members of the same
family with the same combination of canonical folds are scored
(NB--excluding any primer-encoded differences). However, for the
purposes of humanization, residues in framework regions identical
to members of other human germline families, which do not have the
same combination of canonical folds, can be considered "human",
despite the fact that these are scored "negative" according to the
stringent conditions described above. This assumption is based on
the "mix and match" approach for humanization, in which each of
FR1, FR2, FR3 and FR4 is separately compared to its closest
matching human germline sequence and the humanized molecule
therefore contains a combination of different FRs as was done by Qu
and colleagues (Qu et al., Clin. Cancer Res. 5:3095-3100 (1999))
and Ono and colleagues (Ono et al., Mol. Immunol. 36:387-395
(1999)). The boundaries of the individual framework regions may be
assigned using the IMGT numbering scheme, which is an adaptation of
the numbering scheme of Chothia (Lefranc et al., NAR 27: 209-212
(1999); http://im.gt.cines.fr). Antibodies with high human homology
may comprise hypervariable loops or CDRs having human or human-like
canonical folds, as discussed in detail below. In an embodiment at
least one hypervariable loop or CDR in either the VH domain or the
VL domain of the antibody with high human homology may be obtained
or derived from a VH or VL domain of a non-human antibody, for
example a conventional antibody from a species of Camelidae, yet
exhibit a predicted or actual canonical fold structure which is
substantially identical to a canonical fold structure which occurs
in human antibodies. It is well established in the art that
although the primary amino acid sequences of hypervariable loops
present in both VH domains and VL domains encoded by the human
germline are, by definition, highly variable, all hypervariable
loops, except CDR H3 of the VH domain, adopt only a few distinct
structural conformations, termed canonical folds (Chothia et al.,
J. Mol. Biol. 196:901-917 (1987); Tramontano et al. Proteins
6:382-94 (1989)), which depend on both the length of the
hypervariable loop and presence of the so-called canonical amino
acid residues (Chothia et al., J. Mol. Biol. 196:901-917 (1987)).
Actual canonical structures of the hypervariable loops in intact VH
or VL domains can be determined by structural analysis (e.g. X-ray
crystallography), but it is also possible to predict canonical
structure on the basis of key amino acid residues which are
characteristic of a particular structure (discussed further below).
In essence, the specific pattern of residues that determines each
canonical structure forms a "signature" which enables the canonical
structure to be recognised in hypervariable loops of a VH or VL
domain of unknown structure; canonical structures can therefore be
predicted on the basis of primary amino acid sequence alone. The
predicted canonical fold structures for the hypervariable loops of
any given VH or VL sequence in an antibody with high human homology
can be analysed using algorithms which are publicly available from
www.bioinf.org.uk/abs/chothia.html,
www.biochem.ucl.ac.uk/.about.martin/antibodies.html and
www.bioc.unizh.ch/antibody/Sequences/Germlines/Vbase_hVk.html.
These tools permit query VH or VL sequences to be aligned against
human VH or VL domain sequences of known canonical structure, and a
prediction of canonical structure made for the hypervariable loops
of the query sequence. In the case of the VH domain, H1 and H2
loops may be scored as having a canonical fold structure
"substantially identical" to a canonical fold structure known to
occur in human antibodies if at least the first, and preferable
both, of the following criteria are fulfilled:
[0097] 1. An identical length, determined by the number of
residues, to the closest matching human canonical structural
class.
[0098] 2. At least 33% identity, preferably at least 50% identity
with the key amino acid residues described for the corresponding
human H1 and H2 canonical structural classes (note for the purposes
of the foregoing analysis the H1 and H2 loops are treated
separately and each compared against its closest matching human
canonical structural class). The foregoing analysis relies on
prediction of the canonical structure of the H1 and H2 loops of the
antibody of interest. If the actual structures of the H1 and H2
loops in the antibody of interest are known, for example based on
X-ray crystallography, then the H1 and H2 loops in the antibody of
interest may also be scored as having a canonical fold structure
"substantially identical" to a canonical fold structure known to
occur in human antibodies if the length of the loop differs from
that of the closest matching human canonical structural class
(typically by +1 or +2 amino acids) but the actual structure of the
H1 and H2 loops in the antibody of interest matches the structure
of a human canonical fold. Key amino acid residues found in the
human canonical structural classes for the first and second
hypervariable loops of human VH domains (H1 and H2) are described
by Chothia et al., J. Mol. Biol. 227:799-817 (1992), the contents
of which are incorporated herein in their entirety by reference. In
particular, Table 3 on page 802 of Chothia et al., which is
specifically incorporated herein by reference, lists preferred
amino acid residues at key sites for H1 canonical structures found
in the human germline, whereas Table 4 on page 803, also
specifically incorporated by reference, lists preferred amino acid
residues at key sites for CDR H2 canonical structures found in the
human germline. In an embodiment, both HI and H2 in the VH domain
of the antibody with high human homology exhibit a predicted or
actual canonical fold structure which is substantially identical to
a canonical fold structure which occurs in human antibodies.
Antibodies with high human homology may comprise a VH domain in
which the hypervariable loops H1 and H2 form a combination of
canonical fold structures which is identical to a combination of
canonical structures known to occur in at least one human germline
VH domain. It has been observed that only certain combinations of
canonical fold structures at H1 and H2 actually occur in VH domains
encoded by the human germline. In an embodiment H1 and H2 in the VH
domain of the antibody with high human homology may be obtained
from a VH domain of a non-human species, e.g. a Camelidae species,
yet form a combination of predicted or actual canonical fold
structures which is identical to a combination of canonical fold
structures known to occur in a human germline or somatically
mutated VH domain. In non-limiting embodiments H1 and H2 in the VH
domain of the antibody with high human homology may be obtained
from a VH domain of a non-human species, e.g. a Camelidae species,
and form one of the following canonical fold combinations: 1-1,
1-2, 1-3, 1-6, 1-4, 2-1, 3-1 and 3-5. An antibody with high human
homology may contain a VH domain which exhibits both high sequence
identity/sequence homology with human VH, and which contains
hypervariable loops exhibiting structural homology with human VH.
It may be advantageous for the canonical folds present at H1 and H2
in the VH domain of the antibody with high human homology, and the
combination thereof, to be "correct" for the human VH germline
sequence which represents the closest match with the VH domain of
the antibody with high human homology in terms of overall primary
amino acid sequence identity. By way of example, if the closest
sequence match is with a human germline VH3 domain, then it may be
advantageous for H1 and H2 to form a combination of canonical folds
which also occurs naturally in a human VH3 domain. This may be
particularly important in the case of antibodies with high human
homology which are derived from non-human species, e.g. antibodies
containing VH and VL domains which are derived from camelid
conventional antibodies, especially antibodies containing humanised
camelid VH and VL domains. Thus, in an embodiment the VH domain of
the GARP antibody with high human homology may exhibit a sequence
identity or sequence homology of 80% or greater, 85% or greater,
90% or greater, 95% or greater, 97% or greater, or up to 99% or
even 100% with a human VH domain across the framework regions FR1,
FR2, FR3 and FR4, and in addition H1 and H2 in the same antibody
are obtained from a non-human VH domain (e.g. derived from a
Camelidae species), but form a combination of predicted or actual
canonical fold structures which is the same as a canonical fold
combination known to occur naturally in the same human VH domain.
In other embodiments, L1 and L2 in the VL domain of the antibody
with high human homology are each obtained from a VL domain of a
non-human species (e.g. a camelid-derived VL domain), and each
exhibits a predicted or actual canonical fold structure which is
substantially identical to a canonical fold structure which occurs
in human antibodies. As with the VH domains, the hypervariable
loops of VL domains of both VLambda and VKappa types can adopt a
limited number of conformations or canonical structures, determined
in part by length and also by the presence of key amino acid
residues at certain canonical positions. Within an antibody of
interest having high human homology, L1, L2 and L3 loops obtained
from a VL domain of a non-human species, e.g. a Camelidae species,
may be scored as having a canonical fold structure "substantially
identical" to a canonical fold structure known to occur in human
antibodies if at least the first, and preferable both, of the
following criteria are fulfilled:
[0099] 1. An identical length, determined by the number of
residues, to the closest matching human structural class.
[0100] 2. At least 33% identity, preferably at least 50% identity
with the key amino acid residues described for the corresponding
human L1 or L2 canonical structural classes, from either the
VLambda or the VKappa repertoire (note for the purposes of the
foregoing analysis the L1 and L2 loops are treated separately and
each compared against its closest matching human canonical
structural class). The foregoing analysis relies on prediction of
the canonical structure of the L1, L2 and L3 loops in the VL domain
of the antibody of interest. If the actual structure of the L1, L2
and L3 loops is known, for example based on X-ray crystallography,
then L1, L2 or L3 loops derived from the antibody of interest may
also be scored as having a canonical fold structure "substantially
identical" to a canonical fold structure known to occur in human
antibodies if the length of the loop differs from that of the
closest matching human canonical structural class (typically by +1
or +2 amino acids) but the actual structure of the Camelidae loops
matches a human canonical fold. Key amino acid residues found in
the human canonical structural classes for the CDRs of human
VLambda and VKappa domains are described by Morea et al. Methods,
20: 267-279 (2000) and Martin et al., J. Mol. Biol., 263:800-815
(1996). The structural repertoire of the human VKappa domain is
also described by Tomlinson et al. EMBO J. 14:4628-4638 (1995), and
that of the VLambda domain by Williams et al. J. Mol. Biol.,
264:220-232 (1996). The contents of all these documents are to be
incorporated herein by reference. L1 and L2 in the VL domain of an
antibody with high human homology may form a combination of
predicted or actual canonical fold structures which is identical to
a combination of canonical fold structures known to occur in a
human germline VL domain. In non-limiting embodiments LI and L2 in
the VLambda domain of an antibody with high human homology (e.g. an
antibody containing a camelid-derived VL domain or a humanised
variant thereof) may form one of the following canonical fold
combinations: 11-7, 13-7(A,B,C), 14-7(A,B), 12-11, 14-11 and 12-12
(as defined in Williams et al. J. Mol. Biol. 264:220-32 (1996) and
as shown on
http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVL.ht-
ml). In non-limiting embodiments L1 and L2 in the Vkappa domain may
form one of the following canonical fold combinations: 2-1, 3-1,
4-1 and 6-1 (as defined in Tomlinson et al. EMBO J. 14:4628-38
(1995) and as shown on
http://www.bioc.uzh.ch/antibody/Sequences/Germlines/VBase_hVK.html).
[0101] In a further embodiment, all three of L1, L2 and L3 in the
VL domain of an antibody with high human homology may exhibit a
substantially human structure. It is preferred that the VL domain
of the antibody with high human homology exhibit both high sequence
identity/sequence homology with human VL, and also that the
hypervariable loops in the VL domain exhibit structural homology
with human VL.
[0102] In an embodiment, the VL domain of the GARP antibody with
high human homology may exhibit a sequence identity of 80% or
greater, 85% or greater, 90% or greater, 95% or greater, 97% or
greater, or up to 99% or even 100% with a human VL domain across
the framework regions FR1, FR2, FR3 and FR4, and in addition
hypervariable loop L1 and hypervariable loop L2 may form a
combination of predicted or actual canonical fold structures which
is the same as a canonical fold combination known to occur
naturally in the same human VL domain. It is, of course, envisaged
that VH domains exhibiting high sequence identity/sequence homology
with human VH, and also structural homology with hypervariable
loops of human VH will be combined with VL domains exhibiting high
sequence identity/sequence homology with human VL, and also
structural homology with hypervariable loops of human VL to provide
antibodies with high human homology containing VH/VL pairings (e.g.
camelid-derived VH/VL pairings) with maximal sequence and
structural homology to human-encoded VH/VL pairings.
[0103] "Immunospecific", "specific for" or to "specifically
bind"--As used herein, an antibody is said to be "immunospecific",
"specific for" or to "specifically bind" an antigen if it reacts at
a detectable level with the antigen, preferably with an affinity
constant, Ka, of greater than or equal to about 10.sup.4 M.sup.-1,
or greater than or equal to about 10.sup.5 M.sup.-1, greater than
or equal to about 10.sup.6 M.sup.-1, greater than or equal to about
10.sup.7 M.sup.-1, or greater than or equal to 10.sup.8, or greater
than or equal to 10.sup.9 M.sup.-1, or greater than or equal to
10.sup.10 M.sup.-1. Affinity of an antibody for its cognate antigen
is also commonly expressed as a dissociation constant Kd, and in
certain embodiments, an antibody specifically binds to antigen if
it binds with a Kd of less than or equal to 10.sup.-4 M, less than
or equal to about 10.sup.-5 M, less than or equal to about
10.sup.-6 M, less than or equal to 10.sup.-7 M, or less than or
equal to 10.sup.-8 M, or less than or equal to 5.10.sup.-9 M, or
less than or equal to 10.sup.-9 M, or less than or equal to
5.10.sup.-10 M, or less than or equal to 10.sup.-10 M. Affinities
of antibodies can be readily determined using conventional
techniques, for example, those described by Scatchard G et al. (The
attractions of proteins for small molecules and ions. Ann NY Acad
Sci 1949; 51:660-672). Binding properties of an antibody to
antigens, cells or tissues thereof may generally be determined and
assessed using immunodetection methods including, for example,
immunofluorescence-based assays, such as immuno-histochemistry
(IHC) and/or fluorescence-activated cell sorting (FACS).
[0104] "Isolated nucleic acid"--As used herein, is a nucleic acid
that is substantially separated from other genome DNA sequences as
well as proteins or complexes such as ribosomes and polymerases,
which naturally accompany a native sequence. The term embraces a
nucleic acid sequence that has been removed from its naturally
occurring environment, and includes recombinant or cloned DNA
isolates and chemically synthesized analogues or analogues
biologically synthesized by heterologous systems. A substantially
pure nucleic acid includes isolated forms of the nucleic acid. Of
course, this refers to the nucleic acid as originally isolated and
does not exclude genes or sequences later added to the isolated
nucleic acid by the hand of man. The term "polypeptide" is used in
its conventional meaning, i.e., as a sequence of amino acids. The
polypeptides are not limited to a specific length of the product.
Peptides, oligopeptides, and proteins are included within the
definition of polypeptide, and such terms may be used
interchangeably herein unless specifically indicated otherwise.
This term also does not refer to or exclude post-expression
modifications of the polypeptide, for example, glycosylation,
acetylation, phosphorylation and the like, as well as other
modifications known in the art, both naturally occurring and
non-naturally occurring. A polypeptide may be an entire protein, or
a subsequence thereof. Particular polypeptides of interest in the
context of this invention are amino acid subsequences comprising
CDRs and being capable of binding an antigen. An "isolated
polypeptide" is one that has been identified and separated and/or
recovered from a component of its natural environment. In preferred
embodiments, the isolated polypeptide will be purified (1) to
greater than 95% by weight of polypeptide as determined by the
Lowry method, and most preferably more than 99% by weight, (2) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator,
or (3) to homogeneity by SDS-PAGE under reducing or non-reducing
conditions using Coomassie blue or, preferably, silver staining.
Isolated polypeptide includes the polypeptide in situ within
recombinant cells since at least one component of the polypeptide's
natural environment will not be present. Ordinarily, however,
isolated polypeptide will be prepared by at least one purification
step.
[0105] "Identity" or "identical"--As used herein, the term
"identity" or "identical", when used in a relationship between the
sequences of two or more polypeptides, refers to the degree of
sequence relatedness between polypeptides, as determined by the
number of matches between strings of two or more amino acid
residues. "Identity" measures the percent of identical matches
between the smaller of two or more sequences with gap alignments
(if any) addressed by a particular mathematical model or computer
program (i.e., "algorithms"). Identity of related polypeptides can
be readily calculated by known methods. Such methods include, but
are not limited to, those described in Computational Molecular
Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988;
Biocomputing: Informatics and Genome Projects, Smith, D. W., ed.,
Academic Press, New York, 1993; Computer Analysis of Sequence Data,
Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New
Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje,
G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M.
and Devereux, J., eds., M. Stockton Press, New York, 1991; and
Carillo et al., SIAM J. Applied Math. 48, 1073 (1988). Preferred
methods for determining identity are designed to give the largest
match between the sequences tested. Methods of determining identity
are described in publicly available computer programs. Preferred
computer program methods for determining identity between two
sequences include the GCG program package, including GAP (Devereux
et al., Nucl. Acid. Res. \2, 387 (1984); Genetics Computer Group,
University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA
(Altschul et al., J. MoI. Biol. 215, 403-410 (1990)). The BLASTX
program is publicly available from the National Center for
Biotechnology Information (NCBI) and other sources (BLAST Manual,
Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al.,
supra). The well-known Smith Waterman algorithm may also be used to
determine identity.
[0106] "Modified antibody"--As used herein, the term "modified
antibody" includes synthetic forms of antibodies which are altered
such that they are not naturally occurring, e.g., antibodies that
comprise at least two heavy chain regions but not two complete
heavy chains (such as, domain deleted antibodies or minibodies);
multispecific forms of antibodies (e.g., bispecific, trispecific,
etc.) altered to bind to two or more different antigens or to
different epitopes on a single antigen); heavy chain molecules
joined to scFv molecules and the like. ScFv molecules are known in
the art and are described, e.g., in U.S. Pat. No. 5,892,019. In
addition, the term "modified antibody" includes multivalent forms
of antibodies (e.g., trivalent, tetravalent, etc., antibodies that
bind to three or more copies of the same antigen). In another
embodiment, a modified antibody of the invention is a fusion
protein comprising at least one heavy chain region lacking a CH2
domain and comprising a binding domain of a polypeptide comprising
the binding region of one member of a receptor ligand pair.
[0107] "Mammal"--As used herein, the term "mammal" refers to any
mammal, including humans, domestic and farm animals, and zoo,
sports, or pet animals, such as dogs, cats, cattle, horses, sheep,
pigs, goats, rabbits, etc. Preferably, the mammal is human.
[0108] "Monoclonal antibody"--As used herein, the term "monoclonal
antibody" refers to an antibody obtained from a population of
substantially homogeneous antibodies, i.e., the individual
antibodies comprised in the population are identical except for
possible naturally occurring mutations that may be present in minor
amounts. Monoclonal antibodies are highly specific, being directed
against a single antigenic site. Furthermore, in contrast to
polyclonal antibody preparations that include different antibodies
directed against different determinants (epitopes), each monoclonal
antibody is directed against a single determinant on the antigen.
In addition to their specificity, the monoclonal antibodies are
advantageous in that they may be synthesized uncontaminated by
other antibodies. The modifier "monoclonal" is not to be construed
as requiring production of the antibody by any particular method.
For example, the monoclonal antibodies useful in the present
invention may be prepared by the hybridoma methodology first
described by Kohler et al., Nature, 256:495 (1975), or may be made
using recombinant DNA methods in bacterial, eukaryotic animal or
plant cells (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal
antibodies" may also be isolated from phage antibody libraries
using the techniques described in Clackson et al., Nature,
352:624-628 (1991) and Marks et al., J. Mol. Biol., 222:581-597
(1991), for example.
[0109] "Native sequence"--As used herein, the term "native
sequence" refers to a polynucleotide is one that has the same
nucleotide sequence as a polynucleotide derived from nature. A
"native sequence" polypeptide is one that has the same amino acid
sequence as a polypeptide (e.g., antibody) derived from nature
(e.g., from any species). Such native sequence polynucleotides and
polypeptides can be isolated from nature or can be produced by
recombinant or synthetic means. A polynucleotide "variant", as the
term is used herein, is a polynucleotide that typically differs
from a polynucleotide specifically disclosed herein in one or more
substitutions, deletions, additions and/or insertions. Such
variants may be naturally occurring or may be synthetically
generated, for example, by modifying one or more of the
polynucleotide sequences of the invention and evaluating one or
more biological activities of the encoded polypeptide as described
herein and/or using any of a number of techniques well known in the
art. A polypeptide "variant", as the term is used herein, is a
polypeptide that typically differs from a polypeptide specifically
disclosed herein in one or more substitutions, deletions, additions
and/or insertions. Such variants may be naturally occurring or may
be synthetically generated, for example, by modifying one or more
of the above polypeptide sequences of the invention and evaluating
one or more biological activities of the polypeptide as described
herein and/or using any of a number of techniques well known in the
art. Modifications may be made in the structure of the
polynucleotides and polypeptides of the present invention and still
obtain a functional molecule that encodes a variant or derivative
polypeptide with desirable characteristics. When it is desired to
alter the amino acid sequence of a polypeptide to create an
equivalent, or even an improved, variant or region of a polypeptide
of the invention, one skilled in the art will typically change one
or more of the codons of the encoding DNA sequence. For example,
certain amino acids may be substituted for other amino acids in a
protein structure without appreciable loss of its ability to bind
other polypeptides (e.g., antigens) or cells. Since it is the
binding capacity and nature of a protein that defines that
protein's biological functional activity, certain amino acid
sequence substitutions can be made in a protein sequence, and of
course, its underlying DNA coding sequence, and nevertheless obtain
a protein with similar properties. It is thus contemplated that
various changes may be made in the peptide sequences of the
disclosed compositions, or corresponding DNA sequences that encode
said peptides without appreciable loss of their biological utility
or activity. In many instances, a polypeptide variant will contain
one or more conservative substitutions. A "conservative
substitution" is one in which an amino acid is substituted for
another amino acid that has similar properties, such that one
skilled in the art of peptide chemistry would expect the secondary
structure and hydropathic nature of the polypeptide to be
substantially unchanged. As outlined above, amino acid
substitutions are generally therefore based on the relative
similarity of the amino acid side-chain substituents, for example,
their hydrophobicity, hydrophilicity, charge, size, and the like.
Exemplary substitutions that take several of the foregoing
characteristics into consideration are well known to those of skill
in the art and include: arginine and lysine; glutamate and
aspartate; serine and threonine; glutamine and asparagine; and
valine, leucine and isoleucine. Amino acid substitutions may
further be made on the basis of similarity in polarity, charge,
solubility, hydrophobicity, hydrophilicity and/or the amphipathic
nature of the residues. For example, negatively charged amino acids
include aspartic acid and glutamic acid; positively charged amino
acids include lysine and arginine; and amino acids with uncharged
polar head groups having similar hydrophilicity values include
leucine, isoleucine and valine; glycine and alanine; asparagine and
glutamine; and serine, threonine, phenylalanine and tyrosine. Other
groups of amino acids that may represent conservative changes
include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys,
ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his;
and (5) phe, tyr, trp, his. A variant may also, or alternatively,
contain nonconservative changes. In a preferred embodiment, variant
polypeptides differ from a native sequence by substitution,
deletion or addition of five amino acids or fewer. Variants may
also (or alternatively) be modified by, for example, the deletion
or addition of amino acids that have minimal influence on the
immunogenicity, secondary structure and hydropathic nature of the
polypeptide.
[0110] "Pharmaceutically acceptable excipient"--As used herein, the
term "pharmaceutically acceptable excipient" includes any and all
solvents, dispersion media, coatings, antibacterial and antifungal
agents, isotonic and absorption delaying agents and the like. Said
excipient does not produce an adverse, allergic or other untoward
reaction when administered to an animal, preferably a human. For
human administration, preparations should meet sterility,
pyrogenicity, and general safety and purity standards as required
by FDA Office of Biologics standards.
[0111] "Specificity"--As used herein, the term "specificity" refers
to the ability to specifically bind (e.g., immunoreact with) a
given target, e.g., GARP. A polypeptide may be monospecific and
contain one or more binding sites which specifically bind a target,
or a polypeptide may be multispecific and contain two or more
binding sites which specifically bind the same or different
targets. In an embodiment, an antibody of the invention is specific
for more than one target. For example, in an embodiment, a
multispecific binding molecule of the invention binds to GARP and a
second molecule expressed on a tumor cell. Exemplary antibodies
which comprise antigen binding sites that bind to antigens
expressed on tumor cells are known in the art and one or more CDRs
from such antibodies can be included in an antibody of the
invention.
[0112] "Synthetic"--As used herein the term "synthetic" with
respect to polypeptides includes polypeptides which comprise an
amino acid sequence that is not naturally occurring. For example,
non-naturally occurring polypeptides are modified forms of
naturally occurring polypeptides (e.g., comprising a mutation such
as an addition, substitution or deletion) or polypeptides which
comprise a first amino acid sequence (which may or may not be
naturally occurring) that is linked in a linear sequence of amino
acids to a second amino acid sequence (which may or may not be
naturally occurring) to which it is not naturally linked in
nature.
[0113] "Single-chain Fv" also abbreviated as "sFv" or "scFv"--As
used herein, the terms "Single-chain Fv", "sFv" or "scFv" are
antibody fragments that comprise the VH and VL antibody domains
connected into a single polypeptide chain. Preferably, the sFv
polypeptide further comprises a polypeptide linker between the VH
and VL domains that enables the sFv to form the desired structure
for antigen binding. For a review of sFv, see Pluckthun in The
Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and
Moore eds., Springer-Verlag, New York, pp. 269-315 (1994);
Borrebaeck 1995, infra.
[0114] "Variable region" or "variable domain"--As used herein, the
term "variable" refers to the fact that certain regions of the
variable domains VH and VL differ extensively in sequence among
antibodies and are used in the binding and specificity of each
particular antibody for its target antigen. However, the
variability is not evenly distributed throughout the variable
domains of antibodies. It is concentrated in three segments called
"hypervariable loops" in each of the VL domain and the VH domain
which form part of the antigen binding site. The first, second and
third hypervariable loops of the VLambda light chain domain are
referred to herein as L1 (.lamda.), L2 (.lamda.) and L3 (.lamda.)
and may be defined as comprising residues 24-33 (L1(.lamda.),
consisting of 9, 10 or 11 amino acid residues), 49-53 L2 (.lamda.),
consisting of 3 residues) and 90-96 (L3(.lamda.), consisting of 6
residues) in the VL domain (Morea et al., Methods 20:267-279
(2000)). The first, second and third hypervariable loops of the
VKappa light chain domain are referred to herein as L1(.kappa.),
L2(.kappa.) and L3(.kappa.) and may be defined as comprising
residues 25-33 (L1(.kappa.), consisting of 6, 7, 8, 11, 12 or 13
residues), 49-53 (L2(.kappa.), consisting of 3 residues) and 90-97
(L3(.kappa.), consisting of 6 residues) in the VL domain (Morea et
al., Methods 20:267-279 (2000)). The first, second and third
hypervariable loops of the VH domain are referred to herein as H1,
H2 and H3 and may be defined as comprising residues 25-33 (HI,
consisting of 7, 8 or 9 residues), 52-56 (H2, consisting of 3 or 4
residues) and 91-105 (H3, highly variable in length) in the VH
domain (Morea et al., Methods 20:267-279 (2000)). Unless otherwise
indicated, the terms L1, L2 and L3 respectively refer to the first,
second and third hypervariable loops of a VL domain, and encompass
hypervariable loops obtained from both Vkappa and Vlambda isotypes.
The terms H1, H2 and H3 respectively refer to the first, second and
third hypervariable loops of the VH domain, and encompass
hypervariable loops obtained from any of the known heavy chain
isotypes, including [gamma], [epsilon], [delta], a or [mu]. The
hypervariable loops L1, L2, L3, H1, H2 and H3 may each comprise
part of a "complementarity determining region" or "CDR", as defined
below.
[0115] "Valency"--As used herein the term "valency" refers to the
number of potential target binding sites in a polypeptide. Each
target binding site specifically binds one target molecule or
specific site on a target molecule. When a polypeptide comprises
more than one target binding site, each target binding site may
specifically bind the same or different molecules (e.g., may bind
to different ligands or different antigens, or different epitopes
on the same antigen). The subject binding molecules preferably have
at least one binding site specific for a human GARP molecule. In
particular embodiments the GARP antibodies provided herein may be
at least bivalent.
[0116] "Treating" or "treatment" or "alleviation"--As used herein,
the terms "treating" or "treatment" or "alleviation" refers to both
therapeutic treatment and prophylactic or preventative measures;
wherein the object is to prevent or slow down (lessen) the targeted
pathologic condition or disorder. Those in need of treatment
include those already with the disorder as well as those prone to
have the disorder or those in whom the disorder is to be prevented.
A subject or mammal is successfully "treated" for an infection if,
after receiving a therapeutic amount of an antibody according to
the methods of the present invention, the patient shows observable
and/or measurable reduction in or absence of one or more of the
following: reduction in the number of pathogenic cells; reduction
in the percent of total cells that are pathogenic; and/or relief to
some extent, of one or more of the symptoms associated with the
specific disease or condition; reduced morbidity and mortality, and
improvement in quality of life issues. The above parameters for
assessing successful treatment and improvement in the disease are
readily measurable by routine procedures familiar to a
physician.
[0117] "TGF-.beta."--As used herein, the term TGF-.beta. refers to
the three isoforms named TGF-.beta.1, TGF-.beta.2 and TGF-.beta.3.
The peptide structures of the TGF-.beta. isoforms are highly
similar (homologies on the order of 70-80%). They are all encoded
as large protein precursors; TGF-.beta.1 (GenBank Access No:
NM_000660 contains 390 amino acids and TGF-.beta.2 (GenBank Access
No: NM_001135599 and NM_003238) and TGF-.beta.3 (GenBank Access No:
XM_005268028) each contain 412 amino acids. They each have an
N-terminal signal peptide of 20-30 amino acids that they require
for secretion from a cell, a pro-region (named latency associated
peptide or LAP), and a 112-114 amino acid C-terminal region that
becomes the mature TGF-.beta. molecule following its release from
the pro-region by proteolytic cleavage. After proteolytic cleavage,
LAP and mature TGF-.beta. remain non-covalently associated and form
the "latent" TGF-.beta. molecule. In this latent form, mature
TGF-.beta. is prevented from binding to the TGF-.beta. receptor by
LAP. To exert a signal, mature TGF-.beta. must be released from
LAP. Mature TGF-.beta. that is not associated to LAP is called
active TGF-.beta., as it can bind to the TGF-.beta. receptor and
transduce a signal.
[0118] TGF-.beta.1 has the following amino acid sequence:
TABLE-US-00014 (SEQ ID NO: 53)
MPPSGLRLLPLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIR
GQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPE
ADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLL
SRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDV
TGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATI
HGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYI
DFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGA
SAAPCCVPQALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS.
[0119] LAP has the following amino acid sequence:
TABLE-US-00015 (SEQ ID NO: 54)
LSTCKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLA
LYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTH
SIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSW
RYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRD
NTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPL ERAQHLQSSRHRR.
[0120] Mature TGF-.beta.1 has the following amino acid
sequence:
TABLE-US-00016 (SEQ ID NO: 55)
ALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWIHEPKGYHANFCLGPCPY
IWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVGRKPKVEQ
LSNMIVRSCKCS.
[0121] One object of the invention is a protein binding to GARP in
the presence of TGF-.beta.. Another object of the invention is a
protein comprising an antigen binding domain, wherein the antigen
binding domain binds specifically to GARP in the presence of
TGF-.beta..
[0122] In an embodiment, said protein binds to GARP only in the
presence of TGF-.beta..
[0123] GARP is also called Leucin Rich Repeat Containing 32
(LRRC32) and belongs to the Leucin Rich Repeat family. The complete
amino acid sequence of the human GARP protein transcript variant 2
of the present invention (SEQ ID NO: 1) (GenBank Accession
NM_001128922) is:
TABLE-US-00017 MRPQILLLLALLTLGLAAQHQDKVPCKMVDKKVSCQVLGLLQVPSVLPPD
TETLDLSGNQLRSILASPLGFYTALRHLDLSTNEISFLQPGAFQALTHLE
HLSLAHNRLAMATALSAGGLGPLPRVTSLDLSGNSLYSGLLERLLGEAPS
LHTLSLAENSLTRLTRHTFRDMPALEQLDLHSNVLMDIEDGAFEGLPRLT
HLNLSRNSLTCISDFSLQQLRVLDLSCNSIEAFQTASQPQAEFQLTWLDL
RENKLLHFPDLAALPRLIYLNLSNNLIRLPTGPPQDSKGIHAPSEGWSAL
PLSAPSGNASGRPLSQLLNLDLSYNEIELIPDSFLEHLTSLCFLNLSRNC
LRTFEARRLGSLPCLMLLDLSHNALETLELGARALGSLRTLLLQGNALRD
LPPYTFANLASLQRLNLQGNRVSPCGGPDEPGPSGCVAFSGITSLRSLSL
VDNEIELLRAGAFLHTPLTELDLSSNPGLEVATGALGGLEASLEVLALQG
NGLMVLQVDLPCFICLKRLNLAENRLSHLPAWTQAVSLEVLDLRNNSFSL
LPGSAMGGLETSLRRLYLQGNPLSCCGNGWLAAQLHQGRVDVDATQDLIC
RFSSQEEVSLSHVRPEDCEKGGLKNINLITILTFILVSAILLTTLAACC
CVRRQKFNQQYKA.
[0124] In an embodiment, the protein of the invention binds to GARP
when GARP is complexed to TGF-.beta..
[0125] In another embodiment, the protein of the invention binds to
GARP when GARP is complexed to latent TGF-.beta..
[0126] In another embodiment, the protein of the invention binds to
a complex of GARP and TGF-.beta..
[0127] In an embodiment, the protein of the invention binds to a
complex of GARP and TGF-.beta.1; TGF-.beta.2, isoform 1;
TGF-.beta.2, isoform 2; TGF-.beta.3. Preferably, the protein of the
invention binds to a complex of GARP and TGF-.beta.1.
[0128] In another embodiment, the protein of the invention binds to
a complex of GARP and latent TGF-.beta..
[0129] The term "latent TGF-.beta." as used herein comprises a
complex whose C-terminal fragment, or mature TGF-.beta.1, remains
non-covalently bound to the N-terminal fragment known as LAP.
[0130] In another embodiment, the protein of the invention binds to
a complex of GARP and latent TGF-.beta. at a KD (the equilibrium
dissociation constant between the antibody and its antigen) of less
than 10.sup.-10 M.
[0131] In an embodiment, said protein is an antibody molecule
selected from the group consisting of a whole antibody, a humanized
antibody, a single chain antibody, a dimeric single chain antibody,
a Fv, a Fab, a F(ab)'2, a defucosylated antibody, a bi-specific
antibody, a diabody, a triabody, a tetrabody.
[0132] In another embodiment, said protein is an antibody fragment
selected from the group consisting of a unibody, a domain antibody,
and a nanobody.
[0133] In another embodiment, said protein is an antibody mimetic
selected from the group consisting of an affibody, an affilin, an
affitin, an adnectin, an atrimer, an evasin, a DARPin, an
anticalin, an avimer, a fynomer, a versabody and a duocalin.
[0134] A domain antibody is well known in the art and refers to the
smallest functional binding units of antibodies, corresponding to
the variable regions of either the heavy or light chains of
antibodies.
[0135] A nanobody is well known in the art and refers to an
antibody-derived therapeutic protein that contains the unique
structural and functional properties of naturally-occurring heavy
chain antibodies. These heavy chain antibodies contain a single
variable domain (VHH) and two constant domains (CH2 and CH3).
[0136] A unibody is well known in the art and refers to an antibody
fragment lacking the hinge region of IgG4 antibodies. The deletion
of the hinge region results in a molecule that is essentially half
the size of traditional IgG4 antibodies and has a univalent binding
region rather than the bivalent biding region of IgG4
antibodies.
[0137] An affibody is well known in the art and refers to affinity
proteins based on a 58 amino acid residue protein domain, derived
from one of the IgG binding domain of staphylococcal protein A.
[0138] DARPins (Designed Ankyrin Repeat Proteins) are well known in
the art and refer to an antibody mimetic DRP (designed repeat
protein) technology developed to exploit the binding abilities of
non-antibody polypeptides.
[0139] Anticalins are well known in the art and refer to another
antibody mimetic technology, wherein the binding specificity is
derived from lipocalins. Anticalins may also be formatted as dual
targeting protein, called Duocalins.
[0140] Avimers are well known in the art and refer to another
antibody mimetic technology. Versabodies are well known in the art
and refer to another antibody mimetic technology. They are small
proteins of 3-5 kDa with >15% cysteines, which form a high
disulfide density scaffold, replacing the hydrophobic core the
typical proteins have.
[0141] In another embodiment, said protein is an immunoconjugate
comprising an antibody or fragment thereof conjugated to a
therapeutic agent.
[0142] In another embodiment, said protein is a conjugate
comprising the protein of the invention conjugated to an imaging
agent. Said protein could be used for example for imaging
applications.
[0143] Another object of the invention is a protein that binds to
GARP and inhibits TGF-.beta. signaling.
[0144] In an embodiment, said protein binds to GARP when GARP is
complexed to TGF-.beta..
[0145] In another embodiment, said protein binds to GARP when GARP
is complexed to latent TGF-.beta..
[0146] In another embodiment, said protein binds to a complex of
GARP and TGF-.beta..
[0147] In another embodiment, said protein binds to a complex of
GARP and latent TGF-.beta..
[0148] In an embodiment, said protein is an antibody molecule
selected from the group consisting of a whole antibody, a humanized
antibody, a single chain antibody, a dimeric single chain antibody,
a Fv, a Fab, a F(ab)'2, a defucosylated antibody, a bi-specific
antibody, a diabody, a triabody, a tetrabody.
[0149] In another embodiment, said protein is an antibody fragment
selected from the group consisting of a unibody, a domain antibody,
and a nanobody.
[0150] In another embodiment, said protein is an antibody mimetic
selected from the group consisting of an affibody, an affilin, an
affitin, an adnectin, an atrimer, an evasin, a DARPin, an
anticalin, an avimer, a fynomer, a versabody and a duocalin.
[0151] In an embodiment, said protein is an anti-hGARP (anti human
GARP) antibody or antigen binding fragment thereof that inhibits
TGF-.beta. signaling.
[0152] In an embodiment, said protein prevents or inhibits active
TGF-.beta. to be released or inhibits the release of mature
TGF-.beta. from GARP/TGF-.beta..
[0153] In an embodiment, said protein prevents or inhibits the
release of active TGF-.beta. from membrane-bound
GARP/TGF-.beta..
[0154] In an embodiment, said protein prevents or inhibits active
TGF-.beta. to be released or inhibits the release of mature
TGF-.beta. from Tregs.
[0155] In another embodiment, said protein inhibits or prevents
mature TGF-.beta. to bind to TGF-13 receptors.
[0156] In another embodiment, said protein inhibits TGF-.beta.
activity and/or the activation of molecules from the TGF-.beta.
receptor signaling pathway.
[0157] As used herein, the term "inhibit" means that the protein is
capable of blocking, reducing, preventing or neutralizing
TGF-.beta. signaling or the release of mature TGF-.beta. from Tregs
or the binding of mature TGF-.beta. to TGF-.beta. receptors or
TGF-.beta. activity and/or the activation of molecules from the
TGF-.beta. receptor signaling pathway.
[0158] In an embodiment, said protein is a monoclonal antibody.
[0159] In another embodiment, said protein is a polyclonal
antibody.
[0160] In an embodiment, said protein binds to a conformational
epitope.
[0161] In an embodiment, said conformational epitope comprises one
or more amino acids of hGARP.
[0162] In another embodiment, said conformational epitope comprises
an epitope of GARP modified as a result of GARP being complexed
with latent TGF-.beta.. In another embodiment, said conformational
epitope comprises amino acids of hGARP and amino acids of latent
TGF-.beta..
[0163] In another embodiment, said conformational epitope is a
mixed conformational epitope and comprises amino acids from both
GARP and TGF-.beta..
[0164] In another embodiment, said conformational epitope is a
binding-induced conformational epitope and comprises amino acids
from GARP only, but that adopts a different conformation in the
presence of TGF-.beta..
[0165] In an embodiment, said epitope comprises one or more
residues from 101 to 141 residues of hGARP amino acid sequence (SEQ
ID NO: 1).
[0166] These 101 to 141 residues are as set forth in SEQ ID NO: 12:
HLSLAHNRLAMATALSAGGLGPLPRVTSLDLSGNSLYSGLL.
[0167] In another embodiment of the invention, said epitope
comprises the residues 137, 138 and 139: YSG of hGARP amino acid
sequence (SEQ ID NO: 1).
[0168] In another embodiment of the invention, said epitope
comprises the residues 137, 138 and 139: YSG of hGARP amino acid
sequence (SEQ ID NO: 1) and requires the presence of
TGF-.beta..
[0169] In another embodiment of the invention, said epitope
comprises the residues 137, 138 and 139: YSG of hGARP amino acid
sequence (SEQ ID NO: 1) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20 contiguous residues in N-terminal
and/or C-terminal of the residues 137, 138 and 139: YSG of SEQ ID
NO: 1.
[0170] In another embodiment of the invention, said epitope
comprises the residues 137, 138 and 139: YSG of hGARP amino acid
sequence (SEQ ID NO: 1) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20 contiguous residues in N-terminal
and/or C-terminal of the residues 137, 138 and 139: YSG of SEQ ID
NO: 1, and requires the presence of TGF-.beta..
[0171] In an embodiment of the invention, the protein of the
invention binds to epitopes preferably within the region 101-141 of
hGARP and inhibits the release of latent TGF-.beta. from GARP.
[0172] One skilled in the art can determine the ability of a
protein to inhibit TGF-.beta. signaling by measuring for example
activation of molecules from the TGF-.beta. receptor signaling
pathway. One example of such test is the measurement of the
phosphorylation of SMAD2 (as shown in Example 2 of the present
invention).
[0173] Another object of the invention is a protein binding to an
epitope of a complex formed by human GARP and TGF-.beta., said
epitope comprising at least one of the residues 137, 138, or 139 of
GARP (SEQ ID NO: 1) and at least one residue of TGF-.beta. (SEQ ID
NO: 53).
[0174] In one embodiment, said protein is an antibody or an antigen
binding fragment thereof.
[0175] In another embodiment, said antibody or antigen binding
fragment thereof is selected from the group consisting of a whole
antibody, a humanized antibody, a single chain antibody, a dimeric
single chain antibody, a Fv, a Fab, a F(ab)'2, a defucosylated
antibody, a bi-specific antibody, a diabody, a triabody, a
tetrabody; or an antibody fragment selected from the group
consisting of a unibody, a domain antibody, and a nanobody; or an
antibody mimetic selected from the group consisting of an affibody,
an affilin, an affitin, an adnectin, an atrimer, an evasin, a
DARPin, an anticalin, an avimer, a fynomer, a versabody and a
duocalin.
[0176] In one embodiment, the epitope comprises one, two or three
of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1).
[0177] In another embodiment, the epitope comprises at least one of
the residues 137, 138, or 139 of GARP (SEQ ID NO: 1) and at least
one residue from the Latency associated peptide (LAP) of TGF-.beta.
(SEQ ID NO: 54) and at least one residue from mature TGF-.beta.
(SEQ ID NO: 55).
[0178] In another embodiment, the epitope comprises at least one of
the residues 137, 138, or 139 of GARP (SEQ ID NO: 1) and at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
or 20 residue(s) from the Latency associated peptide (LAP) (SEQ ID
NO: 54) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, or 20 residue(s) from mature TGF-.beta. (SEQ ID
NO: 55).
[0179] In another embodiment, the epitope comprises one, two or
three of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1) and
at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, or 20 residue(s) from the Latency associated peptide (LAP)
(SEQ ID NO: 54) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20 residue(s) from mature TGF-.beta.
(SEQ ID NO: 55).
[0180] In another embodiment, the epitope comprises one, two or
three of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1) and
at least 1, 2, 3, 4, 5, 6, 7, or 8 residue(s) from the Latency
associated peptide (LAP) (SEQ ID NO: 54) selected from the group of
residues 58, 100, 146, 269, 270, 271, 272, 273 of TGF-.beta. (SEQ
ID NO: 53) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, or 20 residue(s) from mature TGF-.beta.
(SEQ ID NO: 55).
[0181] In another embodiment, the epitope comprises one, two or
three of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1) and
at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, or 20 residue(s) from the Latency associated peptide (LAP)
(SEQ ID NO: 54) and at least 1, 2, 3, 4, 5, or 6 residue(s) from
mature TGF-.beta. (SEQ ID NO: 55) selected from the group of
residues 284, 336, 337, 338, 341, and 345 of TGF .beta. (SEQ ID NO:
53).
[0182] In another embodiment, the epitope comprises one, two or
three of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1) and
at least 1, 2, 3, 4, 5, 6, 7, or 8 residue(s) from the Latency
associated peptide (LAP) (SEQ ID NO: 54) selected from the group of
residues 58, 100, 146, 269, 270, 271, 272, and 273 of TGF-.beta.
(SEQ ID NO: 53) and at least 1, 2, 3, 4, 5, or 6 residue(s) from
mature TGF-.beta. (SEQ ID NO: 55) selected from the group of
residues 284, 336, 337, 338, 341, and 345 of TGF .beta. (SEQ ID NO:
53).
[0183] In another embodiment, the epitope comprises one, two or
three of the residues 137, 138, and 139 of GARP (SEQ ID NO: 1) and
at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14
residue(s) selected from the group of residues 58, 100, 146, 269,
270, 271, 272, 273, 284, 336, 337, 338, 341, and 345 of TGF-.beta.
(SEQ ID NO: 53).
[0184] In another embodiment, the epitope comprises at least one,
two or three of the residues 137, 138 and 139 of GARP (SEQ ID NO:
1) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, or 19 residue(s) selected from the group of residues
113, 114, 116, 117, 118, 119, 140, 142, 143, 144, 145, 146, 162,
163, 165, 166, 167, 170 and 189 of GARP (SEQ ID NO: 1) and at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
or 20 residue(s) from the Latency associated peptide (LAP) (SEQ ID
NO: 54) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, or 20 residue(s) from mature TGF-.beta. (SEQ ID
NO: 55).
[0185] In another embodiment, the epitope comprises at least one,
two or three of the residues 137, 138 and 139 of GARP (SEQ ID NO:
1) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, or 19 residue(s) selected from the group of residues
113, 114, 116, 117, 118, 119, 140, 142, 143, 144, 145, 146, 162,
163, 165, 166, 167, 170 and 189 of GARP (SEQ ID NO: 1) and at least
1, 2, 3, 4, 5, 6, 7, or 8 residue(s) from the Latency associated
peptide (LAP) selected from the group of residues 58, 100, 146,
269, 270, 271, 272, and 273 of TGF-.beta. and at least 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20
residue(s) from mature TGF-.beta. (SEQ ID NO: 55).
[0186] In another embodiment, the epitope comprises at least one,
two or three of the residues 137, 138 and 139 of GARP (SEQ ID NO:
1) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, or 19 residue(s) selected from the group of residues
113, 114, 116, 117, 118, 119, 140, 142, 143, 144, 145, 146, 162,
163, 165, 166, 167, 170 and 189 of GARP (SEQ ID NO: 1) and at least
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
or 20 residue(s) from the Latency associated peptide (LAP) (SEQ ID
NO: 54) and at least 1, 2, 3, 4, 5, or 6 residue(s) from mature
TGF-.beta. (SEQ ID NO: 55) selected from the group of residues 284,
336, 337, 338, 341, and 345 of TGF .beta. (SEQ ID NO: 53).
[0187] In another embodiment, the epitope comprises at least one,
two or three of the residues 137, 138 and 139 of GARP (SEQ ID NO:
1) and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, or 19 residue(s) selected from the group of residues
113, 114, 116, 117, 118, 119, 140, 142, 143, 144, 145, 146, 162,
163, 165, 166, 167, 170 and 189 of GARP (SEQ ID NO: 1) and at least
1, 2, 3, 4, 5, 6, 7, or 8 residue(s) from the Latency associated
peptide (LAP) selected from the group of residues 58, 100, 146,
269, 270, 271, 272, and 273 of TGF-.beta. and at least 1, 2, 3, 4,
5, and 6 residue(s) from mature TGF-.beta. (SEQ ID NO: 55) selected
from the group of residues 284, 336, 337, 338, 341, and 345 of TGF
.beta. (SEQ ID NO: 53).
[0188] An object of the invention is an antibody against human GARP
or antigen binding fragment thereof wherein the variable region of
the heavy chain comprises at least one of the followings CDRs:
TABLE-US-00018 VH-CDR1: (SEQ ID NO: 2) GFSLTGYGIN or (SEQ ID NO:
52) GYGIN; VH-CDR2: (SEQ ID NO: 3) MIWSDGSTDYNSVLTS; and VH-CDR3:
(SEQ ID NO: 4) DRNYYDYDGAMDY.
[0189] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00019 VL-CDR1: (SEQ ID NO: 5) KASDHIKNWLA; VL-CDR2: (SEQ
ID NO: 6) GATSLEA; and VL-CDR3: (SEQ ID NO: 7) QQYWSTPWT.
[0190] Another object of the invention is an antibody against human
GARP or antigen binding fragment thereof wherein the variable
region of the heavy chain comprises at least one of the followings
CDRs:
TABLE-US-00020 VH-CDR1: (SEQ ID NO: 13) SYYID; VH-CDR2: (SEQ ID NO:
14) RIDPEDGGTKYAQKFQG; and VH-CDR3: (SEQ ID NO: 15)
NEWETVVVGDLMYEYEY.
[0191] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00021 VL-CDR1: (SEQ ID NO: 16)
QASQX.sub.1IX.sub.2SX.sub.3LA,
wherein X.sub.1 is S or T, X.sub.2 is S or V, X.sub.3 is Y or
F;
TABLE-US-00022 VL-CDR2: (SEQ ID NO: 17)
X.sub.1X.sub.2SX.sub.3X.sub.4X.sub.5T,
wherein X.sub.1 is G or R; X.sub.2 is A or T; X.sub.3 is R or I;
X.sub.4 is L or P; X.sub.5 is Q or K; and
TABLE-US-00023 VL-CDR3: QQYX.sub.1SX.sub.2PX.sub.3T,
wherein X.sub.1 is D, A, Y or V; X.sub.2 is A, L or V; X.sub.3 is V
or P (SEQ ID NO: 18).
[0192] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
heavy chain comprises the VH-CDR1 of SEQ ID NO: 13, VH-CDR2 of SEQ
ID NO: 14 and VH-CDR3 of SEQ ID NO: 15 and the variable region of
the light chain comprises at least one of VL-CDR1 as set forth in
SEQ ID NO: 19; SEQ ID NO: 22; SEQ ID NO: 25; SEQ ID NO: 28; or SEQ
ID NO: 31; at least one of VL-CDR2 as set forth in SEQ ID NO: 20;
SEQ ID NO: 23; SEQ ID NO: 26; SEQ ID NO: 29; or SEQ ID NO: 32 and
at least one of VL-CDR3 as set forth in SEQ ID NO: 21; SEQ ID NO:
24; SEQ ID NO: 27; SEQ ID NO: 30; or SEQ ID NO: 33.
[0193] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00024 VL-CDR1: (SEQ ID NO: 19) QASQSISSYLA; VL-CDR2: (SEQ
ID NO: 20) GASRLQT; and VL-CDR3: (SEQ ID NO: 21) QQYDSLPVT.
[0194] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00025 VL-CDR1: (SEQ ID NO: 22) QASQSIVSYLA; VL-CDR2: (SEQ
ID NO: 23) GASRLQT; and VL-CDR3: (SEQ ID NO: 24) QQYASAPVT .
[0195] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00026 VL-CDR1: (SEQ ID NO: 25) QASQSISSYLA; VL-CDR2: (SEQ
ID NO: 26) GTSRLKT; and VL-CDR3: (SEQ ID NO: 27) QQYYSAPVT.
[0196] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00027 VL-CDR1: (SEQ ID NO: 28) QASQTISSFLA; VL-CDR2: (SEQ
ID NO: 29) RASIPQT; and VL-CDR3: (SEQ ID NO: 30) QQYVSAPPT.
[0197] Another object of the invention is an anti-hGARP antibody or
antigen binding fragment thereof wherein the variable region of the
light chain comprises at least one of the followings CDRs:
TABLE-US-00028 VL-CDR1: (SEQ ID NO: 31) QASQSISSYLA; VL-CDR2: (SEQ
ID NO: 32) GASRLKT; and VL-CDR3: (SEQ ID NO: 33) QQYASVPVT.
[0198] In an embodiment of the invention, the anti-hGARP antibody
or antigen binding fragment thereof may comprise the CH1 domain,
hinge region, CH2 domain and CH3 domain of a human antibody, in
particular IgG1, IgG2, IgG3 or IgG4.
[0199] In an embodiment of the invention, the anti-hGARP antibody
or antigen binding fragment thereof comprises in its heavy chain
the following CDRs: VH-CDR1 GFSLTGYGIN (SEQ ID NO: 2), VH-CDR2
MIWSDGSTDYNSVLTS (SEQ ID NO: 3) and VH-CDR3 DRNYYDYDGAMDY (SEQ ID
NO: 4).
[0200] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its heavy
chain the following CDRs: VH-CDR1 GYGIN (SEQ ID NO: 52), VH-CDR2
MIWSDGSTDYNSVLTS (SEQ ID NO: 3) and VH-CDR3 DRNYYDYDGAMDY (SEQ ID
NO: 4).
[0201] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 KASDHIKNWLA (SEQ ID NO: 5),
VL-CDR2 GATSLEA (SEQ ID NO: 6) and VL-CDR3 QQYWSTPWT (SEQ ID NO:
7).
[0202] In an embodiment of the invention, the anti-hGARP antibody
or antigen binding fragment thereof comprises in its heavy chain
the following CDRs: VH-CDR1 SYYID (SEQ ID NO: 13), VH-CDR2
RIDPEDGGTKYAQKFQG (SEQ ID NO: 14) and VH-CDR3 NEWETVVVGDLMYEYEY
(SEQ ID NO: 15).
[0203] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQX.sub.1I X.sub.2SX.sub.3LA
(SEQ ID NO: 16), wherein X.sub.1 is S or T, X.sub.2 is S or V,
X.sub.3 is Y or F; VL-CDR2 X.sub.1X.sub.2SX.sub.3X.sub.4X.sub.5T
(SEQ ID NO: 17), wherein X.sub.1 is G or R; X.sub.2 is A or T;
X.sub.3 is R or I; X.sub.4 is L or P; X.sub.5 is Q or K; and
VL-CDR3 QQYX.sub.1SX.sub.2PX.sub.3T, wherein X.sub.1 is D, A, Y or
V; X.sub.2 is A, L or V; X.sub.3 is V or P (SEQ ID NO: 18).
[0204] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQSISSYLA (SEQ ID NO: 19),
VL-CDR2 GASRLQT (SEQ ID NO: 20), and VL-CDR3 QQYDSLPVT (SEQ ID NO:
21).
[0205] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQSIVSYLA (SEQ ID NO: 22);
VL-CDR2 GASRLQT (SEQ ID NO: 23); and VL-CDR3: QQYASAPVT (SEQ ID NO:
24).
[0206] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQSISSYLA (SEQ ID NO: 25);
VL-CDR2 GTSRLKT (SEQ ID NO: 26); and VL-CDR3 QQYYSAPVT (SEQ ID NO:
27).
[0207] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQTISSFLA (SEQ ID NO: 28);
VL-CDR2 RASIPQT (SEQ ID NO: 29); and VL-CDR3 QQYVSAPPT (SEQ ID NO:
30).
[0208] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises in its light
chain the following CDRs: VL-CDR1 QASQSISSYLA (SEQ ID NO: 31);
VL-CDR2 GASRLKT (SEQ ID NO: 32); and VL-CDR3 QQYASVPVT (SEQ ID NO:
33).
[0209] According to the invention, any of the CDRs 1, 2 and 3 of
the heavy and light chains may be characterized as having an amino
acid sequence that shares at least 60%, 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, 99% identity with the particular CDR or sets of
CDRs listed in the corresponding SEQ ID NO.
[0210] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof is selected from the
group consisting of an antibody having: [0211] (i) the heavy chain
CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino acid sequences as
shown in SEQ ID NO: 2, 3 and 4; and [0212] (ii) the light chain CDR
1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3) amino acid sequences as
shown in SEQ ID NO: 5, 6 and 7 respectively; optionally wherein
one, two, three or more of the amino acids in any of said sequences
may be substituted by a different amino acid.
[0213] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof is selected from the
group consisting of an antibody having: [0214] (i) the heavy chain
CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino acid sequences as
shown in SEQ ID NO: 52, 3 and 4; and [0215] (ii) the light chain
CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3) amino acid sequences as
shown in SEQ ID NO: 5, 6 and 7 respectively; optionally wherein
one, two, three or more of the amino acids in any of said sequences
may be substituted by a different amino acid.
[0216] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof is selected from the
group consisting of an antibody having: [0217] (i) the heavy chain
CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino acid sequences as
shown in SEQ ID NO: 13, 14 and 15; and [0218] (ii) the light chain
CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3) amino acid sequences as
shown in SEQ ID NO: 16, 17 and 18 respectively; optionally wherein
one, two, three or more of the amino acids in any of said sequences
may be substituted by a different amino acid.
[0219] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises: [0220] (i)
the heavy chain CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino
acid sequences as shown in SEQ ID NO: 13, 14 and 15; and [0221]
(ii) the light chain CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3)
amino acid sequences as shown in SEQ ID NO: 19, 20 and 21
respectively; optionally wherein one, two, three or more of the
amino acids in any of said sequences may be substituted by a
different amino acid.
[0222] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises: [0223] (i)
the heavy chain CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino
acid sequences as shown in SEQ ID NO: 13, 14 and 15; and [0224]
(ii) the light chain CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3)
amino acid sequences as shown in SEQ ID NO: 22, 23 and 24
respectively; optionally wherein one, two, three or more of the
amino acids in any of said sequences may be substituted by a
different amino acid.
[0225] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises: [0226] (i)
the heavy chain CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino
acid sequences as shown in SEQ ID NO: 13, 14 and 15; and [0227]
(ii) the light chain CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3)
amino acid sequences as shown in SEQ ID NO: 25, 26 and 27
respectively; optionally wherein one, two, three or more of the
amino acids in any of said sequences may be substituted by a
different amino acid.
[0228] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises: [0229] (i)
the heavy chain CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino
acid sequences as shown in SEQ ID NO: 13, 14 and 15; and [0230]
(ii) the light chain CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3)
amino acid sequences as shown in SEQ ID NO: 28, 29 and 30
respectively; optionally wherein one, two, three or more of the
amino acids in any of said sequences may be substituted by a
different amino acid.
[0231] In another embodiment of the invention, the anti-hGARP
antibody or antigen binding fragment thereof comprises: [0232] (i)
the heavy chain CDR 1, 2 and 3 (VH-CDR1, VH-CDR2, VH-CDR3) amino
acid sequences as shown in SEQ ID NO: 13, 14 and 15; and [0233]
(ii) the light chain CDR 1, 2 and 3 (VL-CDR1, VL-CDR2, VL-CDR3)
amino acid sequences as shown in SEQ ID NO: 31, 32 and 33
respectively; optionally wherein one, two, three or more of the
amino acids in any of said sequences may be substituted by a
different amino acid.
[0234] In an embodiment, the anti-hGARP antibody or antigen binding
fragment thereof comprises a variable heavy chain CDR3 comprising
an amino acid sequence of SEQ ID NO: 4 (DRNYYDYDGAMDY), or sequence
variant thereof, wherein the sequence variant comprises one, two or
three amino acid substitutions in the recited sequence.
[0235] In an embodiment, the anti-hGARP antibody or antigen binding
fragment thereof comprises a variable heavy chain CDR3 comprising
an amino acid sequence of SEQ ID NO: 15, or sequence variant
thereof, wherein the sequence variant comprises one, two or three
amino acid substitutions in the recited sequence.
[0236] Another object of the invention is the anti-hGARP antibody
MHGARP8 or antigen binding fragment thereof comprising a heavy
chain variable region of sequence SEQ ID NO: 8 and a light chain
variable region of sequence SEQ ID NO: 9.
TABLE-US-00029 (SEQ ID NO: 8)
MAVLALLFCLVTFPSCILSQVQLKESGPGLVAPSQSLSITCTVSGFSLTG
YGINWVRQPPGKGLEWLGMIWSDGSTDYNSVLTSRLRISKDNSNSQVFLK
MNSLQVDDTARYYCARDRNYYDYDGAMDYWGQGTSVTVSS. (SEQ ID NO: 9)
MKFPSQLLLFLLFRITGIICDIQVTQSSSYLSVSLGDRVTITCKASDHIK
NWLAWYQQKPGIAPRLLVSGATSLEAGVPSRFSGSGSGKNFTLSITSLQT
EDVATYYCQQYWSTPWTFGGGTTLEIR.
[0237] Another object of the invention is the anti-hGARP antibody
MHGARP8 or antigen binding fragment thereof comprising a heavy
chain variable region of sequence SEQ ID NO: 50 and a light chain
variable region of sequence SEQ ID NO: 51, wherein SEQ ID NO: 50
and SEQ ID NO: 51 correspond, respectively, to SEQ ID NO: 8 and SEQ
ID NO: 9 wherein the signal peptide sequences were removed.
TABLE-US-00030 (SEQ ID NO: 50)
QVQLKESGPGLVAPSQSLSITCTVSGFSLTGYGINWVRQPPGKGLEWLGM
IWSDGSTDYNSVLTSRLRISKDNSNSQVFLKMNSLQVDDTARYYCARDRN
YYDYDGAMDYWGQGTSVTVSS. (SEQ ID NO: 51)
DIQVTQSSSYLSVSLGDRVTITCKASDHIKNWLAWYQQKPGIAPRLLVSG
ATSLEAGVPSRFSGSGSGKNFTLSITSLQTEDVATYYCQQYWSTPWTFGG GTTLEIR.
[0238] Another object of the invention is the anti-hGARP antibody
LHG10 or antigen binding fragment thereof comprising a heavy chain
variable region of sequence SEQ ID NO: 34 and a light chain
variable region of sequence SEQ ID NO: 35.
TABLE-US-00031 (SEQ ID NO: 34)
EVQLVQPGAELRNSGASVKVSCKASGYRFTSYYIDWVRQAPGQGLEWMGR
IDPEDGGTKYAQKFQGRVTFTADTSTSTAYVELSSLRSEDTAVYYCARNE
WETVVVGDLMYEYEYWGQGTQVTVSS. (SEQ ID NO: 35)
DIQMTQSPTSLSASLGDRVTITCQASQSISSYLAWYQQKPGQAPKLLIYG
ASRLQTGVPSRFSGSGSGTSFTLTISGLEAEDAGTYYCQQYDSLPVTFGQ GTKVELK.
[0239] Another object of the invention is the anti-hGARP antibody
LHG10.3 or antigen binding fragment thereof comprising a heavy
chain variable region of sequence SEQ ID NO: 34 and a light chain
variable region of sequence SEQ ID NO: 36.
TABLE-US-00032 (SEQ ID NO: 36)
DIQMTQSPSSLSASLGDRVTITCQASQSIVSYLAWYQQKPGQAPKLLIYG
ASRLQTGVPSRFSGSGSGTSFTLTISGLEAEDAGTYYCQQYASAPVTFGQ GTGVELK.
[0240] Another object of the invention is the anti-hGARP antibody
LHG10.4 or antigen binding fragment thereof comprising a heavy
chain variable region of sequence SEQ ID NO: 34 and a light chain
variable region of sequence SEQ ID NO: 37.
TABLE-US-00033 (SEQ ID NO: 37)
DIQMTQSPSSLSASLGDRVTITCQASQSISSYLAWYQQKPGQAPKLLIYG
TSRLKTGVPSRFSGSGSGTSFTLTISGLEAEDAGTYYCQQYYSAPVTFGQ GTKVELK.
[0241] Another object of the invention is the anti-hGARP antibody
LHG10.5 or antigen binding fragment thereof comprising a heavy
chain variable region of sequence SEQ ID NO: 34 and a light chain
variable region of sequence SEQ ID NO: 38.
TABLE-US-00034 (SEQ ID NO: 38)
DIQMTQSPSSLSPSLGDRVTITCQASQTISSFLAWYHQKPGQPPKLLIYR
ASIPQTGVPSRFSGSGSGTSFTLTIGGLEAEDAGTYYCQQYVSAPPTFGQ GTKVELK.
[0242] Another object of the invention is the anti-hGARP antibody
LHG10.6 thereof comprising a heavy chain variable region of
sequence SEQ ID NO: 34 and a light chain variable region of
sequence SEQ ID NO: 39.
TABLE-US-00035 (SEQ ID NO: 39)
DIQMTQSPSSLSASLGDRVTITCQASQSISSYLAWYQQKPGQAPNILIYG
ASRLKTGVPSRFSGSGSGTSFTLTISGLEAEDAGTYYCQQYASVPVTFGQ GTKVELK.
[0243] In an embodiment of the invention, one, two, three or more
of the amino acids of the heavy chain or light chain variable
regions as described here above may be substituted by a different
amino acid.
[0244] In another embodiment, an antibody of the invention
comprises heavy and light chain variable regions comprising amino
acid sequences that are homologous to the amino acid sequences of
the MHGARP8 antibody described herein, wherein the antibodies
retain the desired functional properties of the protein of the
invention.
[0245] In an embodiment of the invention, the sequence of the heavy
chain variable region of an anti-hGARP antibody of the invention
encompasses sequences that have 60%, 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, 99% identity with SEQ ID NO: 8 or with SEQ ID NO:
50.
[0246] In an embodiment of the invention, the sequence of light
chain variable region of an anti-hGARP antibody of the invention
encompasses sequences that have 60%, 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, 99% identity with SEQ ID NO: 9 or with SEQ ID NO:
51.
[0247] In another embodiment, an antibody of the invention
comprises heavy and light chain variable regions comprising amino
acid sequences that are homologous to the amino acid sequences of
the LHG10 antibody described herein, and wherein the antibodies
retain the desired functional properties of the protein of the
invention.
[0248] In an embodiment of the invention, the sequence of the heavy
chain variable region of an anti-hGARP antibody of the invention
encompasses sequences that have 60%, 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, 99% identity with SEQ ID NO: 34.
[0249] In an embodiment of the invention, the sequence of light
chain variable region of an anti-hGARP antibody of the invention
encompasses sequences that have 60%, 70%, 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, 99% identity with SEQ ID NO: 35; 36; 37; 38 or
39.
[0250] In any of the antibodies of the invention, e.g. MHGARP8 or
LHG10, the specified variable region and CDR sequences may comprise
conservative sequence modifications. Conservative sequence
modifications refer to amino acid modifications that do not
significantly affect or alter the binding characteristics of the
antibody containing the amino acid sequence. Such conservative
modifications include amino acid substitutions, additions and
deletions. Modifications can be introduced into an antibody of the
invention by standard techniques known in the art, such as
site-directed mutagenesis and PCR-mediated mutagenesis.
Conservative amino acid substitutions are typically those in which
an amino acid residue is replaced with an amino acid residue having
a side chain with similar physicochemical properties. Specified
variable region and CDR sequences may comprise one, two, three,
four or more amino acid insertions, deletions or substitutions.
Where substitutions are made, preferred substitutions will be
conservative modifications Families of amino acid residues having
similar side chains have been defined in the art. These families
include amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g. glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine, tryptophan),
nonpolar side chains (e.g., alanine, valine, leucine, isoleucine,
proline, phenylalanine, methionine), beta-branched side chains
(e.g. threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one
or more amino acid residues within the CDR regions of an antibody
of the invention can be replaced with other amino acid residues
from the same side chain family and the altered antibody can be
tested for retained function (i.e., the properties set forth
herein) using the assays described herein. anti-hGARP antibodies
may also be CDR-grafted antibodies in which the CDRs are derived
from a camelid antibody, for example a camelid anti-hGARP antibody
raised by active immunization with hGARP.
[0251] In an embodiment, the invention provides an antibody that
binds essentially the same epitope as the MHGARP8 or LHG10
antibody.
[0252] In some embodiments of this invention, anti-hGARP antibodies
comprising VH and VL domains, or CDRs thereof may comprise CH1
domains and/or CL domains, the amino acid sequence of which is
fully or substantially human Where the antigen binding polypeptide
of the invention is an antibody intended for human therapeutic use,
it is typical for the entire constant region of the antibody, or at
least a part thereof, to have a fully or substantially human amino
acid sequence. Therefore, one or more or any combination of the CH1
domain, hinge region, CH2 domain, CH3 domain and CL domain (and CH4
domain if present) may be fully or substantially human with respect
to its amino acid sequence. Advantageously, the CH1 domain, hinge
region, CH2 domain, CH3 domain and CL domain (and CH4 domain if
present) may all have a fully or substantially human amino acid
sequence. In the context of the constant region of a humanized or
chimeric antibody, or an antibody fragment, the term "substantially
human" refers to an amino acid sequence identity of at least 90%,
or at least 95%, or at least 97%, or at least 99% with a human
constant region. The term "human amino acid sequence" in this
context refers to an amino acid sequence which is encoded by a
human immunoglobulin gene, which includes germline, rearranged and
somatically mutated genes. The invention also contemplates
polypeptides comprising constant domains of "human" sequence which
have been altered, by one or more amino acid additions, deletions
or substitutions with respect to the human sequence, excepting
those embodiments where the presence of a "fully human" hinge
region is expressly required. The presence of a "fully human" hinge
region in the anti-hGARP antibodies of the invention may be
beneficial both to minimize immunogenicity and to optimize
stability of the antibody. It is considered that one or more amino
acid substitutions, insertions or deletions may be made within the
constant region of the heavy and/or the light chain, particularly
within the Fc region Amino acid substitutions may result in
replacement of the substituted amino acid with a different
naturally occurring amino acid, or with a non-natural or modified
amino acid. Other structural modifications are also permitted, such
as for example changes in glycosylation pattern (e.g. by addition
or deletion of N- or O-linked glycosylation sites). Depending on
the intended use of the antibody, it may be desirable to modify the
antibody of the invention with respect to its binding properties to
Fc receptors, for example to modulate effector function. For
example cysteine residue(s) may be introduced in the Fc region,
thereby allowing interchain disulfide bond formation in this
region. The homodimeric antibody thus generated may have improved
effector function. See Caron et al., J. Exp. Med. 176: 1191-1195
(1992) and Shopes, B. J. Immunol. 148:2918-2922 (1992).
Alternatively, a GARP antibody can be engineered which has dual Fc
regions and may thereby have enhanced complement lysis and ADCC
capabilities. See Stevenson et al., Anti-Cancer Drug Design
3:219-230 (1989). The invention also contemplates immunoconjugates
comprising an antibody as described herein conjugated to a
cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an
enzymatically active toxin of bacterial, fungal, plant or animal
origin, or fragments thereof), or a radioactive isotope (i.e., a
radioconjugate). Fc regions may also be engineered for half-life
extension, as described by Chan and Carter, 2010 Nature Reviews:
Immunology, 10:301-316, incorporated herein by reference. Variant
anti-hGARP antibodies in which the Fc region is modified by protein
engineering, as described herein, may also exhibit an improvement
in efficacy (e.g. in therapeutics/diagnostics), as compared to an
equivalent antibody (i.e. equivalent antigen-binding properties)
without the Fc modification.
[0253] In yet another embodiment, the Fc region is modified to
increase the ability of the antibody to mediate antibody dependent
cellular cytotoxicity (ADCC) and/or to increase the affinity of the
antibody for an Fc.gamma. receptor by modifying one or more amino
acids. In still another embodiment, the glycosylation of an
antibody is modified. For example, an aglycoslated antibody can be
made (i.e., the antibody lacks glycosylation). Glycosylation can be
altered to, for example, increase the affinity of the antibody for
the GARP target antigen. Such carbohydrate modifications can be
accomplished by; for example, altering one or more sites of
glycosylation within the antibody sequence. For example, one or
more amino acid substitutions can be made that result in
elimination of one or more variable region framework glycosylation
sites to thereby eliminate glycosylation at that site. Such
aglycosylation may increase the affinity of the antibody for
antigen. Also envisaged are variant anti-hGARP antibodies having an
altered type of glycosylation, such as a hypofucosylated antibody
having reduced amounts of fucosyl residues or a non-fucosylated
antibody (as described by Natsume et al., 2009 Drug Design
Development and Therapy, 3:7-16) or an antibody having increased
bisecting GlcNac structures. Such altered glycosylation patterns
have been demonstrated to increase the ADCC activity of antibodies,
producing typically 10-fold enhancement of ADCC relative to an
equivalent antibody comprising a "native" human Fc domain. Such
carbohydrate modifications can be accomplished by, for example,
expressing the antibody in a host cell with altered glycosylation
enzymatic machinery (as described by Yamane-Ohnuki and Satoh, 2009
mAbs 1(3):230-236).
[0254] In an embodiment of the invention, the anti-hGARP antibody
comprises an Fc region having the sequence SEQ ID NO: 47.
TABLE-US-00036 (SEQ ID NO: 47)
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0255] In another embodiment of the invention, the anti-hGARP
antibody comprises the heavy chain constant domain region having
the sequence SEQ ID NO: 48, wherein X is N or is mutated into Q to
inhibit ADCC.
TABLE-US-00037 (SEQ ID NO: 48)
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYXSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0256] In an embodiment of the invention, the residue 297 of SEQ ID
NO: 48 is aglycosylated.
[0257] In another embodiment of the invention, the N residue at the
position 297 of SEQ ID NO: 48 is mutated into Q.
[0258] In an embodiment of the invention, the anti-hGARP antibody
comprises the light chain constant domain region having the
sequence SEQ ID NO: 49.
TABLE-US-00038 (SEQ ID NO: 49)
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGEC.
[0259] In further embodiments of the invention, anti-hGARP
antibodies may be lacking effector function, either because the Fc
region of the antibody is of an isotype which naturally lacks
effector function, or which exhibits significantly less potent
effector function than human IgG1, for example human IgG2 or human
IgG4, or because the Fc region of the antibody has been engineered
to reduce or substantially eliminate effector function, as
described in Armour K L, et al., Eur. J. Immunol., 1999,
29:2613-2624.
[0260] In further embodiments, the Fc region of the anti-hGARP
antibody may be engineered to facilitate the preferential formation
of bispecific antibodies, in which two antibody heavy chains
comprising different variable domains pair to form the Fc region of
the bispecific antibody. Examples of such modifications include the
"knobs-into-hole" modifications described by Ridgway J B, Presta L
G, Carter P., 1996 Protein Eng. July; 9(7):617-21 and Merchant A M,
et al. 1998 Nat Biotechnol. July; 16(7):677-81.
[0261] In an embodiment of the invention, the anti-hGARP antibody
of the invention may exhibit one or more effector functions
selected from antibody-dependent cell-mediated cytotoxicity (ADCC),
complement dependent cytotoxicity (CDC) and antibody-dependent
cell-mediated phagocytosis (ADCP) against cells expressing human
GARP protein on the cell surface. The antibody may exhibit ADCC
against GARP-related dysfunctional cells. The antibody may exhibit
enhanced ADCC function in comparison to a reference antibody which
is an equivalent antibody comprising a native human Fc domain. In a
non-limiting embodiment, the ADCC function may be at least
10.times. enhanced in comparison to the reference antibody
comprising a native human Fc domain. In this context "equivalent"
may be taken to mean that the antibody with enhanced ADCC function
displays substantially identical antigen-binding specificity and/or
shares identical amino acid sequence with the reference antibody,
except for any modifications made (relative to native human Fc) for
the purposes of enhancing ADCC. The antibody may contain the hinge
region, CH1 domain, CH2 domain and CH3 domain of a human IgG, most
preferably human IgG1. The antibody may include modifications in
the Fc region, such as for example substitutions, deletions or
insertion or other structural modifications to enhance or reduce
Fc-dependent functionalities.
[0262] One object of this invention relates to anti-hGARP
antibodies or antigen binding fragment thereof which inhibit
TGF-.beta. signaling, and that may be particularly suitable for
therapeutic applications which benefit from antibody effector
function, i.e. ADCC, CDC, ADCP, and in particular enhanced effector
function. Hence, the GARP antibodies described herein which exhibit
effector function (or enhanced effector function) and which inhibit
TGF-.beta. may be particularly advantageous for certain therapeutic
applications, e.g. cancer, chronic infection, and fibrosis
treatments which benefit from antibody effector function.
[0263] Another object of the invention is an isolated
polynucleotide sequence encoding the heavy chain variable region of
sequence SEQ ID NO: 8 or of SEQ ID NO: 50. Preferably, said nucleic
sequence is SEQ ID NO: 10:
TABLE-US-00039 ATGGCTGTCCTGGCATTACTCTTCTGCCTGGTAACATTCCCAAGCTGTAT
CCTTTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCT
CACAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACCGGC
TATGGTATAAACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCT
GGGAATGATATGGAGTGATGGAAGCACAGACTATAATTCAGTTCTCACAT
CCAGACTGAGGATCAGTAAGGATAATTCCAATAGCCAGGTTTTCTTAAAA
ATGAACAGTCTGCAAGTTGATGACACAGCCAGGTACTATTGTGCCAGAGA
TCGAAACTACTATGATTACGACGGGGCTATGGACTACTGGGGTCAAGGAA
CCTCAGTCACCGTCTCCTCA.
[0264] Another object of the invention is an isolated
polynucleotide sequence encoding the light chain variable region of
sequence SEQ ID NO: 9 or of SEQ ID NO: 51. Preferably, said nucleic
sequence is SEQ ID NO: 11:
TABLE-US-00040 ATGAAGTTTCCTTCTCAACTTCTGCTCTTCCTGCTGTTCAGAATCACAGG
CATAATATGTGACATCCAGGTGACACAATCTTCATCCTACTTGTCTGTAT
CTCTAGGAGACAGGGTCACCATTACTTGCAAGGCAAGTGACCACATTAAA
AATTGGTTAGCCTGGTATCAGCAGAAACCAGGAATTGCTCCTAGGCTCTT
AGTTTCTGGTGCAACCAGTTTGGAAGCTGGGGTTCCTTCAAGATTCAGTG
GCAGTGGATCTGGAAAGAATTTCACTCTCAGCATTACCAGTCTTCAGACT
GAAGATGTTGCTACTTATTACTGTCAACAGTATTGGAGTACACCGTGGAC
GTTCGGTGGAGGCACCACTCTGGAGATCAGA.
[0265] Another object of the invention is an expression vector
comprising the nucleic sequences encoding the anti-hGARP antibody
of the invention. In an embodiment, the expression vector of the
invention comprises at least one of SEQ ID NO: 10 and SEQ ID NO: 11
or any sequence having a nucleic acid sequence that shares at
least: 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%
identity with said SEQ ID NO: 10 and SEQ ID NO: 11.
[0266] Another object of the invention is an isolated host cell
comprising said vector. Said host cell may be used for the
recombinant production of the antibodies of the invention. In an
embodiment, host cells may be prokaryotic, yeast, or eukaryotic
cells, and are preferably mammalian cells, such as, for example:
monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney line (293 or 293 cells subcloned for growth
in suspension culture, Graham et al., J. Gen. Virol. 36:59 (1977));
baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary
cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216
(1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251
(1980)); mouse myeloma cells SP2/0-AG14 (ATCC CRL 1581; ATCC CRL
8287) or NSO (HPA culture collections no. 85110503); monkey kidney
cells (CV1 ATCC CCL 70); African green monkey kidney cells
(VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA,
ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat
liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC
CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor
(MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y.
Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human
hepatoma line (Hep G2), as well as DSM's PERC-6 cell line.
Expression vectors suitable for use in each of these host cells are
also generally known in the art. It should be noted that the term
"host cell" generally refers to a cultured cell line. Whole human
beings into which an expression vector encoding an antigen binding
polypeptide according to the invention has been introduced are
explicitly excluded from the definition of a "host cell".
[0267] Another object of the invention is a method of producing an
anti-hGARP antibody or antigen binding fragment thereof which
comprises culturing host cells containing the isolated
polynucleotide sequence encoding the anti-hGARP antibody under
conditions suitable for expression of the anti-hGARP antibody, and
recovering the expressed anti-hGARP antibody. This recombinant
process can be used for large scale production of GARP antibodies
according to the invention, including antibodies monoclonal
antibodies intended for in vitro, ex vivo, in vivo therapeutic,
diagnostic uses. These processes are available in the art and will
be known by the skilled person.
[0268] Another object of the invention is a hybridoma cell line
which can be used to produce said antibody of the invention.
[0269] A preferred hybridoma cell line according to the invention
was deposited with the BCCM/LMBP Plasmid Collection, Department of
Biomedical Molecular Biology, Ghent University, `Fiers-Schell-Van
Montagu` building, Technologiepark 927, B-9052 Gent--Zwijnaarde
BELGIUM (Table 2):
TABLE-US-00041 TABLE 2 Cell line Deposition No. Date of deposit
MHGARP8 LMBP 10246CB May 30, 2013 hybridoma
[0270] Fragments and derivatives of antibodies of this invention
(which are encompassed by the term "antibody" or "antibodies" as
used in this application, unless otherwise stated or clearly
contradicted by context), preferably a MHGARP8-like antibody, can
be produced by techniques that are known in the art. "Fragments"
comprise a region of the intact antibody, generally the antigen
binding site or variable region. Examples of antibody fragments
include Fab, Fab', Fab'-SH, F(ab')2, and Fv fragments; diabodies;
any antibody fragment that is a polypeptide having a primary
structure consisting of one uninterrupted sequence of contiguous
amino acid residues (referred to herein as a "single-chain antibody
fragment" or "single chain polypeptide"), including without
limitation (1) single-chain Fv molecules (2) single chain
polypeptides containing only one light chain variable domain, or a
fragment thereof that contains the three CDRs of the light chain
variable domain, without an associated heavy chain moiety and (3)
single chain polypeptides containing only one heavy chain variable
region, or a fragment thereof containing the three CDRs of the
heavy chain variable region, without an associated light chain
moiety; and multi-specific antibodies formed from antibody
fragments. Fragments of the present antibodies can be obtained
using standard methods. For instance, Fab or F(ab')2 fragments may
be produced by protease digestion of the isolated antibodies,
according to conventional techniques. It will be appreciated that
immune-reactive fragments can be modified using known methods, for
example to slow clearance in vivo and obtain a more desirable
pharmacokinetic profile the fragment may be modified with
polyethylene glycol (PEG). Methods for coupling and
site-specifically conjugating PEG to a Fab' fragment are described
in, for example, Leong et al, Cytokines 16 (3): 106-119 (2001) and
Delgado et al, Br. J. Cancer 73 (2): 175-182 (1996), the
disclosures of which are incorporated herein by reference.
[0271] Alternatively, the DNA of a hybridoma producing an antibody
of the invention, preferably a MHGARP8-like or LHG10-like antibody,
may be modified so as to encode a fragment of the invention. The
modified DNA is then inserted into an expression vector and used to
transform or transfect an appropriate cell, which then expresses
the desired fragment.
[0272] In certain embodiments, the DNA of a hybridoma producing an
antibody of this invention, preferably a MHGARP8-like or LHG10-like
antibody, can be modified prior to insertion into an expression
vector, for example, by substituting the coding sequence for human
heavy- and light-chain constant domains in place of the homologous
non-human sequences (e.g., Morrison et al., PNAS pp. 6851 (1984)),
or by covalently joining to the immunoglobulin coding sequence all
or part of the coding sequence for a non-immunoglobulin
polypeptide. In that manner, "chimeric" or "hybrid" antibodies may
be prepared that have the binding specificity of the original
antibody. Typically, such non-immunoglobulin polypeptides are
substituted for the constant domains of an antibody of the
invention.
[0273] Thus, according to another embodiment, the antibody of this
invention, preferably a MHGARP8 or LHG10-like antibody, is
humanized. "Humanized" forms of antibodies according to this
invention are specific chimeric immunoglobulins, immunoglobulin
chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or
other antigen-binding subsequences of antibodies) which contain
minimal sequence derived from the murine immunoglobulin. For the
most part, humanized antibodies are human immunoglobulins
(recipient antibody) in which residues from a
complementary-determining region (CDR) of the recipient are
replaced by residues from a CDR of the original antibody (donor
antibody) while maintaining the desired specificity, affinity, and
capacity of the original antibody.
[0274] In some instances, Fv framework (FR) residues of the human
immunoglobulin may be replaced by corresponding non-human residues.
Furthermore, humanized antibodies can comprise residues that are
not found in either the recipient antibody or in the imported CDR
or framework sequences. These modifications are made to further
refine and optimize antibody performance. In general, the humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the CDR regions correspond to those of the original antibody and
all or substantially all of the FR regions are those of a human
immunoglobulin consensus sequence. The humanized antibody optimally
also will comprise at least a region of an immunoglobulin constant
region (Fc), typically that of a human immunoglobulin. For further
details see Jones et al., Nature, 321, pp. 522 (1986); Reichmann et
al, Nature, 332, pp. 323 (1988); Presta, Curr. Op. Struct. Biol.,
3, pp. 394 (1992); Verhoeyen et al. Science, 239, pp. 1534; and
U.S. Pat. No. 4,816,567, the entire disclosures of which are herein
incorporated by reference. Methods for humanizing the antibodies of
this invention are well known in the art.
[0275] The choice of human variable domains, both light and heavy,
to be used in making the humanized antibodies is very important to
reduce antigenicity. According to the so-called "best-fit" method,
the sequence of the variable domain of an antibody of this
invention is screened against the entire library of known human
variable-domain sequences. The human sequence that is closed to the
mouse sequence is then accepted as the human framework (FR) for the
humanized antibody (Sims et al., J. Immunol. 151, pp. 2296 (1993);
Chothia and Lesk, J. Mol. Biol. 196, pp. 901). Another method uses
a particular framework from the consensus sequence of all human
antibodies of a particular subgroup of light or heavy chains. The
same framework can be used for several different humanized
antibodies (Carter et al., PNAS 89, pp. 4285 (1992); Presta et al.
J. Immunol., 151 (1993)). It is further important that antibodies
be humanized with retention of high affinity for GARP and other
favorable biological properties. To achieve this goal, according to
a preferred method, humanized antibodies are prepared by a process
of analysis of the parental sequences and various conceptual
humanized products using three-dimensional models of the parental
and humanized sequences. Three-dimensional immunoglobulin models
are commonly available and are familiar to those skilled in the
art. Computer programs are available which illustrate and display
probable three-dimensional structures of selected candidate
immunoglobulin sequences. Inspection of these displays permits
analysis of the likely role of the residues in the functioning of
the candidate immunoglobulin sequence, i.e., the analysis of
residues that influence the ability of the candidate immunoglobulin
to bind its antigen. In this way, FR residues can be selected and
combined from the consensus and import sequences so that the
desired antibody characteristic, such as increased affinity for the
target antigen(s), is achieved. In general, the CDR residues are
directly and most substantially involved in influencing antigen
binding. Another method of making "humanized" monoclonal antibodies
is to use a XenoMouse (Abgenix, Fremont, Calif.) as the mouse used
for immunization. A XenoMouse is a murine host according to this
invention that has had its immunoglobulin genes replaced by
functional human immunoglobulin genes. Thus, antibodies produced by
this mouse or in hybridomas made from the B cells of this mouse,
are already humanized. The XenoMouse is described in U.S. Pat. No.
6,162,963, which is herein incorporated in its entirety by
reference.
[0276] Human antibodies may also be produced according to various
other techniques, such as by using, for immunization, other
transgenic animals that have been engineered to express a human
antibody repertoire (Jakobovitz et al. Nature 362 (1993) 255), or
by selection of antibody repertoires using phage display methods.
Such techniques are known to the skilled person and can be
implemented starting from monoclonal antibodies as disclosed in the
present application.
[0277] In an embodiment, Camelidae hypervariable loops (or CDRs)
may be obtained by active immunization of a species in the family
Camelidae with a desired target antigen. As discussed and
exemplified in detail herein, following immunization of Camelidae
(either the native animal or a transgenic animal engineered to
express the immunoglobulin repertoire of a camelid species) with
the target antigen, B cells producing (conventional Camelidae)
antibodies having specificity for the desired antigen can be
identified and polynucleotide encoding the VH and VL domains of
such antibodies can be isolated using known techniques.
[0278] In an embodiment, the invention provides a recombinant
antigen binding polypeptide immunoreactive with a target antigen,
the polypeptide comprising a VH domain and a VL domain, wherein at
least one hypervariable loop or complementarity determining region
in the VH domain or the VL domain is obtained from a VH or VL
domain of a species in the family Camelidae, which antigen binding
polypeptide is obtainable by a process comprising the steps of:
[0279] (a) immunizing a species in the family Camelidae with a
target antigen or with a polynucleotide encoding said target
antigen and raising an antibody to said target antigen; [0280] (b)
determining the nucleotide sequence encoding at least one
hypervariable loop or complementarity determining region (CDR) of
the VH and/or the VL domain of a Camelidae conventional antibody
immunoreactive with said target antigen; and [0281] (c) expressing
an antigen binding polypeptide immunoreactive with said target
antigen, said antigen binding polypeptide comprising a VH and a VL
domain, wherein at least one hypervariable loop or complementarity
determining region (CDR) of the VH domain or the VL domain has an
amino acid sequence encoded by the nucleotide sequence determined
in part (a).
[0282] Isolated Camelidae VH and VL domains obtained by active
immunization can be used as a basis for engineering antigen binding
polypeptides according to the invention. Starting from intact
Camelidae VH and VL domains, it is possible to engineer one or more
amino acid substitutions, insertions or deletions which depart from
the starting Camelidae sequence.
[0283] In an embodiment, such substitutions, insertions or
deletions may be present in the framework regions of the VH domain
and/or the VL domain. The purpose of such changes in primary amino
acid sequence may be to reduce presumably unfavourable properties
(e.g. immunogenicity in a human host (so-called humanization),
sites of potential product heterogeneity and or instability
(glycosylation, deamidation, isomerization, etc.) or to enhance
some other favourable property of the molecule (e.g. solubility,
stability, bioavailability, etc.).
[0284] In another embodiment, changes in primary amino acid
sequence can be engineered in one or more of the hypervariable
loops (or CDRs) of a Camelidae VH and/or VL domain obtained by
active immunization. Such changes may be introduced in order to
enhance antigen binding affinity and/or specificity, or to reduce
presumably unfavourable properties, e g immunogenicity in a human
host (so-called humanization), sites of potential product
heterogeneity and or instability, glycosylation, deamidation,
isomerization, etc., or to enhance some other favourable property
of the molecule, e.g. solubility, stability, bioavailability,
etc.
[0285] The antibodies of the present invention, preferably a
MHGARP8 or LHG10-like antibody, may also be derivatized to
"chimeric" antibodies (immunoglobulins) in which a region of the
heavy/light chain(s) is identical with or homologous to
corresponding sequences in the original antibody, while the
remainder of the chain(s) is identical with or homologous to
corresponding sequences in antibodies derived from another species
or belonging to another antibody class or subclass, as well as
fragments of such antibodies, so long as they exhibit the desired
biological activity and binding specificity (Cabilly et al., supra;
Morrison et al., Proc. Natl. Acad. Sci., pp. 6851 (1984)).
[0286] An object of the invention is a composition comprising at
least one of the protein of the invention as described here
above.
[0287] Another object of the invention is a pharmaceutical
composition comprising at least one of the protein of the invention
as described here above and a pharmaceutically acceptable
excipient.
[0288] Pharmaceutically acceptable excipients that may be used in
these compositions include, but are not limited to, ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, such as human
serum albumin, buffer substances such as phosphates, glycine,
sorbic acid, potassium sorbate, partial glyceride mixtures of
saturated vegetable fatty acids, water, salts or electrolytes, such
as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances (for example sodium carboxymethylcellulose),
polyethylene glycol, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, polyethylene glycol
and wool fat.
[0289] Another object of the invention is the protein of the
invention for inhibiting TGF-.beta. activity in a subject in need
thereof.
[0290] Another object of the invention is a method for inhibiting
TGF-.beta. activity in a subject in need thereof, comprising
administering to the subject an effective amount of the protein of
the invention.
[0291] Another object of the invention is the protein of the
invention or the pharmaceutical composition as defined here above
for treating a TGF-.beta.-related disorder in a subject in need
thereof.
[0292] Another object of the invention is a method for treating a
TGF-.beta.-related disorder in a subject in need thereof,
comprising administering to the subject an effective amount of the
protein of the invention.
[0293] Diseases or disorders where the methods of the invention can
be used include all diseases where inhibition of TGF-.beta. can be
beneficial.
[0294] Said TGF-.beta.-related disorders include, but are not
limited to, inflammatory diseases, chronic infection, cancer,
fibrosis, cardiovascular diseases, cerebrovascular disease (e.g.
ischemic stroke), and neurodegenerative diseases.
[0295] For use in administration to a subject, the composition will
be formulated for administration to the subject. The compositions
of the present invention may be administered orally, parenterally,
by inhalation spray, topically, rectally, nasally, buccally,
vaginally or via an implanted reservoir. The term administration
used herein includes subcutaneous, intravenous, intramuscular,
intra-articular, intra-synovial, intrasternal, intrathecal,
intrahepatic, intralesional and intracranial injection or infusion
techniques.
[0296] Sterile injectable forms of the compositions of this
invention may be aqueous or an oleaginous suspension. These
suspensions may be formulated according to techniques known in the
art using suitable dispersing or wetting agents and suspending
agents. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium. For
this purpose, any bland fixed oil may be employed including
synthetic mono- or diglycerides. Fatty acids, such as oleic acid
and its glyceride derivatives are useful in the preparation of
injectables, as are natural pharmaceutically acceptable oils, such
as olive oil or castor oil, especially in their polyoxyethylated
versions. These oil solutions or suspensions may also contain a
long-chain alcohol diluent or dispersant, such as carboxymethyl
cellulose or similar dispersing agents that are commonly used in
the formulation of pharmaceutically acceptable dosage forms
including emulsions and suspensions. Other commonly used
surfactants, such as Tweens, Spans and other emulsifying agents or
bioavailability enhancers which are commonly used in the
manufacture of pharmaceutically acceptable solid, liquid, or other
dosage forms may also be used for the purposes of formulation.
[0297] Schedules and dosages for administration of the antibody in
the pharmaceutical compositions of the present invention can be
determined in accordance with known methods for these products, for
example using the manufacturers' instructions. For example, an
antibody present in a pharmaceutical composition of this invention
can be supplied at a concentration of 10 mg/mL in either 100 mg (10
mL) or 500 mg (50 mL) single-use vials. The product is formulated
for intravenous (IV) administration in 9.0 mg/mL sodium chloride,
7.35 mg/mL sodium citrate dihydrate, 0.7 in g/mL polysorbate 80,
and Sterile Water for Injection. The pH is adjusted to 6.5. It will
be appreciated that these schedules are exemplary and that an
optimal schedule and regimen can be adapted taking into account the
affinity and tolerability of the particular antibody in the
pharmaceutical composition that must be determined in clinical
trials.
[0298] Another object of the invention is a method for reducing
immunosuppression in the tumor environment in a subject in need
thereof, comprising administering to the subject a therapeutically
effective amount of the protein of the invention.
[0299] Another object of the invention is a method for boosting the
immune system in a subject in need thereof, comprising
administering to the subject a therapeutically effective amount of
the protein of the invention.
[0300] Another object of the invention is a method for inhibiting
the immune suppressive function of human Tregs in a subject in need
thereof, comprising administering to the subject a therapeutically
effective amount of the protein of the invention.
[0301] Another object of the invention is a method for treating
cancer in a subject in need thereof, comprising administering to
the subject a therapeutically effective amount of the protein of
the invention.
[0302] Another object of the invention is a method for treating
cancer in a subject in need thereof, wherein the pharmaceutical
composition of the invention is to be administered as an
immunostimulatory antibody for treatment of cancer patients.
[0303] Another object of the invention is a method for treating
cancer in a subject in need thereof, comprising administering to
the subject a therapeutically effective amount of the protein of
the invention in combination with another treatment for cancer or
an immunotherapeutic agent.
[0304] Another object of the invention is a combination of the
protein of the invention and another treatment for cancer or
another immunotherapeutic agent for treating or for use in treating
cancer.
[0305] In an embodiment of the invention, said immunotherapeutic
agent is a tumor vaccine.
[0306] In another embodiment of the invention, said
immunotherapeutic agent is an immunostimulatory antibody.
[0307] Without willing to be bound to a theory, the inventors
believe the protein of the invention will prevent immunosuppression
in the tumor environment, thereby increasing the efficacy of the
immunotherapeutic agent.
[0308] Various cancers can be treated by the present invention such
as for an adrenocortical carcinoma, anal cancer, bladder cancer,
brain tumor, glioma, breast carcinoma, carcinoid tumor, cervical
cancer, colon carcinoma, endometrial cancer, esophageal cancer,
extrahepatic bile duct cancer, Ewing's tumor, extracranial germ
cell tumor, eye cancer, gall bladder cancer, gastric cancer, germ
cell tumor, gestational trophoblastic tumor, head and neck cancer,
hypopharyngeal cancer, islet cell carcinoma, kidney cancer,
laryngeal cancer, leukemia, lip and oral cavity cancer, liver
cancer, lung cancer, lymphoma, melanoma, mesothelioma, merkel cell
carcinoma, metastatic squamous head and neck cancer, myeloma,
neoplasm, nasopharyngeal cancer, neuroblastoma, oral cancer,
oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic
cancer, sinus and nasal cancer, parathyroid cancer, penile cancer,
pheochromocytoma cancer, pituitary cancer, plasma cell neoplasm,
prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell
carcinoma, salivary gland cancer, skin cancer, Kaposi's sarcoma,
T-cell lymphoma, soft tissue sarcoma, stomach cancer, testicular
cancer, thymoma, thyroid cancer, urethral cancer, uterine cancer,
vaginal cancer, vulvar cancer, or Wilms' tumor.
[0309] Suitable tumor antigens for use as a tumor vaccine known in
the art include for example: (a) cancer-testis antigens such as
NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family
polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3,
MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for
example, to address melanoma, lung, head and neck, NSCLC, breast,
gastrointestinal, and bladder tumors), (b) mutated antigens, for
example, p53 (associated with various solid tumors, e.g.,
colorectal, lung, head and neck cancer), p21/Ras (associated with,
e.g., melanoma, pancreatic cancer and colorectal cancer), CD 4
(associated with, e.g., melanoma), MUM 1 (associated with, e.g.,
melanoma), caspase-8 (associated with, e.g., head and neck cancer),
CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701,
beta catenin (associated with, e.g., melanoma), TCR (associated
with, e.g., T-cell non-Hodgkins lymphoma), BCR-ab1 (associated
with, e.g., chronic myelogenous leukemia), triosephosphate
isomerase, IA 0205, CDC-27, and LDLR-FUT, (c) over-expressed
antigens, for example, Galectin 4 (associated with, e.g.,
colorectal cancer), Galectin 9 (associated with, e.g., Hodgkin's
disease), proteinase 3 (associated with, e.g., chronic myelogenous
leukemia), WT 1 (associated with, e.g., various leukemias),
carbonic anhydrase (associated with, e.g., renal cancer), aldolase
A (associated with, e.g., lung cancer), PRAME (associated with,
e.g., melanoma), HER-2/neu (associated with, e.g., breast, colon,
lung and ovarian cancer), alpha-fetoprotein (associated with, e.g.,
hepatoma), SA (associated with, e.g., colorectal cancer), gastrin
(associated with, e.g., pancreatic and gastric cancer), telomerase
catalytic protein, MUC-1 (associated with, e.g., breast and ovarian
cancer), G-250 (associated with, e.g., renal cell carcinoma), and
carcinoembryonic antigen (associated with, e.g., breast cancer,
lung cancer, and cancers of the gastrointestinal tract such as
colorectal cancer), (d) shared antigens, for example,
melanoma-melanocyte differentiation antigens such as MART-1/Melan
A, gp100, MC1R, melanocyte-stimulating hormone receptor,
tyrosinase, tyrosinase related protein-1/TRP1 and tyrosinase
related protein-2/TRP2 (associated with, e.g., melanoma), (e)
prostate associated antigens such as PAP, PSA, PSMA, PSH-P1,
PSM-P1, PSM-P2, associated with e.g., prostate cancer, (f)
immunoglobulin idiotypes (associated with myeloma and B cell
lymphomas, for example), and (g) other tumor antigens, such as
polypeptide- and saccharide-containing antigens including (i)
glycoproteins such as sialyl Tn and sialyl Le<x> (associated
with, e.g., breast and colorectal cancer) as well as various
mucins; glycoproteins may be coupled to a carrier protein (e.g.,
MUC-1 may be coupled to LH); (ii) lipopolypeptides (e.g., MUC-1
linked to a lipid moiety); (iii) polysaccharides (e.g., Globo H
synthetic hexasaccharide), which may be coupled to a carrier
proteins (e.g., to KLH), (iv) gangliosides such as GM2, GM12, GD2,
GD3 (associated with, e.g., brain, lung cancer, melanoma), which
also may be coupled to carrier proteins (e.g., KLH). Other tumor
antigens include pi 5, Hom/Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK,
MYL-RAR, Epstein Barr virus antigens, EBNA, human papillomavirus
(HPV) antigens, including E6 and E7, hepatitis B and C virus
antigens, human T-cell lymphotropic virus antigens, TSP-180,
p185erbB2, p180erbB-3, c-met, mn-23H 1, TAG-72-4, CA 19-9, CA 72-4,
CAM 17.1, NuMa, K-ras, p 16, TAGE, PSCA, CT7, 43-9F, 5T4, 791
Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA
195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, Ga733 (EpCAM),
HTgp-175, M344, MA-50, MG7-Ag, MOV 18, NB/70K, NY-CO-1, RCAS1,
SDCCAG16, TA-90 (Mac-2 binding protein\cyclophilin C-associated
protein), TAAL6, TAG72, TLP, TPS, and the like.
[0310] Suitable immunostimulatory antibodies include, but are not
limited to: anti-CTLA-4, anti-PD1, anti-PDL1 and anti-KIR
antibodies.
[0311] In an embodiment of the invention, the method for treating
cancer in a subject in need thereof, comprises administering to the
subject the protein of the invention prior to, concurrent to and/or
posterior to another anti-cancer agent or cancer treatment, such as
chemotherapy treatment.
[0312] Another object of the present invention is a method to
prevent infectious diseases such as HIV, malaria, or Ebola, or
improve vaccination against these infections, comprising
administering to the subject a therapeutically effective amount of
the protein of the invention.
[0313] In an embodiment, the protein of the invention may be used
in vitro or in vivo to identify samples, tissues, organs or cells
that express GARP.
[0314] Examples of assays in which the protein of the invention may
be used, include, but are not limited to, ELISA, sandwich ELISA,
RIA, FACS, tissue immunohistochemistry, Western-blot, and
immunoprecipitation.
[0315] In an embodiment of the invention, the sample is a
biological sample. Examples of biological samples include, but are
not limited to, bodily fluids, preferably blood, more preferably
blood serum, plasma, synovial fluid, bronchoalveolar lavage fluid,
sputum, lymph, ascitic fluids, urine, amniotic fluid, peritoneal
fluid, cerebrospinal fluid, pleural fluid, pericardial fluid, and
alveolar macrophages, tissue lysates and extracts prepared from
diseased tissues.
[0316] In an embodiment of the invention, the term "sample" is
intended to mean a sample taken from an individual prior to any
analysis.
[0317] In another embodiment, the protein of the invention may be
labeled for diagnostic or detection purposes. By labeled herein is
meant that a compound has at least one element, isotope or chemical
compounds attached to enable the detection of the compound.
Examples of labels include, but are not limited to, isotopic labels
such as radioactive or heavy isotopes; magnetic, electric or
thermal labels and colored or luminescent dyes. For example:
lanthanide complexes, quantum dots, fluorescein, rhodamine,
tetramethylrhodamine, eosin, erythrosin, coumarin,
methyl-coumarins, pyrene, malachite green, stilbene, Lucifer
yellow, cascade blue, texas red, alexa dyes, cy dyes.
[0318] One object of the invention is a method for identifying
activated Tregs in a sample based on the use of the protein of the
invention.
[0319] Another object of the invention is a method for identifying
soluble or complexed latent TGF-.beta. based on the use of the
protein of the invention.
[0320] Another object of the invention is a kit comprising at least
one protein of the invention.
[0321] By "kit" is intended any manufacture (e.g., a package or a
container) comprising at least one reagent, i.e. for example an
antibody, for specifically detecting the expression of GARP. The
kit may be promoted, distributed, or sold as a unit for performing
the methods of the present invention. Furthermore, any or all of
the kit reagents may be provided within containers that protect
them from the external environment, such as in sealed containers.
The kits may also contain a package insert describing the kit and
methods for its use.
[0322] Kits for performing the sandwich ELISA methods of the
invention generally comprise a capture antibody, optionally
immobilized on a solid support (e.g., a microtiter plate), and a
revelation antibody coupled with a detectable substance, such as,
for example HRP, a fluorescent label, a radioisotope,
beta-galactosidase, and alkaline phosphatase.
EXAMPLES
[0323] The present invention is further illustrated by the
following examples.
Example 1
New Monoclonal Antibodies Directed Against Human GARP (Anti-hGARP
Monoclonals)
[0324] DBA/2 or Balb/c mice were immunized with murine P1HTR cells
transfected with human GARP. Sera from immunized mice were tested
for the presence of anti-hGARP antibodies, by screening for binding
to hGARP-expressing BW cells by FACS. Splenocytes from mice with
high titers of anti-hGARP antibodies were fused to SP2/neo cells.
Hybridomas were selected in HAT medium and cloned under limiting
dilution. Supernatants of +/-1600 hybridoma clones were screened by
FACS for the presence of antibodies binding to hGARP-expressing BW
cells. Thirty-eight clones producing anti-hGARP monoclonal
antibodies were identified in this screening. Nine clones were
selected and amplified for large scale-production and purification
of nine new anti-hGARP monoclonals (MHGARP1 to 9).
[0325] As shown in FIG. 1, MHGARP1 to 9 bind to murine BW5147 cells
transfected with hGARP, but not to untransfected cells. MHGARP1 to
9 also bind 293T cells transfected with hGARP and two human T cells
lines (clone Th A2 and Jurkat) transduced with a hGARP-encoding
lentivirus, but not the corresponding parental cells (not shown).
This recognition pattern is identical to that of a commercially
available anti-hGARP mAb (clone Plato-1) used here as a positive
control. These results show that MHGARP1 to 9 recognize hGARP on
cell surfaces.
[0326] As shown in FIG. 7, five additional MHGARP antibodies were
produced and purified. MHGARP antibodies (MHG-1 to -14 on the
figure) do not bind clone ThA2 (human CD4+ T helper cells, which do
not express hGARP), but bind ThA2 transduced with hGARP.
Example 2
MHGARP8, but None of 12 Other Anti-hGARP Monoclonals, Inhibits
Active TGF-.beta. Production by Human Treg Cells
[0327] A human Treg clone (1E+06 cells/ml) was stimulated in
serum-free medium with coated anti-CD3 (1 .mu.g/ml) and soluble
anti-CD28 (1 .mu.g/ml) antibodies, in the presence or absence of 20
.mu.g/ml of an anti-hGARP monoclonal antibody. Thirteen anti-hGARP
monoclonals were tested in this assay: the above mentioned nine new
monoclonals (MHGARP1 to 9), and commercially available antibody
clones Plato-1 (Enzo Life Sciences, catalog No. ALX-804-867), 272G6
(Synaptic Systems, catalog No. 221 111), 50G10 (Synaptic Systems,
catalog No. 221 011) and 7B11 (BioLegend, catalog No. 352501).
Cells were collected after 24 hours, lysed and submitted to
SDS-PAGE under reducing conditions. Gels were blotted on
nitrocellulose membranes with the iBlot system (Life Technologies).
After blocking, membranes were hybridized with primary antibodies
directed against phosphorylated SMAD2 (pSMAD2, Cell Signaling
Technologies) or .beta.-ACTIN (SIGMA), then hybridized with
secondary HRP-coupled antibodies and revealed with Enhanced
ChemiLuminescent (ECL) substrate (ThermoFisher Scientific). The
presence of pSMAD2 indicates production of active TGF-.beta.1 by
the stimulated Treg clone. ECL signals were quantified by measuring
the density of the 55 kDa pSMAD2 and 40 kDa .beta.-ACTIN bands on
autoradiographs, using the Image J software.
[0328] To examine whether hGARP is required for active TGF-.beta.
production by TCR-stimulated Treg cells, a human Treg clone was
stimulated through its T cell receptor (TCR), alone or in the
presence of anti-hGARP mAbs. Active TGF-.beta. produced by
stimulated Tregs triggers an autocrine signal, which leads to the
phosphorylation and activation of SMAD2 and SMAD3 transcription
factors. The presence of phosphorylated SMAD2 (pSMAD2) was measured
by Western Blot (WB) as read-out for active TGF-.beta. production
by the stimulated Treg clone. As shown in FIG. 2, pSMAD2 was
reduced more than 10 fold in the presence of MHGARP8. This
reduction is similar to that observed in the presence of an
anti-TGF-.beta. mAb, used here as a positive control. None of the
twelve other anti-hGARP mAbs (eight other in-house produced MHGARP
and four commercially available anti-GARP antibodies) inhibited
active TGF-.beta. production by the Treg clone. Altogether, our
data demonstrate that GARP is required for active TGF-.beta.
production by human Tregs, as MHGARP8, an antibody directed against
hGARP, prevented active TGF-.beta. production.
Example 3
MHGARP8, but not Other Anti-hGARP mAbs, Recognizes a Conformational
Epitope that Requires the Presence of TGF-.beta.
Mapping the Regions Recognized by Anti-hGARP Monoclonals
[0329] Murine BW5147 T cells were electroporated with plasmids
encoding the HA-tagged proteins schematized in FIG. 3, part A,
corresponding to hGARP, mGARP or mGARP/hGARP chimeras. Stable
clones selected in neomycin were stained with biotinylated
anti-hGARP antibodies (anti-hGARP1 to 9) and streptavidin-PE, with
the commercial anti-hGARP antibody (clone Plato-1) and a secondary
anti-mIgG2b-AF488, or with an anti-HA antibody and secondary
anti-mouse IgG1-AF488. Histograms are gated on live cells. Black
histograms show signals on untransfected BW cells, white histograms
show signals on BW cells expressing the HA-tagged hGARP, and grey
histograms show signals on BW cells expressing HA-tagged mGARP or
mGARP/hGARP chimeras.
[0330] Parental BW5147 T cells (BW non-transfected) or clones
stably transfected with hGARP alone (BW+hGARP) or with hTGFB1
(BW+hGARP+hTGF-131) were stained with biotinylated anti-hGARP
antibodies (anti-hGARP1 to 9) and streptavidin-PE, with the
commercial anti-hGARP antibody (clone Plato-1) and a secondary
anti-mIgG2b-AF488, or with anti-mLAP-AF647 or anti-hLAP-APC
antibodies.
[0331] The mechanism by which MHGARP8, but not other anti-hGARP
mAbs, inhibits active TGF-.beta. production by Tregs was
investigated. It was hypothesized that MHGARP8 may recognize an
epitope in hGARP that is distinct from the epitopes recognized by
the other anti-hGARP mAbs.
[0332] With the exception of MHGARP-1, the MHGARP mAbs of the
instant application do not recognize murine GARP (mGARP). Plasmids
were therefore constructed encoding HA-tagged hGARP, mGARP or
hGARP/mGARP chimeras to map the hGARP regions recognized by the
mAbs of the instant application. Murine BW cells were transfected
and stable clones were derived expressing the HA-tagged proteins
(schematically represented in FIG. 3). All clones expressed similar
levels of HA-tagged protein on the surface, as indicated by similar
fluorescence intensities after staining with an anti-HA mAb (FIG.
3, part A). As expected, all the MHGARP mAbs bound to the clone
expressing HA-tagged hGARP, whereas none, except MHGARP-1, bound to
the clone expressing HA-tagged mGARP. Four groups of mAbs emerged
from the analysis of binding to the HA-tagged hGARP/mGARP chimeras
(FIG. 3, part A). Monoclonal antibodies in the first group
(MHGARP-6, -7 and -9) bound none of the chimeras, indicating that
they recognize an epitope located between aa 20 and 101 of hGARP
(region 20-101). mAbs in the second group (MHGARP-2, -3 and -8)
bound to only 1 of the 5 chimeras, and thus recognize an epitope in
region 101-141. A third group comprises MHGARP-5, which bound to 2
of the chimeras and therefore recognizes region 141-207. This group
probably also contains MHGARP-1, which is cross-reactive but bound
these 2 chimeras more efficiently than it bound mGARP or the 3
other chimeras. Finally, mAbs in the fourth group (MHGARP-4 and
Plato-1) bound 4 of the 5 chimeras, and thus recognize region
265-333.
[0333] Based on the above, the anti-hGARP mAbs were grouped into
four families of antibodies that recognize four distinct regions of
the hGARP protein. MHGARP-8, which displays neutralizing activity,
binds to region 101-141. This region is also recognized by MHGARP-2
and -3, which are not neutralizing. Therefore, the ability to bind
region 101-141 is not sufficient to confer neutralizing
activity.
[0334] To further define the epitopes recognized by MHGARP-2, -3
and -8, the binding of the anti-hGARP antibodies was compared to
clones of BW cells expressing hGARP alone (BW+hGARP), or hGARP and
hTGF-.beta.1 (BW+hGARP+hTGF-.beta.1). With the notable exception of
MHGARP8, all anti-hGARP antibodies stained BW+hGARP+hTGF-.beta.1
with the same intensity as BW+hGARP, indicating that the two clones
express the same levels of hGARP on the cell surface. The MHGARP8
antibody in contrast, stained BW+hGARP+hTGF-.beta.1 more intensely
than BW+hGARP (FIG. 3, part B). This indicates that although hGARP
levels are similar on the two clones, the epitope recognized by
MHGARP8 is more abundant on BW+hGARP+hTGF-.beta.1 than on BW+hGARP
cells.
[0335] A plausible explanation for this observation is that the
epitope recognized by MHGARP8 appears only when hGARP is bound to
murine (m) or human (h) TGF-.beta.1. This could be due to one of
two mechanisms: either the epitope comprises amino-acids from both
hGARP and TGF-.beta.1 (mixed conformational epitope), or it
comprises amino-acids from hGARP only, but that adopt a different
conformation in the presence of TGF-.beta.1 (binding-induced
conformational epitope). BW cells express murine TGF-.beta.1, and
murine TGF-.beta.1 binds to hGARP (FIG. 3, part B). Therefore,
binding of MHGARP8 to BW+hGARP (in the absence of transfected
hTGF-.beta.1) could be due to recognition of hGARP/mTGF-.beta.1
complexes.
[0336] To explore the hypothesis that MHGARP8 recognizes GARP when
it is bound to TGF-.beta.1, co-immunoprecipitation experiments were
performed. The different anti-GARP antibodies were used to
immunoprecipitate GARP from BW+hGARP+hTGF-.beta.1 cells, then
analyzed to determine if TGF-.beta. was co-immunoprecipitated with
GARP. As shown in FIG. 3, part C, all anti-GARP antibodies
efficiently immunoprecipitated GARP (FIG. 3, part C, top panels).
Co-immunoprecipitation of TGF-.beta.1 was observed with MHGARP-6,
-7, -8, and -9 mAbs, indicating that these antibodies bind GARP
bound to TGF-.beta.1. In contrast, MHGARP-1, -2, -3, -4 and -5
immunoprecipitated GARP as efficiently as the other anti-GARP mAbs,
but they did not co-immunoprecipitate TGF-.beta. (FIG. 3, part C,
bottom panels). This indicates that MHGARP-1, -2, -3, -4 and -5
recognize free GARP, but not GARP that is bound to TGF-.beta.. It
is important to note that MHGARP-2 and -3, which require the
GARP.sub.101-141 region for binding, recognize only free GARP,
whereas neutralizing MHGARP8, which also requires GARP.sub.101-141,
recognizes GARP bound to TGF-.beta..
[0337] To confirm this observation, 293T cells, which express low
levels of endogenous TGF-131, were used to co-transfect hGARP with
increasing amounts of hTGFB1 (FIG. 3, part D). Binding of MHGARP-1,
-2, -3, -4 and -5 decreased dose-dependently when hTGFB1 was
co-transfected with hGARP. It was completely abrogated at the
highest doses of hTGFB1. This confirms that MHGARP-1 to -5 bind
only free GARP. Binding of MHGARP-6, -7, and -9 was not modified by
co-transfection of hTGFB1, indicating that these mAbs bind hGARP
whether or not it is bound to TGF-.beta.1 (i.e. they bind both free
GARP and GARP bound to TGF-.beta.1). In striking contrast, binding
of MHGARP8 increased dose-dependently when hTGFB1 was
co-transfected with hGARP. This suggests again that in contrast to
all other antibodies, MHGARP8 does not bind free GARP, but only
GARP bound to TGF-.beta.1.
[0338] To demonstrate that MHGARP8 binding requires the presence of
TGF-.beta.1, siRNAs were used to silence the expression of TGFB1 in
Jurkat cells transduced with hGARP (FIG. 3, part E). The siRNA
against TGFB1 mRNA efficiently reduced expression of TGF-.beta.1,
as illustrated by the decrease in surface LAP detected on
Jurkat+hGARP cells (FIG. 3, part E, right panel). Reduced
expression of TGF-.beta.1 in Jurkat+hGARP decreased the binding of
the MHGARP8 antibody, but it did not modify the binding of the
other anti-GARP antibodies (FIG. 3, part E, foreground histograms).
This confirms that in contrast to the other anti-GARP antibodies,
MHGARP8, does not bind free GARP, but only binds GARP in the
presence of TGF-.beta.1.
[0339] Finally, the unlikely hypothesis that presentation of
TGF-.beta. on the cell surface, irrespective of hGARP expression,
is sufficient for binding by MHGARP8, was evaluated. In other
words, whether MHGARP8 recognizes a mixed or a binding-induced
conformational epitope that requires expression of both hGARP and
TGF-.beta. was analyzed. For this, 293T cells were transfected with
constructs encoding hGARP, mGARP or the hGARP/mGARP chimeras
described above, with or without a construct encoding hTGF-.beta.1.
Transfected cells were analyzed by FACS to measure binding of the
MHGARP8 antibody, and presentation of hTGF-B1 on the cell surface
with an anti-hLAP antibody (FIG. 4). By comparison to
unstransfected cells, transfection of hGARP, mGARP or hGARP/mGARP
constructs alone (no hTGFB1) induced low levels of surface LAP, due
to low levels of endogenous hTGFB1 expression (FIG. 4, part A,
left). Surface LAP levels dramatically increased upon transfection
of hTGFB1 in cells transfected with hGARP, mGARP, or any
hGARP/mGARP construct (FIG. 4, part B, left histogram). This
indicates that hTGF-.beta.1 is presented on the cell surface by
hGARP, by mGARP and by all the hGARP/mGARP chimeras Importantly,
MHGARP8 bound only to the surface of cells transfected with hGARP,
or with the hGARP/mGARP constructs encoding amino-acids 101 to 141
of hGARP (FIG. 4, part A B, right). It did not bind to cells
transfected with hTGFB1 and mGARP, nor to cells transfected with
hTGFB1 and hGARP/mGARP constructs that do not encode hGARP101-141
(FIG. 4, part B, right), although these cells presented high levels
of LAP on their surface (FIG. 4, part B, left). This demonstrates
that presentation of TGF-.beta.1 on the cell surface (by mGARP or
hGARP/mGARP chimeras) is not sufficient for binding by MHGARP8.
Binding of MHGARP8 requires the presence of both hGARP (region
101-141) and TGF-.beta.1 on the cell surface.
[0340] As indicated above, MHGARP8 does not bind mGARP. Its binding
to hGARP requires a region comprising amino-acids 101 to 141. To
further define the epitope recognized by MHGARP8, the sequences of
region 101-141 in human and murine GARP were compared. In this
region, only 13 amino-acids differ between hGARP and mGARP (FIG. 5,
amino-acids highlighted by grey boxes). Three HA-tagged mutant
forms of hGARP were constructed. In each mutant (Mut I, Mut II and
Mut III), three consecutive amino-acids were replaced by the
corresponding amino-acids of the mGARP protein (FIG. 5, black
boxes). Stable clones of BW cells transfected with these HA-tagged
forms of wild type (WT) or mutant hGARP were derived. All clones
expressed similar levels of HA-tagged protein on the surface, as
demonstrated by staining with an anti-HA antibody (FIG. 5,
histograms on the right). The clones were then analyzed after
staining with MHGARP-2, -3 and -8, i.e., antibodies which require
region 101-141 of hGARP for binding. The three antibodies bound to
cells expressing WT, Mut I and Mut II forms of hGARP. In contrast,
binding was greatly reduced on cells expressing the Mut III form of
hGARP, indicating that MHGARP-2, -3 and -8 require amino-acids
137-138-139 of hGARP for binding.
[0341] Altogether, the data show that MHGARP8 is the only available
anti-GARP antibody that inhibits active TGF-.beta.1 production by
human Tregs. This neutralizing activity is linked to binding of
MHGARP8 to an epitope that is distinct from those bound by all
other anti-GARP antibodies: binding of MHGARP8 requires both region
101-141 of hGARP and the presence of hTGF-.beta., whereas binding
of non-neutralizing antibodies require other regions of hGARP (for
MHGARP-1, -4, -5, -6, -7 and -9), or occurs only in the absence of
TGF-.beta.1 (for MHGARP-2 and -3). In region hGARP101-141,
amino-acids 137 to 139 are required for the binding of MHGARP-2, -3
and -8.
[0342] The affinity of the MHGARP8 antibody to immobilized
shGARP-TGF.beta. was measured by BIACOR analysis. The Kd of said
antibody is 0.2 nM.
Example 4
MHGARP8 Inhibits Human Treg Cell Function In Vivo
[0343] To examine whether MHGARP8 also inhibits human Tregs in
vivo, a model of xenogeneic GvHD induced by transfer of human PBMCs
(Peripheral Blood Mononuclear Cells) into immuno-compromised
NOD-Scid-IL2Rg.sup.-/- (NSG) mice was used. NSG mice lack
functional T, B and NK cells. This allows efficient engraftment of
human hematopoietic stem cells (HSCs), which proliferate and
generate a functional human immune system in recipient mice. When
human PBMCs are used instead of HSCs, efficient engraftment of T
cells occurs, but is soon accompanied by the development of a
xenogeneic Graft-versus-Host Disease (GvHD). In this model, GvHD
results from the activity of human donor cytotoxic T lymphocytes
that recognize tissues of the recipient NSG mice as foreign
(Shultz, et al. Nature 2012, 12:786-798). The severity of the GvHD
can be decreased by co-transferring human Treg cells with human
PBMCs (Hannon et al. Transfusion 2014).
[0344] Human PBMCs were isolated from total blood of a
hemochromatosis donor by centrifugation on density gradients
(Lymphoprep.TM.), and frozen for later use. Autologous Tregs were
generated as follows: CD4+ T cells were isolated from the blood of
the same donor using the RosetteSep.TM. Human CD4+ T Cell
Enrichment Cocktail (StemCell Technologies) and stained with
anti-CD4, anti-CD25 and anti-CD127 antibodies coupled to
fluorochromes. CD4+CD25hiCD127lo cells were sorted by flow
cytometry (>99% purity) then stimulated with anti-CD3/CD28
coated beads (Dynabeads.RTM. Human T-Activator CD3/CD28 for T-Cell
Expansion and Activation, Life Technologies) in the presence of
IL-2 (120 IU/ml) during 14 days. These expanded Treg cells were
frozen for later use.
[0345] NSG mice were irradiated (2.5 Gy) on day -1, then injected
in the tail vein with human PBMCs (2.7.times.106 per mouse) alone,
or mixed with expanded human Tregs (1.4.times.106 per mouse) on day
0. Mice also received weekly i.p. injections of MHGARP8 antibody
(400 .mu.g on day -1 (day minus 1), 200 .mu.g at later time
points), or control PBS. Mice were monitored bi-weekly for GvHD
development as indicated in the text.
[0346] Human PBMCs with or without Tregs were transferred into NSG
mice, and the mice were treated with i.p. injections of MHGARP8
antibody or control PBS. The large number of human Treg cells
required for the transfers were obtained through short in vitro
amplification of CD4+CD25+CD127lo cells sorted from human PBMCs by
flow cytometry. Objective signs of GvHD development in the
recipient mice were monitored bi-weekly. We performed two
independent experiments, which yielded similar results. In
experiment 1 (FIG. 6, part A), signs of GvHD (mean score .gtoreq.1)
appeared 29 days after injection of human PBMCs (group I; n=2).
Disease severity increased quickly, and one of the 2 mice was
euthanized for ethical reasons on day 55. In mice injected with
PBMCs and Tregs (group II; n=3), the appearance of GvHD was delayed
by comparison to PBMCs alone (mean score .gtoreq.1 reached after 58
days). This indicates that Tregs, as expected, partially protected
NSG mice against GvHD Importantly, treatment of mice receiving
PBMCs and Tregs with the MHGARP8 antibody (group III, n=6)
aggravated the disease: signs of GvHD appeared earlier (36 days)
than in mice from group II. The effect of MHGARP8 appears to depend
on the presence of Tregs, as no difference in disease score was
observed between mice receiving PBMCs only (group I) or PBMCs and
MHGARP8 (group IV; n=4). This experiment was repeated with a larger
number of mice per group (FIG. 6, part B). Again, co-injection of
Tregs with PBMCs delayed the appearance of GvHD by comparison to
PBMCs alone (day 46 in group II versus day 28 in group I), and
treatment with the MHGARP8 antibody aggravated GvHD in mice
receiving PBMCs and Tregs (day 28 in group III) by comparisons to
untreated mice (day 46 in group II). Altogether, this shows that
MHGARP8 inhibits the immune-suppressive function of human Tregs in
vivo.
Example 5
New Anti-hGARP Monoclonal Antibodies (mAbs) Using Immunization of
Llamas Approach
[0347] Production of recombinant soluble GARP-TGF.beta.1
complex
[0348] Human and murine GARP-TGF.beta.1 complex was produced as a
soluble complex using a truncated GARP expression construct. The
human GARP protein sequence was truncated after Leucine 628,
followed by a cleavable TEV-3x strep tag
(EAAENLYFQGAAWSHPQFEKGAAWSHPQFEKGAAWSHPQFEKGAA*) (SEQ ID NO: 40).
Murine GARP protein sequence was truncated after leucine 629,
followed by the same cleavable TEV-3x strep tag. The
GARP-TGF.beta.1 complexes were produced by co-expression of the
truncated GARP and the TGF.beta.1 in HEK293E cells, followed by
purification via the Strep-Tag.
Immunization of Llamas
[0349] Immunizations of llamas and harvesting of peripheral blood
lymphocytes (PBLs) as well as the subsequent extraction of RNA and
amplification of antibody fragments were performed as described by
De Haard and colleagues (De Haard H, et al., J. Bact.
187:4531-4541, 2005). Four llamas were immunized with BW cells
over-expressing human GARP and TGF .beta.1 (FIG. 7, part A) as
confirmed by flow cytometry using MHGARP8 (MHG-8) monoclonal
antibody described in this patent application. The llamas were
immunized with intramuscular injections in the neck once per week
for a period of six weeks. Approximately 10.sup.7 cells were
injected into the neck muscles and Freund's incomplete adjuvant was
injected in a second region located a few centimeters from the
injection site of the cells. Another four llamas were immunized
with a mix of human GARP cDNA and human TGF.beta.1 cDNA expression
vectors, once per two weeks, with four repetitive injections.
[0350] Blood samples of 10 ml were collected pre- and
post-immunization to investigate the immune response. Three to four
days after the last immunization, 400 ml of blood was collected for
extraction of total RNA from the PBLs prepared using a Ficoll-Paque
gradient and the method described by Chomczynski P, et al., Anal.
Biochem. 162: 156-159, 1987. On average, RNA yields of 450 .mu.g
were achieved, which was used for random cDNA synthesis and PCR
amplification of the V-regions of the heavy and the light chains
(V.lamda. and V.kappa.) for construction of the Fab containing
phagemid libraries as described by De Haard H et al., (J Biol Chem.
1999 Jun. 25; 274(26): 18218-30), to obtain diverse libraries of
good diversity (1-7.times.10.sup.8).
[0351] The immune response to the GARP-TGF .beta.1 complex was
investigated by ELISA on coated recombinant soluble GARP-TGF
.beta.1 complex (1 .mu.g/ml). Five-fold serial dilutions of sera,
starting from 10% sera were prepared and 100 .mu.l of diluted sera
was added onto the coated wells and incubated for 1 hour at RT.
After washing with 3.times.PBS/Tween, the plates were blocked with
PBS supplemented with 1% casein (FIG. 8). Binding of conventional
llama IgG1 to its target GARP-TGF.beta. was measured in ELISA using
a mouse anti llama IgG1 antibody (clone 27E10, Daley L P, et al.
Clin. Diagn Lab Immunol. 12, 2005) and a HRP-conjugated donkey
anti-mouse antibody (Jackson) for detection.
Selections and Screenings of GARP-TGF.beta.1 Specific Fabs
[0352] Phage expressing Fabs were produced according to standard
protocols and selections performed on immobilized recombinant
soluble GARP-TGF.beta.1 with total elution of the GARP-TGF.beta.1
binding phage with trypsin according to standard phage display
protocols.
[0353] Two to three rounds of selections were performed to enrich
for human GARP-TGF.beta.1 specific Fabs expressed by the phage.
hGARP and hTGF.beta.1 (LAP) counter selections were used to enrich
for Fabs binding the hGARP-TGF.beta.1 complexes. Individual
colonies were isolated and periplasmic fractions (penis) in 96-well
plates were produced by IPTG induction from all the libraries
according to standard protocols.
[0354] Screening of the hGARP-TGF.beta. specific Fabs was performed
using ELISA. hGARP-TGF.beta.1 was immobilized on a maxisorb plate.
After blocking with 1% casein in PBS for 1 h, Fab from 20 .mu.l
periplasmic extracts were allowed to bind to hGARP-TGF.beta.1.
Characterization of Monoclonal Antibodies
[0355] GARP-TGF.beta.1/GARP specific clones were sequenced in the
VH and the VL regions and divided into VH families based on the
sequence of the CDR3 in the VH. Seventeen families were identified.
Of each VH family identified at least one representative clone was
cloned into a full human IgG1 (LHG1-LHG17). These monoclonal
antibodies were analyzed on Biacore for their binding
characteristics to soluble human GARP-TGF.beta.1 complex.
Recombinant soluble human GARP-TGF.beta.1 was immobilized at
approximately 4,000 RU on a CMS chip (GE Healthcare).
[0356] Binding of monoclonal antibodies to the human and cynomolgus
GARP-TGF.beta.1 complex expressed on HEK-293 cells was analyzed by
FACS. Cynomolgus GARP and cynomolgus TGF.beta.1 encoding sequences
were cloned from a cDNA sample from cynomolgus peripheral blood
lymphocytes (PBMCs). Primers were based on the predicted sequences
of cynomolgus GARP (XM_005579140.1; SEQ ID NO: 41) and cynomolgus
TGF.beta.1 (XM_005589338.1; SEQ ID NO: 42) by amplification of
overlapping parts of the full sequence. For both cynomolgus GARP
and cynomolgus TGF.beta.1 three separate PCR amplicons were DNA
sequence analyzed. They fully aligned with the predicted sequences.
Cynomolgus GARP and cynomolgus TGF.beta.1 were cloned into pCDNA3.1
for transient over-expression in HEK293E cells. Binding to
cynomolgus GARP-TGF.beta.1 was compared to binding to human
GARP-TGF.beta.1 on FACS. LHG-10 and the shuffled variants (LHG-10.3
to LHG-10.6) can be considered as cross-reactive with cynomolgus
GARP-TGF.beta.1 (FIG. 9).
[0357] Primers used:
TABLE-US-00042 >cyno TGFB S1: (SEQ ID NO: 43) cgcctc CCCCATGCCG
ccctccg >cyno TGFB S2: (SEQ ID NO: 44) acaattcctg gcgatacctc
>cyno TGFB AS1: (SEQ ID NO: 45) CTCAACCACTGCCGCACAAC >cyno
TGFB AS2: (SEQ ID NO: 46) TCAGCTGCATTTGCAGGAGC
VK Shuffling for Improved Affinity
[0358] VK chain shuffling was used to improve the affinity of the
mAb LHG-10 (FIG. 10). In this method, the heavy chain of the
parental clone (VHCH1 of LHG-10) was reintroduced in the
phagemid-light chain library. The heavy chain was extracted from an
expression vector, which lacks the bacteriophage derived gene 3
necessary for display, to further avoid contamination of the
parental light chain in the selection procedure. The heavy chain
was cloned into the phagemid-light chain library and the ligated
DNA was electroporated into E. coli TG1 cells to create the light
chain shuffled library. The size of libraries was above
10.sup.8.
[0359] Affinity selections, combined with off-rate washes, were
performed to select for chain shuffled Fabs with an improved
affinity for human GARP-TGF.beta.1. A set-up was chosen where Fab
expressing phages were incubated with different concentrations of
recombinant soluble human GARP-TGF.beta.1 directly coated to the
microsorb plate.
[0360] By adding the recombinant soluble human GARP-TGF.beta.1 in
excess over the coated recombinant soluble human GARP-TGF.beta.1,
the binding of the higher affinity phage was favored. Each round
the time of washing was increased (Table 3) to select for phages
with a better off-rate by washing away the lower affinity variants.
Phages were eluted with trypsin and used for infection of E. coli
TG1 cells. In total, five rounds of selection were done. In
addition the amount of input phage was decreased in subsequent
rounds to reduce background on the one hand and on the other hand
to lower the mAb concentration thereby increasing the stringency of
the selection.
TABLE-US-00043 TABLE 3 Parameters varied for each round of
selection for VK shuffling RI RII RIII RIV RV Concentrations 10
.mu.g/ml 10 .mu.g/ml 10 .mu.g/ml 10 .mu.g/ml 10 .mu.g/ml
rhGARP-TGF.beta. 1 .mu.g/ml 1 .mu.g/ml 1 .mu.g/ml 1 .mu.g/ml 1
.mu.g/ml 0.1 .mu.g/ml 0.1 .mu.g/ml 0.1 .mu.g/ml 0.1 .mu.g/ml 0.1
.mu.g/ml Vol. Phage 10 .mu.l 1 .mu.l 1 .mu.l 1 .mu.l 1 .mu.l Time
of 0 h 2 h O/N O/3N O/6N washing Conditions -- 37.degree. C.,
37.degree. C., 37.degree. C., 37.degree. C., 100 .mu.g/ml 100
.mu.g/ml 100 .mu.g/ml 100 .mu.g/ml rhGARP-TGF.beta.
rhGARP-TGF.beta. rhGARP-TGF.beta. rhGARP-TGF.beta. in 1% casein in
1% casein in 1% casein in 1% casein
[0361] Screenings of at least 24 clones from selection rounds III,
IV and V were performed. The clones were grown in deep well plates
(1 ml expressions) and periplasmic fractions were prepared. These
periplasmic extracts were analyzed on Biacore for improved
off-rates. Top four Fab clones with improved off-rates were cloned
into hIgG1 (LHG-10 series) and also an effector-dead variant hIgG1
with an N297Q substitution in the Fc region (LHG-10-D series), and
the resultant IgGs were analyzed for improved binding
characteristics on Biacore (Table 4). In addition, the LHG-10-D
IgGs were checked for cross-reactivity on cyno GARP/cyno
TGF-.beta.1 in a FACS-based assay using HEK-293E cells transfected
with cyno GARP/cyno TGF.beta.1 or human GARP/human TGF.beta.1.
MHGARP8 was also tested in this cross-reactivity assay. All
LHG-10-D and MHG-8 are cross-reactive against cyno GARP/cyno
TGF.beta.1 (FIG. 9).
TABLE-US-00044 TABLE 4 Binding characteristics of shuffled clones
fold Fold fold ka (1/Ms) improvement kd (1/s) improvement KD
improvement MHGA 1.25E+05 N/A 3.39E-05 N/A 2.64E-10 N/A RP8 LHG-
1.42E+05 1.0 2.62E-05 1.0 1.85E-10 1.0 10-D LHG- 2.31E+05 0.6
5.18E-06 5.1 2.24E-11 8.3 10.3-D LHG- 3.71E+05 0.4 1.21E-05 2.2
3.27E-11 5.7 10.4-D LHG- 3.83E+05 0.4 1.07E-05 2.4 2.80E-11 6.6
10.5-D LHG- 2.84E+05 0.5 6.15E-06 4.3 2.16E-11 8.6 10.6-D LHG-10
2.39E+05 1.0 3.12E-05 1.0 1.31E-10 1.0 LHG- 2.87E+05 0.8 6.38E-06
4.9 2.22E-11 5.9 10.3 LHG- 4.48E+05 0.5 1.30E-05 2.4 2.91E-11 4.5
10.4 LHG- 4.15E+05 0.6 1.37E-05 2.3 3.31E-11 4.0 10.5 LHG- 2.76E+05
0.9 4.40E-06 7.1 1.59E-11 8.2 10.6
Example 6
Two Anti-hGARP mAbs (MHGARP8 and LHG-10) Inhibit Active TGF-.beta.1
Production by Human Tregs
[0362] Stimulated human Tregs produce active TGF-.beta.1 close to
their cell surfaces. Autocrine and paracrine TGF-.beta.1 activity
induces SMAD2 phosphorylation in Tregs themselves, and in Th cells
co-cultured with Tregs (Stockis, J. et al. Eur. J. Immunol. 2009,
39:869-882). To test if GARP is required for TGF-.beta.1 activation
by Tregs, human Tregs were stimulated in the presence or absence of
anti-hGARP mAbs, and phosphorylation of SMAD2 was measured by
Western Blot. As a source of human Tregs we used
CD4.sup.+CD25.sup.hiCD127.sup.lo cells sorted from PBMCs and
amplified in vitro during 12-14 days (Gauthy E et al PLoS One. 2013
Sep. 30; 8(9):e76186). As determined by methyl-specific qPCR,
amplified cell populations contain 44 to 82% cells with a
demethylated FOXP3i1 allele, indicating that they are still highly
enriched in Tregs.
[0363] As expected, phosphorylated SMAD2 was detected in the
stimulated Tregs, but not in non-stimulated Tregs, nor in Tregs
stimulated in the presence of a neutralizing anti-TGF-.beta.1
antibody (FIG. 11). Phosphorylated SMAD2 was greatly reduced in
Tregs stimulated in the presence of MHGARP8 (named MHG-8 on FIG.
11, part A) or LHG-10 (FIG. 11, part B), indicating that these two
anti-hGARP mAbs block active TGF-.beta. production. The 29 other
new anti-hGARP mAbs, as well as four commercially available
anti-hGARP mAbs, did not block TGF-.beta. production by Tregs (FIG.
11).
[0364] The inhibitory activity of MHGARP8 and LHG-10 shows that
GARP is required for active TGF-.beta.1 production by human
Tregs.
Example 7
MHGARP8 and LHG-10 Inhibit the Suppressive Activity of Human Tregs
in Vitro
[0365] We previously showed that human Tregs suppress other T cells
at least in part through production of active TGF-.beta.1 (Stockis,
J. et al. Eur. J. Immunol. 2009, 39:869-882). We therefore tested
whether MHGARP8 (MHG-8) and LHG-10 also inhibit human Treg function
in in vitro suppression assays. A Treg clone was used as a source
of Tregs, and freshly isolated CD4.sup.+CD25.sup.-CD127.sup.hi
cells or a CD4.sup.+ T cell clone (Th cells) as targets for
suppression. Tregs and Th cells were stimulated with >CD3 and
>CD28 in the presence or absence of various additional mAbs. As
shown in FIG. 12, clone Treg A1 inhibited the proliferation of
CD4.sup.+CD25.sup.-CD127.sup.hi Th cells by 66% in the absence of
anti-hGARP mAb. Suppression was reduced to 36% and 32% in the
presence of MHG-8 or LHG-10, respectively, but was not reduced in
the presence of 6 other anti-hGARP mAbs. Suppression by clone Treg
A1 on another Th target (clone Th A2) was also measured in the
presence of MHGARP8, an anti-hTGF-.beta.1 mAb or an isotype
control. MHGARP8 (MHG-8) inhibited the in vitro suppressive
activity of Treg A1 in a manner similar to that of the
anti-TGF-.beta.1 antibody, whereas the isotype control showed no
effect (FIG. 12).
Example 8
Epitopes Recognized by Inhibitory Anti-hGARP mAbs
[0366] Only a minority (2/35) of anti-hGARP mAbs block active
TGF-.beta. production and suppression by Tregs. This could be due
to their ability to bind epitope(s) that are distinct from those
bound by non-inhibitory mAbs. Therefore the regions required for
binding by inhibitory and non-inhibitory mAbs were mapped.
[0367] GARP associates with pro- or latent TGF-.beta.1 to form
disulfide-linked GARP/TGF-.beta.1 complexes (FIG. 13 and Stockis
2009b Eur. J. Immunol. 2009. 39: 3315-3322 and Gauthy E et al). We
first sought to determine whether anti-hGARP mAbs also bind
GARP/TGF-.beta.1 complexes, using co-immunoprecipitation (IP)
experiments in murine BW cells transfected with hGARP and hTGFB1.
Thirty-two anti-hGARP mAbs were tested: 31 mAbs of the instant
invention and the commercially available Plato-1 mAb. All mAbs
efficiently immunoprecipitated GARP (top panel of FIG. 14, part A,
showing IPs with 12 representative mAbs). Pro-TGF-.beta.1, as well
as LAP and mature TGF-.beta.1 (i.e. latent TGF-.beta.1) were
co-immunoprecipitated with 24 mAbs indicating that they bind
GARP/TGF-.beta.1 complexes (6 mAbs shown in FIG. 14, part A, middle
and lower panels). In contrast, 8 mAbs (3 shown in FIG. 14, part A)
did not co-immunoprecipitate pro- or latent TGF-.beta.1, suggesting
they bind free GARP but not GARP/TGF-.beta.1 complexes.
[0368] This was confirmed by FACS analyses of transfected 293T
cells (FIG. 14, part B). Untransfected 293T cells express no GARP
and very low levels of endogenous TGF-.beta.1. No latent TGF-.beta.
is detected on their surface with an anti-LAP antibody.
Transfection of GARP or TGFB1 alone induces no or low surface LAP,
respectively, whereas co-transfection of GARP and TGFB1 induces
high surface LAP as a result of latent TGF-.beta.1 binding and
presentation by GARP (FIG. 14, part B, left histograms). Three
groups of anti-hGARP mAbs emerged from the analysis of transfected
293T cells, and are classified in 3 columns in FIG. 13, part B. A
first group (left column) comprises the 8 mAbs that did not
co-immunoprecipitate pro- or latent TGF-.beta.1: they bound 293T
cells transfected with hGARP alone, but not with hGARP and hTGFB1.
This confirms that these mAbs bind free GARP only, as binding to
surface GARP is lost in the presence of TGF-.beta.1 (FIG. 14, part
B, shows 3 representative mAbs of this group). A second group
comprises most other mAbs (19 mAbs, middle column of FIG. 13, part
B): they bound 293T cells equally well upon transfection with hGARP
alone or with hGARP and hTGFB1, indicating that they bind both free
GARP and GARP/TGF-.beta.1 complexes (FIG. 14, part B, shows 6 mAbs
of this group). Interestingly, a third group of 5 mAbs bound 293T
cells transfected with hGARP and hTGFB1, but not cells transfected
with hGARP alone (right column of FIG. 13, part B). These mAbs bind
GARP/TGF-.beta.1 complexes but not free GARP, and include
inhibitory MHGARP8 (MHG-8) and LHG-10 (FIG. 14, part B, shows 3
mAbs of this group).
[0369] From the above, we concluded that most mAbs bind free GARP
only (8/32) or free GARP and GARP/TF-.beta.1 complexes (19/32).
Only five mAbs, including inhibitory MHGARP8 (MHG-8) and LHG-10 but
also three non-inhibitory mAbs, bind GARP/TGF-.beta.1 complexes,
but not free GARP. This pattern of recognition does not explain why
only MHGARP8 and LHG-10 are inhibitory.
[0370] We next sought to define the regions of hGARP required for
binding by the various mAbs. The vast majority of the anti-hGARP
mAbs do not cross-react on mouse GARP (mGARP). Therefore plasmids
were constructed encoding HA-tagged mGARP/hGARP chimeras (FIG. 15,
part A, left panel) and transfected into 293T cells, with or
without hTFGB1 depending on the binding requirements determined
above. All chimeras were expressed at similar levels on the surface
of 293T cells, as evidenced by staining with an anti-HA mAb (FIG.
15, part A, histograms on the right). Binding patterns to
mGARP/hGARP chimeras (FIG. 15, part A, 10 representative mAbs)
allowed to identify the region of hGARP required for binding by
each anti-hGARP mAb. This is summarized in FIG. 15, part B, where
mAbs are distributed in rows corresponding to various regions of
hGARP: mAbs in the first row require a region comprising
amino-acids 20 to 101 (hGARP.sub.20-101), mAbs in the second row
require hGARP.sub.101-141, those in the third require
hGARP.sub.141-207, the fourth, hGARP.sub.265-332, and finally, a
fifth group requires hGARP.sub.332-628. However, even when
considering the regions required for binding, the epitope
recognized by inhibitory MHGARP8 (named MHG-8 on the figure) and
LHG-10 could not be distinguished from that of non-inhibitory mAbs:
MHGARP8 and LHG-10, like LHG-3, -12 and -13, bind GARP/TGF-.beta.
complexes that contain hGARP.sub.101-141.
[0371] Sequences of mouse and human GARP.sub.101-141 differ at 14
amino-acid (aa) positions, comprising three clusters of three
contiguous positions (FIG. 15, part B, left panel). We constructed
three mutated versions of hGARP. In each mutant, a series of three
contiguous aa from region 101-141 were replaced by the aa found in
mGARP. We transfected 293T cells with the HA-tagged mutants, alone
or with hTGFB1 depending on the binding requirement of the mAbs
tested. Binding patterns to mutants revealed three types of mAbs
(FIG. 15, part B, right panel), which required amino-acids
hGARP.sub.111-113, hGARP.sub.126-127, or hGARP.sub.137-139 for
binding, respectively. Six mAbs, including MHGARP8 (named MHG-8 on
the figure) and LHG-10, required hGARP.sub.137-139 (FIG. 13B).
Whereas four of six can bind free hGARP, MHG-8 and LHG-10 are the
only mAbs that require hGARP.sub.137-139 in the context of
GARP/TGF-.beta.1 complexes.
[0372] From the above, we concluded that inhibition of TGF-.beta.
production by MHGARP8 and LHG-10 is associated with the ability to
bind an epitope that is distinct from those recognized by all
other, non-inhibitory, anti-hGARP mAbs.
Example 9
Inhibition of Human Tregs Function by Anti-hGARP In Vivo
[0373] We next sought to evaluate whether inhibitory anti-hGARP
mAbs could inhibit human Treg function in vivo. We used a model of
xenogeneic graft-versus-host disease (GVHD) induced by transfer of
human peripheral blood mononuclear cells (PBMCs) into
immuno-compromised NOD/Scid/IL2Rg.sup.-/- (NSG) mice. NSG mice have
defective cytokine signaling and lack functional T, B and NK cells,
allowing very efficient engraftment of human T cells upon i.v.
injection of PBMCs. Thirty to forty days after PBMC transfer,
recipient mice develop xenogeneic GVHD, due to the activity of
human cytotoxic T lymphocytes against murine tissues (Shultz, Nat
Rev Immunol. 2012 November; 12(11):786-98). In this model,
co-transfer of human Tregs with human PBMCs attenuates GVHD (Hannon
et al. Transfusion. 2014 February; 54(2):353-63), providing a model
to test the inhibitory activity of anti-hGARP mAbs on human Tregs
in vivo.
[0374] We transferred human PBMCs (3.times.10.sup.6/mouse) with or
without autologous Tregs (1.5.times.10.sup.6/mouse) in NSG mice
(FIG. 16, part A). As a source of human Tregs, we used blood
CD4.sup.+CD25.sup.hiCD127.sup.lo cells that had been shortly
amplified in vitro, as described above. In addition, mice were
injected with MHGARP8 (named MHG-8 on the figure),
anti-TGF-.beta.1, an isotype control or PBS, one day before the
graft and weekly thereafter. Objective signs of GVHD were monitored
bi-weekly, to establish a disease score based on weight loss,
reduced mobility, anemia or icterus, and hair loss. We performed
four independent experiments (FIG. 16, part B), and detailed
results are shown for one (FIG. 16, part C). Depending on the
experiment, onset of disease (mean GVHD score .gtoreq.1) was
observed 28 to 41 days after PBMC transfer in groups of mice that
received no mAb or an isotype control. Co-transfer of Tregs delayed
disease, which occurred 46 to 72 days after transfer, indicating
that human Tregs were able to suppress human T cell responses
against xenogeneic antigens. Administration of MHGARP8 to mice
transferred with PBMCs and Tregs abrogated the protective effect of
Tregs: disease occurred as early as in mice receiving PBMCs only
(28 to 44 days after transfer). Inhibition of Treg suppressive
function by MHGARP8 was similar to that observed with a
neutralizing anti-TGF-.beta.1 antibody. An isotype control had no
effect.
[0375] Altogether, this shows that MHGARP8 inhibits the
immune-suppressive function of human Tregs in vivo.
[0376] We verified that MHGARP-8 did not aggravate GVHD in mice
grafted with PBMCs alone, thus that its effect depended on the
co-injection of Tregs (FIG. 17). We also examined whether
abrogation of Treg protection by MHGARP-8 depended on its ability
to block TGF-.beta. production. MHGARP-8 was compared to LHG-10.6,
which also blocks TGF-.beta. production by Tregs, and to LHG-3,
which does not. Antibody LHG-10.6 is a variant of LHG-10 with
increased affinity for GARP/TGF-.beta.1 complexes that was selected
by phage display from Fabs in which the heavy chain of LHG-10 was
combined to the V.kappa. library. Like MHGARP-8, LHG-10.6
aggravated GVHD, whereas non-blocking antibody LHG-3 had no effect
(FIG. 17). This suggested that MHGARP-8 and LHG-10.6 abrogate Treg
protection by blocking Treg production of TGF-.beta.1, and not by
inducing Treg depletion. To further exclude the latter possibility,
a mutated version of LHG-10.6, named LHG-10.6N297Q, was also
tested. The N297Q mutation results in loss of Fc glycosylation,
thus loss of Fc receptor- and Clq-binding, and consequently loss of
ADCC and CDC functions. LHG-10.6N297Q aggravated GVHD in mice
grafted with PBMCs and Tregs as potently as LHG-10.6, confirming
that anti-GARP antibodies do not act by depleting Tregs (FIG.
17).
[0377] Human cytokines in the serum of mice 20 days after cell
transfer were measured (FIG. 18, part A). Human IL-2 and IFN.gamma.
were detected at high levels in mice grafted with PBMCs only,
indicating a strong xenogeneic activation of human T cells. They
were significantly reduced by the cotransfer of Tregs, confirming
suppressive activity. MHGARP-8 decreased the suppression by Tregs,
but had no effect in mice transferred with PBMCs alone Finally,
IL-10 levels were not increased but instead reduced in the presence
of Tregs, suggesting that Tregs do not suppress through production
of IL-10 in this model (FIG. 18, part A). Noteworthy, effects of
MHGARP-8 on suppression of cytokine production were measured at an
early time point before disease onset, to preclude confounding
effects from severe inflammation that develops in some groups at
later time points. This likely explains why the effects of MHGARP-8
are less pronounced on cytokine production than on disease
progression.
[0378] In spleens collected 20 days after transfer, human
hematopoietic cells (hCD45+) comprised mostly T lymphocytes (CD4+
and CD8+), which had considerably proliferated in mice grafted with
PBMCs alone. This proliferation was inhibited by the co-transfer of
Tregs, an effect that was decreased by MHGARP-8 (FIG. 18, part B).
Notably, the numbers and proportions of Tregs (hCD3+hCD4+hFOXP3+
cells or cells with a demethylated FOXP3i1 allele) were not reduced
in mice treated with MHGARP-8. On the contrary, Treg numbers were
significantly increased in mice transferred with Tregs and treated
with MHGARP-8 as compared to untreated mice (FIG. 18, part C). This
suggests that the MHGARP-8-mediated blockade of autocrine
TGF-.beta.1 activity favors Treg proliferation, while concomitantly
inhibiting Treg function. It also supports the hypothesis that
inhibitory anti-GARP mAbs do not act by depleting Tregs.
[0379] However, it could still be that inhibitory mAbs deplete a
minor subpopulation of Tregs without affecting total Treg numbers.
For example, this could occur if only a small proportion of Tregs
expressed GARP as a result of activation in this model. In vitro,
GARP was shown to be expressed only on activated Tregs. First, the
proportions and numbers of GARP+ Tregs were measured at several
time points after the transfer of human PBMCs.+-.Tregs in NSG mice
(FIG. 18, part D). Three days after transfer, approximately 50% of
CD4+FOXP3+ cells expressed GARP, indicating that GARP+ cells do not
represent a minor subpopulation of Tregs. Proportions of GARP+
cells decreased progressively to 10-20% of CD4+FOXP3+ by day 20,
and no difference was observed between untreated mice and mice
treated with the anti-GARP mAb LHG-10.6, which is inhibitory, or
LHG-3, which is not. The numbers of GARP+ Tregs were not reduced in
mice treated with either anti-GARP mAb by comparison to untreated
mice. They were even increased at day 20 in mice treated with
LHG-10.6 compared to all other conditions. Second, another
identification procedure for activated human Tregs, as proposed by
Miyara et al. was used (M. Miyara, et al Immunity 30, 899-911
(2009)) who defined these cells as a subset of FOXP3+Treg cells
characterized by high FOXP3 levels and no CD45RA expression
(CD4+FOXP3hiCD45RA- cells). A subpopulation of human FOXP3hi cells
appeared in mice 7 days after the transfer of human PBMCs.+-.Tregs.
FOXP3hi cells expressed the highest levels of GARP and most were
CD45RA-. Therefore in vivo, GARP expression was maximal in the
activated human CD4+FOXP3hiCD45RA-Tregs. The numbers of
CD4+FOXP3hiCD45RA-cells were not decreased in mice treated with
anti-GARP mAbs by comparison to untreated mice (FIG. 18, part D),
confirming that inhibitory anti-GARP mAbs did not act in this model
by depleting GARP-expressing cells.
[0380] Altogether, these results indicate that the inhibitory
anti-GARP mAbs are capable of inhibiting the immunosuppressive
activity of human Tregs in vivo without inducing Treg
depletion.
Example 10
X-Ray Crystal Structures of the Fab-Fragment Generated from
Antibody MHGARP8 in Complex with the GARP/TGF-.beta. Complex
[0381] The Fab fragment of MHG-8 was prepared by papain digestion
of MHG-8 and purified using Protein A affinity chromatography and
gel filtration chromatography. The MHG-8 Fab fragment was added to
the GARP/TGF.beta. complex to allow binding of the Fab to its
antigen. The Fab-fragment purified in this way was mixed with the
GARP/TGFbeta complex and applied on a gel filtration column in 20
mM Tris/HCl pH 8.0, 50 mM NaCl. The Fab/GARP/TGF.beta. complex was
concentrated on a 50 kD Vivascience ultrafiltration device to a
final concentration of 18 mg/mL, as determined by Nanodrop (UV).
This MHG-8 Fab/GARP/TGF.beta. complex (where TGF.beta. is comprised
of LAP and mature TGF.beta.) was purified and used for
crystallization.
Methods
Crystallisation
[0382] The purified protein was used in crystallisation trials
employing a standard screen with approximately 1,200 different
conditions. Conditions initially obtained have been optimised using
standard strategies, systematically varying parameters critically
influencing crystallisation, such as temperature, protein
concentration, drop ratio, and others. These conditions were also
refined by systematically varying pH or precipitant
concentrations.
Data Collection and Processing (Table 5)
[0383] The application of the Free Mounting System (FMS) was
necessary to obtain well diffracting crystals. The crystals were
coated with oil and transferred to the N2 cryo-stream at 100K.
Crystals have been flash-frozen and measured at a temperature of
100 K. The X-ray diffraction data have been collected from complex
crystals at the SWISS LIGHT SOURCE (SLS, Villigen, Switzerland)
using cryogenic conditions. The crystals belong to space group P
21. Data were processed using the programs XDS and XSCALE.
TABLE-US-00045 TABLE 5 X-ray source PXI/X06SA (SLS.sup.1)
Wavelength [.ANG.] 1.00001 Detector PILATUS 6M Temperature [K] 100
Space group P 2.sub.1 Cell: a; b; c; [.ANG.] 103.89; 175.11; 145.81
.alpha.; .beta.; .gamma.; [.degree.] 90.0; 92.2; 90.0 Resolution
[.ANG.] 3.15 (3.40-3.15) Unique reflections 83391 (16806)
Multiplicity 3.0 (2.9) Completeness [%] 92.7 (92.2) R.sub.sym
[%].sup.3 8.9 (67.7) R.sub.meas [%].sup.4 10.7 (81.7)
Mean(I)/sd.sup.5 10.24 (1.75) .sup.1SWISS LIGHT SOURCE (SLS,
Villigen, Switzerland) .sup.2values in parenthesis refer to the
highest resolution bin. .sup.3 Rsym = h i n h I ^ h - I h , i h i n
h I h , i with I ^ h = l n k i n h I h , i ##EQU00001## where
I.sub.h, i is the intensity value of the ith measurement of h
.sup.4 Rmeas = h n h n h - 1 i n h I ^ h - I h , i h i n h I h , i
with I ^ h = l n h i n h I h , i ##EQU00002## where I.sub.h, i is
the intensity value of the ith measurement of h .sup.5calculated
from independent reflections
Structure Modelling and Refinement
[0384] The phase information necessary to determine and analyse the
structure was obtained by molecular replacement. The published
structures of latent TGFbeta (PDB-ID 3RJR), Leucine-rich repeat and
immunoglobulin-like domain-containing nogo receptor interacting
protein 1 (PDB-ID 4OQT) and Fab-fragment (PDB-ID 1FNS) were used as
a search models. Subsequent model building and refinement was
performed according to standard protocols with the software
packages CCP4 and COOT. For the calculation of the free R-factor, a
measure to crossvalidate the correctness of the final model, about
0.6% of measured reflections were excluded from the refinement
procedure (see Table 6). Automatically generated local NCS
restraints have been applied (keyword "ncsr local" of newer REFMAC5
versions). The water model was built with the "Find
waters"-algorithm of COOT by putting water molecules in peaks of
the Fo-Fc map contoured at 3.0 followed by refinement with REFMAC5
and checking all waters with the validation tool of COOT. The
criteria for the list of suspicious waters were: B-factor greater
80 .ANG.2, 2Fo-Fc map less than 1.2.sigma., distance to closest
contact less than 2.3 .ANG. or more than 3.5 .ANG.. The suspicious
water molecules and those in the ligand binding site (distance to
ligand less than 10 .ANG.) were checked manually.
[0385] The occupancy of side chains, which were in negative peaks
in the Fo-Fc map (contoured at -3.0.sigma.), were set to zero and
subsequently to 0.5 if a positive peak occurred after the next
refinement cycle. The Ramachandran Plot of the final model shows
79.3% of all residues in the most favoured region, 19.4% in the
additionally allowed region, and 1.1% in the generously allowed
region. The residues Asn31(L), Ala51(L), Asn31(K), and Ala51(K) are
found in the disallowed region of the Ramachandran plot (Table 5).
They are either confirmed by the electron density map or could not
be modelled in another sensible conformation. Statistics of the
final structure and the refinement process are listed in Table
6.
TABLE-US-00046 TABLE 6 Resolution [.ANG.] 145.70-3.15 Number of
reflections (working/test) 82901/490 R.sub.cryst [%] 24.1
R.sub.free [%].sup.2 27.5 Total number of atoms: Protein 25251
Water 0 .beta.-D-mannose 44 .beta.-D-N-acetyl-glucose 168 Deviation
from ideal geometry: .sup.3 Bond lengths [.ANG.] 0.007 Bond angles
[.degree.] 1.26 Bonded B's [.ANG..sup.2].sup.4 12.5 Ramachandran
plot: .sup.5 Most favoured regions [%] 79.3 Additional allowed
regions [%] 19.4 Generously allowed regions [%] 1.1 Disallowed
regions [%] 0.1 .sup.1 values as defined in REFMAC5, without sigma
cut-off .sup.2Test-set contains 0.6% of measured reflections .sup.3
Root mean square deviations from geometric target values
.sup.4Calculated with MOLEMAN .sup.5 Calculated with PROCHECK
Results
[0386] The structure of the Fab:GARP/TGF-.beta. complex was solved
at a resolution of 3.15 .ANG..
[0387] The crystal structure of the Fab:GARP/TGF-.beta. complex
allowed the identification of the epitope recognized by the
antibody MHGARP8. The Fab-fragment binds a composite three
dimensional epitope on the Fab:GARP/TGF-.beta. complex. The
interaction surface on the Fab:GARP/TGF-.beta. complex is formed by
several continuous and discontinuous sequences from both hGARP
(Tables 7a and 7b respectively) and TGF-.beta. (Table 7c), showing
interactions between TGF.beta. residues and MHG-8 heavy chain
residues.
TABLE-US-00047 TABLE 7a Interactions between GARP residues (left
side) and MHG-8 heavy chain residues (right side) Residue Number
Chain Residue Number Chain Tyr 137 hGARP Asp 103 Heavy chain Ser
138 hGARP Tyr 102 Heavy chain Gly 139 hGARP Tyr 102 Heavy chain Asp
103 Heavy chain Tyr 104 Heavy chain Leu 140 hGARP Tyr 104 Heavy
chain Glu 142 hGARP Tyr 102 Heavy chain Arg 143 hGARP Tyr 104 Heavy
chain Asp 105 Heavy chain Thr 162 hGARP Asp 103 Heavy chain Arg 163
hGARP Asn 100 Heavy chain Tyr 101 Heavy chain Tyr 102 Heavy chain
Thr 165 hGARP Tyr 101 Heavy chain Tyr 102 Heavy chain Arg 166 hGARP
Tyr 101 Heavy chain His 167 hGARP Tyr 101 Heavy chain Tyr 102 Heavy
chain Glu 189 hGARP Tyr 101 Heavy chain
TABLE-US-00048 TABLE 7b Interactions between GARP residues (left
side) and MHG-8 light chain residues (right side) Residue Number
Chain Residue Number Chain Thr 113 hGARP Trp 92 Light chain Ser 93
Light chain Ala 114 hGARP Ser 93 Light chain Ser 116 hGARP Trp 92
Light chain Ala 117 hGARP His 28 Light chain Ile 29 Light chain Trp
92 Light chain Gly 118 hGARP His 28 Light chain Lys 30 Light chain
Trp 92 Light chain Gly 119 hGARP Trp 92 Light chain Gly 139 hGARP
Trp 32 Light chain Glu 142 hGARP Lys 30 Light chain Trp 32 Light
chain Arg 143 hGARP Trp 32 Light chain Tyr 91 Light chain Trp 92
Light chain Ser 93 Light chain Trp 96 Light chain Leu 144 hGARP Trp
92 Light chain Leu 145 hGARP Lys 30 Light chain Gly 146 hGARP Lys
30 Light chain Arg 170 hGARP ASN 31 Light chain Trp 32 Light
chain
TABLE-US-00049 TABLE 7c Interactions between TGF.beta. residues
(left side) and MHG-8 heavy chain residues (right side) Residue
Number Chain Residue Number Chain Arg 58 1TGFbeta Asp 54 Heavy
chain Glu 100 1TGFbeta Asn 73 Heavy chain Glu 146 1TGFbeta Arg 68
Heavy chain Gln 269 1TGFbeta Asp 54 Heavy chain Gly 55 Heavy chain
Ser 56 Heavy chain Thr 57 Heavy chain His 270 1TGFbeta Thr 57 Heavy
chain Tyr 59 Heavy chain Arg 68 Heavy chain Ile 69 Heavy chain Leu
271 1TGFbeta Thr 57 Heavy chain Tyr 59 Heavy chain Gln 272 1TGFbeta
Thr 57 Heavy chain Asp 58 Heavy chain Tyr 59 Heavy chain Ser 273
1TGFbeta Thr 57 Heavy chain Tyr 284 1TGFbeta Gly 26 Heavy chain Phe
27 Heavy chain Ser 28 Heavy chain Ser 76 Heavy chain Tyr 336
1TGFbeta Tyr 104 Heavy chain Ser 337 1TGFbeta Asp 54 Heavy chain
Lys 338 1TGFbeta Trp 52 Heavy chain Asp 54 Heavy chain Ser 56 Heavy
chain Tyr 104 Heavy chain Ala 341 1TGFbeta Asp 54 Heavy chain Gln
345 1TGFbeta Thr 30 Heavy chain
Example 11
Impact of Mutations in GARP or TGF-.beta.1 on the Binding and
Activity of Inhibitory Anti-GARP Antibodies MHG-8 and LHG-10
Impact of Mutations in GARP or TGF-.beta.1 on the Binding of
Inhibitory Anti-GARP Antibodies MHG-8 and LHG-10 Used in Saturating
Conditions.
[0388] Resolution of the crystal structure of MHG-8
Fab/GARP/TGF-.beta.1 complexes and analysis with the CONTACT
software allowed the identification of 22 amino-acids in GARP, 8
amino-acids in LAP and 6 amino-acids in mature TGF-.beta.1 that are
located less than 5 .ANG. away from an amino-acid of the light or
heavy chain of the MHG-8 Fab (Tables 7a, b and c, and Table 8).
Directed mutagenesis was used to construct plasmids encoding
HA-tagged forms of GARP or TGF-.beta.1 that are mutated at one,
two, or three of these 36 positions (all mutations constructed are
indicated in Table 8). 293T cells were then transfected with these
plasmids and the ability of anti-GARP, anti-LAP or anti-HA
antibodies to bind to the GARP/TGF-.beta.1 complexes containing
mutated forms of GARP or TGF-.beta.1 was determined by flow
cytometry. Antibodies were used at a saturating concentration of 5
.mu.g/ml for labeling. Binding of each antibody to a given mutant
GARP/TGF-.beta.1 complex was compared to their binding to wild type
(WT) complexes, by determining an I.sub.m/wt value (i.e. intensity
of binding to mutant by comparison to WT). This value was
calculated as follows: I.sub.m/wt of antibody X=[Geom on
mutant-Geom on control]/[Geom on WT-Geom on control]
where Geom corresponds to the geometric mean of the fluorescence
intensity measured by FACS on 293T cells transfected with empty
plasmid (control) or plasmids encoding the mutant or WT forms of
GARP/TGF-.beta.1 complexes.
[0389] The level of residual binding of anti-GARP or anti-LAP
antibodies to each mutant was then calculated by comparison to WT,
taking into account the expression levels of mutant and WT forms as
measured with anti-HA antibodies. Residual binding was calculated
as follows: Residual binding by an anti-GARP or anti-LAP
antibody=[I.sub.m/wt with anti-GARP or anti-LAP
antibody]/[I.sub.m/wt with anti-HA antibody]
[0390] Results obtained on all mutants are detailed in FIG. 19,
parts A-D for binding by inhibitory anti-GARP antibodies MHG-8 and
LHG-10, non-inhibitory anti-GARP antibody MHG-6, and anti-LAP
antibody, respectively. They are also summarized in Table 8 for
MHG-8 and LHG-10.
TABLE-US-00050 TABLE 8 Effects of GARP and TGF.beta.1 mutations on
the binding and inhibitory activity of mAbs MHG-8 and LHG-10 Aa of
GARP, Effects of Effects of CDR of LAP or Corresponding mutations
on mutations on MHG-8 mature aa in mouse MHG-8 binding LHG-10
binding in contact TGF-.beta.1 GARP/TGF-.beta.1 and activity and
activity with GARP, in contact complexes, Loss of Loss of LAP or
with Fab Mutation if different Loss of Reduced inhibitory Loss of
Reduced inhibitory mature MHG-8.sup.1 constructed from human
binding.sup.2 avidity.sup.3 Activity.sup.4 binding.sup.2
avidity.sup.3 activity.sup.4 TGF-.beta.1 GARP Thr113 M111T/ Met - -
- - - - L3 A112G/ T113M Ala114 A114R - nt - - nt - L3 Ser116 S116N
Asn - nt - - nt - L3 Ala117 A117R - nt - - nt - L1/L3 Gly118 G118L/
- - + - - ? L1/L3 Gly119 G119L L3 Tyr137 Y137H His - - + +/- - - H3
Ser138 S138G Gly - - - - - - H3 Gly139 G139N Asn + NE + - - - H3/
L1 Y137H/ + NE + + + + S138G/ G139N Leu140 L140K/ + NE + - - - H3
Glu142 E142L H3/L1 Arg143 R143A + NE nt - nt nt H3/ R143Y + NE +
+/- - ? L1/ L3 Leu144 L144Q/ Mutant not evaluable because not L3
Leu145 L145Q/ expressed on surface L1 Gly146 G146K L1 Thr162 T162D
- + ? + + + H3 Arg163 R163E + + + + + + H3 R163A/ + nt nt - nt nt
T165A R163E/ + NE nt +/- nt nt T165A Thr165 T165A Ala - - - - - -
H3 Arg166 R166M/ - + - - - - H3 His167 H167E H3 Arg170 R170A Trp -
- - - - - L1 Glu189 E189A - - - - - - H3 LAP Arg58 R58A - - - - - +
H2 Glu100 E100A - nt - - nt - H2 Glu146 E146R - - - - - - H2 Gln269
Q269Y - - - - - - H2 His270 H270Y - - - - - - H2 Leu271 H2 Gln272
Q272Y His - - - - - - H2 Ser273 H2 L271R/ - nt - - nt - Q272Y/
S273W Mature Tyr284 Y284A - - - - - - H1 TGF-.beta.1 Tyr336 Y336A -
+ - +/- - ? H3 Y336Q - nt nt - - nt Ser337 S337A - nt - - - - H2
Lys338 K338E + + + + - + H2/ H3 Ala341 A341Y - nt - - nt - H2
Gln345 Q345A - nt - - nt - H1 .sup.1Amino-acids located at less
than 5 angstrom from an amino-acid of MHG-8 as determined with the
CONTACT software .sup.2+: <50% residual binding on mutant by
comparison to WT; -: .gtoreq.50% residual binding on mutant by
comparison to WT; +/-: residual binding .gtoreq.50% but error bar
(sdt deviation) crosses the 50% threshold .sup.3+: ratio of EC50
(mutant vs WT) >2; -: ratio of EC50 (mutant vs WT) .ltoreq.2;
NE: non evaluable; nt: not tested .sup.4+: residual inhibitory
activity <21%; not: not tested; ?: not conclusive, should be
re-tested
[0391] FIG. 19, part A, demonstrates that binding by MHG-8 was lost
(i.e. residual binding <50%) on the following GARP mutants:
[0392] triple mutation Y137H/S138G/G139N (2% residual binding),
confirming previous observations Kuende et al., 20151; [0393]
single mutation G139N (2% residual binding), but not single
mutations Y137H and S138G, indicating a more prominent role of GARP
Gly139 than Tyr137 and Ser138 in binding by MHG-8; [0394] double
mutation L140K/E142L (7% residual binding); [0395] single mutations
R143A and R143Y (1% residual binding); [0396] double mutations
R163A/T165A (36% residual binding) and R163E/T165A (4% residual
binding); [0397] single mutation R163E (19% residual binding), but
not single mutation T165A, indicating a more prominent role of
Arg163 than Thr165 for binding by MHG-8.
[0398] Altogether, of the 22 aa in GARP that are in contact with
the MHG-8 Fab as determined by analysis of the crystal structure,
only 5 aa (Gly139, Leu140/Glu142, Arg143 and Arg163) appear to be
required for binding to the MHG-8 mAb.
[0399] In addition, FIG. 19, part A demonstrates that only one
mutation in TGF-.beta.1 results in loss of binding by MHG-8. This
mutation corresponds to K338E (25% residual binding). Thus, of the
8 aa from LAP and 6 aa from mature TGF-.beta.1 that are in contact
with MHG-8 Fab in the crystal, only one aa in mature TGF-.beta.1
(Lys338) is required for binding to the MHG-8 mAb.
[0400] FIG. 19, part B shows residual binding by LHG-10 on GARP
mutants. The results can be summarized as follows: [0401] triple
mutation Y137H/S138G/G139N induces loss of binding by LHG-10 (6%
residual binding), confirming previous observations [Cuende et al.,
2015]; [0402] single mutation Y137H induces a partial loss of
binding (62% residual binding, but standard deviation of the mean
value crosses the 50% threshold), whereas single mutations G139N
and S138G do not affect binding. The mode of binding of LHG-10 to
GARP is thus different from that of MHG-8 (see above); [0403]
double mutation L140K/E142L does not induce loss of binding to
LHG-10, in contrast to what was observed for MHG-8, confirming that
the mode of binding of LHG-10 to GARP is different from that of
MHG-8; [0404] single mutation R143Y only induces a partial loss of
binding (68% residual binding), whereas mutation R143A does not.
Thus, aa Arg143 appears more important for binding by MHG-8 than
binding by LHG-10; [0405] single mutation T162D induces loss of
binding by LHG-10 (49% residual binding), whereas it had no effect
on binding by MHG-8; [0406] single mutation R163E induces loss of
binding by LHG-10 (48% residual binding).
[0407] Altogether, of the 22 aa in GARP that are in contact with
the MHG-8 Fab as determined by analysis of the crystal structure,
only two aa (Thr162 and Arg163) appear to be required for binding
by the LHG-10 mAb. In addition, two other aa (Tyr137 and Arg143)
appear to also play a role, as mutations of the aa induce partial
loss of binding by LHG-10. Of the four aa important for binding by
LHG-10, two are also required for binding by MHG-8 (Arg143 and
Arg163), whereas two are unique to LHG-10 (Tyr137 and Thr 162).
[0408] FIG. 19, part B, also shows that one mutation in mature
TGF-.beta.1 (K338E, 15% residual binding) induces loss of binding
to LHG-10. This mutation also induced loss of binding to MHG-8. One
other mutation in mature TGF-.beta.1 (Y336A, 56% residual binding)
induced partial loss of binding to LHG-10, whereas it did not
affect binding to MHG-8.
[0409] As expected, none of the mutations tested induced loss of
binding to MHG-6, a non-inhibitory anti-GARP antibody that binds
GARP/TGF-.beta.1 complexes on an epitope distant from that bound by
MHG-8 and LHG-10 (FIG. 19, part C) Similarly, none of the mutations
induced loss of binding to the anti-LAP antibody (FIG. 19, part
D).
Impact of Mutations in GARP or TGF-.beta.1 on the Avidity of
Inhibitory Anti-GARP Antibodies MHG-8 and LHG-10 for
GARP/TGF-.beta.1 Complexes.
[0410] Mutations that do not induce loss of binding by MHG-8 or
LHG-10 (>50% residual binding) could nevertheless induce a
reduced avidity of the antibodies for the mutated GARP/TGF-.beta.1
complexes by comparison to WT. The avidity of each antibody on the
WT and on the various mutated forms of GARP/TGF-.beta.1 complexes
was determined by performing FACS analyses of 293T cells
transfected as described above, using 5-to-5 serial dilutions of
antibodies for labeling (final concentrations of 5, 1, 0.2, 0.04,
0.008 and 0.0016 .mu.g/ml). Intensities of staining at each
concentration of antibody relative to the maximal intensity
measured at 5 .mu.g/ml were determined as follows:
Relative staining intensity=[Geom with X .mu.g/ml of antibody-Geom
in the absence of antibody]/[Geom with 5 .mu.g/ml of antibody-Geom
in the absence of antibody]
[0411] The relative staining intensities were plotted according to
the concentration of antibody used for staining, and a non-linear
regression analysis was used with the Prism software to determine
an EC.sub.50 value for binding of the antibody to the WT and to
each of the various mutant GARP/TGF-.beta.1 complexes. If the ratio
between the EC.sub.50 measured on the mutant and the EC.sub.50
measured on the WT was >2, the mutation was considered to induce
a reduced avidity for binding by the antibody. The ratio of
EC.sub.50 (mutant vs WT) for MHG-8 and LHG-10 are indicated below
each mutation on FIG. 19, parts A and B, respectively. The data
from this experiment is also summarized in Table 8.
[0412] The avidity of the antibodies for mutations that induce a
complete loss of binding (<10% residual binding) cannot be
evaluated (NE=non evaluable in FIG. 19, parts A and B).
[0413] Further, most mutations that induce incomplete loss of
binding (10 to 50% residual binding) also induce reduced avidity.
This is the case for mutations R163E in GARP and K338E in
TGF-.beta.1 for binding by MHG-8, and for mutations T162D and R163E
in GARP for binding by LHG-10. Unexpectedly, a few mutations that
induced partial loss of binding at 5 .mu.g/ml did not appear to
induce reduced avidity. This was the case for mutations Y137H and
R143Y in GARP and mutations Y336A and K338E in TGF-.beta.1 for
binding by LHG-10. However, in these apparently paradoxical cases,
the concentration of 5 .mu.g/ml of LHG-10 used by default as the
maximum concentration did not yield a saturated signal. This could
induce an error in the calculated EC.sub.50, explaining the
apparent discrepancy.
[0414] Interestingly, three mutations that did not induce loss of
binding (>50% residual binding) when MHG-8 was used at 5
.mu.g/ml, nevertheless reduced the avidity of MHG-8 for the
GARP/TGF-.beta.1 complexes. These mutations correspond to T162D and
R166/H167E in GARP, and Y336A in TGF-.beta.1. Mutations T162D in
GARP and Y336A in TGF-.beta.1 induced loss of binding by LHG-10,
indicating that Thr162 of GARP and Tyr336 of TGF-.beta.1 are
important amino acids for the binding of both MHG-8 and LHG-10,
although the effect of mutations at these positions are not
completely identical.
Impact of Mutations in GARP or TGF-.beta.1 on the Inhibitory
Activity of Anti-GARP Antibodies MHG-8 and LHG-10.
[0415] Mutations that neither induce loss of binding nor reduce the
avidity of MHG-8 or LHG-10 for GARP/TGF-.beta.1 complexes could
nevertheless result in a decreased ability of the antibodies to
inhibit active TGF-.beta.1 production from GARP/TGF-.beta.1
complexes. This would indicate the existence of points of contact
between GARP/TGF-.beta.1 complexes and MHG-8 and/or LHG-10 that are
important for the inhibitory activity of the antibodies but are not
required for their binding. In order to examine this possibility,
functional assays were developed to measure active TGF-.beta.1
production from wild type or mutant GARP/TGF-.beta.1 complexes in
transfected 293T cells, in the presence or absence of anti-GARP
antibodies.
[0416] To measure the capacity of MHG-8 and LHG-10 to inhibit
active TGF-.beta.1 production from GARP/TGF-.beta.1 complexes
containing mutant forms of GARP, a clone of 293T cells stably
transfected with integrin .beta.6, which pairs with the
endogenously expressed integrin .alpha.V to form a well-known
activator of latent TGF-.beta.1, was used. This clone, named
293T+ITGB6, was transiently co-transfected with mutant forms of
GARP, with wild type TGF-.beta.1 and with a CAGA-Luc reporter
plasmid in which luciferase expression is driven by a TGF-.beta.1
responsive promoter.
[0417] To measure the capacity of MHG-8 and LHG-10 to inhibit
active TGF-.beta.1 production from GARP/TGF-.beta.1 complexes
containing mutant forms of TGF-.beta.1, a clone of 293T cells
stably transfected with integrin B6 and GARP was used. This clone,
named 293T+ITGB6+GARP, was transiently co-transfected with mutant
forms of TGF-.beta.1 and with the CAGA-Luc plasmid.
[0418] Transiently transfected cells (293T+ITGB6 or
293T+ITGB6+GARP) were incubated during 24 hours with inhibitory
anti-GARP antibodies MHG-8 or LHG-10, or with control antibodies
corresponding to a neutralizing anti-TGF-.beta.1 antibody (positive
control), or the non-inhibitory anti-GARP antibody LHG-14 (negative
control). All antibodies were used at 20 .mu.g/ml. Cells were then
lysed and incubated with a luciferase substrate and the luminescent
signal was measured in a luminometer.
[0419] To compare various mutants tested in different experiments,
the inhibitory activity of antibodies were experessed as
follows:
Residual inhibitory activity (%)=100.times.[Inhibition by antibody
X on the mutant complex]/[Inhibition by antibody X on the WT
complex]
where Inhibition by antibody X=1-[luminescent signal with antibody
X]/[luminescent signal with the control, non inhibitory anti-GARP
antibody LHG-14]
[0420] Results obtained are detailed in FIG. 20, parts A-C for
MHG-8, LHG-10 and anti-TGF-.beta.1, respectively, and summarized in
Table 8.
[0421] As expected, mutations that induce loss of binding by MHG-8
or LHG-10 (underlined in FIG. 20, parts A and B) induce a complete
or almost complete loss of their inhibitory activity (residual
inhibitory activity .ltoreq.21%). Mutations that reduce the avidity
of the antibodies without inducing complete loss of binding
(indicated in italics in FIG. 20, parts A and B) do not appear to
affect the inhibitory activity of the antibodies when used at 20
.mu.g/ml in this assay.
[0422] Interestingly, a few mutations that did not induce loss of
binding nor reduced the avidity of the antibodies induced a severe
loss of inhibitory activity. These mutations are highlighted by a
box in FIG. 20, parts A and B. They comprise mutations G118L/G119L
and Y137H of GARP, on which MHG-8 only exerts 11% and 20% residual
inhibitory activity, respectively. These mutations also appear to
at least partially affect the inhibitory activity of LHG-10.
Further, mutation R58A does not affect binding by antibody LHG-10,
but completely abolishes its inhibitory activity.
[0423] As expected, none of the mutations tested affect the
inhibitory activity of the anti-TGF-.beta.1 antibody, used here as
a positive control.
Materials and Methods
Mice
[0424] Mice (DBA/2, Balb/c, and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ or
NSG from The Jackson Laboratory) were bred at the animal facility
of the Universite Catholique de Louvain, Belgium. Handling of mice
and experimental procedures were conducted in accordance with
national and institutional guidelines for animal care.
Cells and Transfections
[0425] P1.HTR cells, a highly transfectable variant of the P815
mastocytoma derived from DBA/2 mice, were electroporated with a
plasmid encoding the full-length human GARP and selected in
puromycin (1.6 .mu.g/ml) under limiting dilution conditions. Two
clones expressing high surface hGARP (P1.HTR+hGARP) were isolated
and used to immunize H-2d mice. A stable clone of murine BW5147.C2
cells expressing high levels of human GARP (BW5147+hGARP) was
derived as described (E. Gauthy et al., PLoS One 8, e76186 (2013)).
This clone was electroporated with a plasmid encoding full-length
human TGF-b1, and selected in neomycin (3 mg/ml) under limiting
dilution conditions. A subclone expressing high levels of surface
hGARP/hTGF-.beta.1 complexes (BW5147+hGARP+hTGFB1) was isolated and
used to immunize llamas. Human Treg and Th clones were derived and
cultured as previously described (J. Stockis, et al. Eur. J.
Immunol. 39, 869-882 (2009).). Total human PBMCs were purified from
the blood of hemochromatosis donors by centrifugation on a
Lymphoprep.RTM. gradient. Human polyclonal Tregs were obtained by
sorting CD4+CD25+CD127lo cells by FACS from total PBMCs, followed
by in vitro stimulation with anti-CD3/CD28 coated beads in the
presence of IL-2 during 12-13 days, as described (E. Gauthy et al.
PLoS One 8, e76186 (2013).). 293T cells were transiently
transfected with hGARP- and hTGF-.beta.1-encoding plasmids using
the TransIT-LT1 transfection Reagent (Mirus Bio).
Generation of MHG mAbs
[0426] DBA/2 or Balb/c mice were immunized with live P1.HTR+hGARP
cells, following a previously described injection scheme (M. M.
Lemaire, et al. J. Immunol. Methods, (2011)). Lymphocytes from mice
with high titers of anti-hGARP antibodies, as determined by FACS,
were fused to SP2/neo cells in the presence of polyethylene glycol.
Hybridomas were selected in HAT medium and cloned under limiting
dilution conditions. Supernatants of hybridoma clones were screened
by FACS for the presence of antibodies binding to BW5147+hGARP
cells. Fourteen positive clones were selected, further subcloned to
ensure clonality, and amplified for large scale-production and
purification of 14 new anti-hGARP mAbs (MHG-1 to -14).
Generation of LHG mAbs
[0427] Immunizations of llamas, harvesting of peripheral blood
lymphocytes (PBLs), RNA preparation and amplification of antibody
fragments were performed as described (C. Basilico, et al. J. Clin.
Invest. 124, 3172-3186 (2014)). Briefly, four llamas were injected
six times at weekly intervals with 10.sup.7 BW5147+hGARP+hTGFB1
cells and Freund's incomplete adjuvant in two regions of the neck
muscles located a few centimeters apart. Another four llamas were
injected four times biweekly with a mix of plasmids containing
hGARP cDNA and hTGFB1 cDNA, respectively. Blood samples (10 ml)
were collected to monitor IgG1 responses against hGARP/TGF-.beta.1
complexes by ELISA, using immobilized recombinant GARP/TGF-.beta.1
complexes (produced in HEK-293E cells co-transfected with hTGFB1
and hGARP truncated from the transmembrane-coding region) for
capture, followed by a mouse anti-llama IgG1 antibody (clone 27E10)
and a HRP-conjugated donkey anti-mouse antibody (Jackson) for
detection. Three-to-four days after the last immunization, 400 ml
of blood were collected from responding llamas, PBLs were isolated
on a Ficoll-Paque gradient and total RNA was extracted as described
(P. Chomczynski, et al. Anal. Biochem. 162, 156-159 (1987)). On
average, 450 .mu.g of RNA were obtained and used for random cDNA
synthesis followed by PCR amplification of the immunoglobulin heavy
and light chain variable regions (VH, V.lamda. and V.kappa.). Two
independent phagemid libraries, coding for VH/V.lamda. and
VH/V.kappa. Fabs, respectively, were constructed as previously
described (C. Basilico, et al. J. Clin. Invest. 124, 3172-3186
(2014).) to obtain a diversity of 1-7.times.10.sup.8 Fabs in each
library. Phages expressing Fabs were produced and selected
according to standard protocols. Briefly, 2 to 3 rounds of phage
selections were performed by binding on immobilized recombinant
GARP/TGF-.beta.1, washing and elution with trypsin. In some
instances, counter selections with soluble hGARP (hGARP1-628 fused
to a TEV-3.times.StrepTag produced in 293E cells) and soluble
latent TGF-.beta.1 were used to enrich for Fabs binding
hGARP/TGF-.beta.1 complexes only. Individual colonies were isolated
and periplasmic fractions containing soluble Fabs were produced by
IPTG induction. Fabs in periplasmic fractions were then screened by
ELISA for binding to immobilized hGARP/TGF-.beta.1. VH and VL
regions of Fab clones binding to hGARP/TGF-.beta.1 complexes were
sequenced. Fab clones were divided into 17 families, based on
similarities in the sequences coding for the VH CDR3 region. VH and
VL sequences from one representative clone of each family were
subcloned in a full human IgG1 backbone, and the resulting plasmids
were transfected into HEK-293E cells to produce and purify 17 new
anti-hGARP mAbs (LHG-1 to -17).
Analysis of FOXP3i1 Methylation
[0428] Proportions of cells with a demethylated FOXP3i1 in human
PBMCs, in human polyclonal Treg populations or in splenocytes from
NSG mice grafted with human cells were measured by methyl-specific
qPCR as described (I. J. de Vries, et al. Clin. Cancer Res. 17,
841-848 (2011)), using the following primers (sense, antisense and
Taqman probe, 5'-3', with underlined nucleotides corresponding to
LNA.RTM. modified bases): total FOXP3i1 alleles:
AAACCTACTACAAAACAAAACAAC (SEQ ID NO: 56)/GGAGGAAGAGAAGAGGGTA (SEQ
ID NO: 57)/CCTATAAAATAAAATATCTACCCTC (SEQ ID NO: 58); demethylated
FOXP3i1 alleles: TCTACCCTCTTCTCTTCCTCCA (SEQ ID NO:
59)/GATTTTTTTGTTATTGATGTTATGGT (SEQ ID NO: 60)/AAACCCAACACATCCAACCA
(SEQ ID NO: 61).
Assay to Measure Active TGF-.beta.1 Production by Human Treg
Cells
[0429] A human Treg clone (10.sup.6 cells/ml) was stimulated in
serum-free medium with coated anti-CD3 (Orthoclone OKT3;
Janssen-Cilag, 1 .mu.g/ml) and soluble anti-CD28 (BD Biosciences; 1
.mu.g/ml), in the presence or absence of 10 .mu.g/ml of an
anti-hGARP mAb (clones tested: MHG-1 to -14; LHG-1 to -17; Plato-1
from Enzo Life Sciences; 272G6 and 50G10 from Synaptic Systems;
7B11 from BioLegend) or of an anti-hTGF-.beta. antibody (clone
1D11, R&D systems). Cells were lysed after 24 hours and
submitted to SDS-PAGE under reducing conditions. Gels were blotted
on nitrocellulose membranes with the iBlot system (Life
Technologies). After blocking, membranes were incubated with
primary antibodies directed against phosphorylated SMAD2 (pSMAD2,
Cell Signaling Technologies) or .beta.-ACTIN (SIGMA), then with
secondary HRP coupled antibodies and revealed with an ECL substrate
(ThermoFisher Scientific). The presence of pSMAD2 indicates
production of active TGF-.beta.1 by the stimulated Treg clone. ECL
signals were quantified by measuring the density of the 55 kDa
pSMAD2 and 40 kDa (3-ACTIN bands on autoradiographs, using the
Image J software.
Flow Cytometry
[0430] Intact or permeabilized cells were labeled according to
standard protocols, using combinations of the following primary
and/or secondary reagents as indicated in the figures. Primary
antibodies: biotinylated MHG-1 to 14; LHG-1 to -17; anti-hGARP
clone Plato 1 (Enzo Life Sciences); antihCD45-PerCP, anti-hCD3-FITC
or anti-hCD3-APC, anti-hCD4-FITC or anti-hCD4-APC,
antihCD45RA-PE-Cy7 (Biolegend); anti-hCD8a-APC-H7,
anti-CD25-PE-Cy7, anti-hCD127-PE (BD Biosciences); anti-hFOXP3-PE
or anti-hFOXP3-APC (eBiosciences); anti-hLAP-APC (R&D Systems);
anti-HA (Eurogentec). Secondary antibodies or reagents:
anti-hIgG1-biotine (Jackson ImmunoResearch); anti-mIgG1-AF647,
anti-mIgG2b-AF647, LIVE/DEAD Fixable Near-IR Dead cell stain kit
(Life Technologies); Streptavidine-PE (BD Biosciences). Labeled
cells were analyzed on a LSR Fortessa cytometer or sorted on a
FACSARIA III (both from BD Biosciences), and results were computed
with the FlowJo Software (Treestar).
In Vitro Suppression Assays
[0431] 2.times.10.sup.4 Th cells were seeded alone or with the
indicated numbers of Tregs, and stimulated with coated anti-CD3
(Orthoclone OKT3, Janssen-Cilag, 1 .mu.g/ml) and soluble anti-CD28
(BDBiosciences, 1 .mu.g/ml), in the presence or absence of 10
.mu.g/ml of an anti-hGARP mAb (MHG or LHG), an anti-TGF-b antibody
(clone 1D11, R&D Systems) or an isotype control (mIgG1 clone
11711, R&D Systems). [methyl-3H]Thymidine (0.5 mCi/well) was
added during the last 16 hours of a 4 day-culture.
Xenogeneic Graft-Versus-Host Disease in NSG Mice
[0432] NSG mice were irradiated (1.5 Gy) one day before tail vein
injections of human PBMCs (3.times.10.sup.6 per mouse) alone, or
mixed with autologous polyclonal Tregs (1.5.times.10.sup.6 per
mouse). One day before graft and weekly thereafter, mice received
i.p. injections of PBS or 400 .mu.g of MHG-8 (mIgG1), an
anti-TGF-b1 antibody (mIgG1 clone 13A1/A26) or an isotype control
(mIgG1 anti-TNP clone B8401H5.M). Mice were monitored bi-weekly for
the development of GVHD. A global disease score was established by
adding up scores attributed in the presence of the following
symptoms: weight loss (1 if >10%; 2 if >20%); anemia or
icterus (1 if white or yellow ears; 2 if white or yellow ears and
tail); humped posture (1); reduced activity (1 if limited activity;
2 if no activity); hair loss (1). Mice were euthanized when
reaching a global score >6. Death corresponds to a maximum score
of 8.
Cytokine Concentrations in Sera
[0433] Concentrations of human IL-2, IL-10, and IFNg in mouse serum
were determined using a Bio-Plex Pro Human Cytokine 17-plex Assay
according to the manufacturer's recommendations (Bio-Rad
Laboratories). Limits of detection in this assay were: 0.12 pg/ml
for IL-2; 1.56 pg/ml for IFN.gamma.; 2.48 pg/ml for IL-10.
EQUIVALENTS
[0434] The disclosure may be embodied in other specific forms
without departing from the spirit or essential characteristics
thereof. The foregoing embodiments are therefore to be considered
in all respects illustrative rather than limiting of the
disclosure. Scope of the disclosure is thus indicated by the
appended claims rather than by the foregoing description, and all
changes that come within the meaning and range of equivalency of
the claims are therefore intended to be embraced herein.
Sequence CWU 1
1
661662PRTHomo sapiens 1Met Arg Pro Gln Ile Leu Leu Leu Leu Ala Leu
Leu Thr Leu Gly Leu 1 5 10 15 Ala Ala Gln His Gln Asp Lys Val Pro
Cys Lys Met Val Asp Lys Lys 20 25 30 Val Ser Cys Gln Val Leu Gly
Leu Leu Gln Val Pro Ser Val Leu Pro 35 40 45 Pro Asp Thr Glu Thr
Leu Asp Leu Ser Gly Asn Gln Leu Arg Ser Ile 50 55 60 Leu Ala Ser
Pro Leu Gly Phe Tyr Thr Ala Leu Arg His Leu Asp Leu 65 70 75 80 Ser
Thr Asn Glu Ile Ser Phe Leu Gln Pro Gly Ala Phe Gln Ala Leu 85 90
95 Thr His Leu Glu His Leu Ser Leu Ala His Asn Arg Leu Ala Met Ala
100 105 110 Thr Ala Leu Ser Ala Gly Gly Leu Gly Pro Leu Pro Arg Val
Thr Ser 115 120 125 Leu Asp Leu Ser Gly Asn Ser Leu Tyr Ser Gly Leu
Leu Glu Arg Leu 130 135 140 Leu Gly Glu Ala Pro Ser Leu His Thr Leu
Ser Leu Ala Glu Asn Ser 145 150 155 160 Leu Thr Arg Leu Thr Arg His
Thr Phe Arg Asp Met Pro Ala Leu Glu 165 170 175 Gln Leu Asp Leu His
Ser Asn Val Leu Met Asp Ile Glu Asp Gly Ala 180 185 190 Phe Glu Gly
Leu Pro Arg Leu Thr His Leu Asn Leu Ser Arg Asn Ser 195 200 205 Leu
Thr Cys Ile Ser Asp Phe Ser Leu Gln Gln Leu Arg Val Leu Asp 210 215
220 Leu Ser Cys Asn Ser Ile Glu Ala Phe Gln Thr Ala Ser Gln Pro Gln
225 230 235 240 Ala Glu Phe Gln Leu Thr Trp Leu Asp Leu Arg Glu Asn
Lys Leu Leu 245 250 255 His Phe Pro Asp Leu Ala Ala Leu Pro Arg Leu
Ile Tyr Leu Asn Leu 260 265 270 Ser Asn Asn Leu Ile Arg Leu Pro Thr
Gly Pro Pro Gln Asp Ser Lys 275 280 285 Gly Ile His Ala Pro Ser Glu
Gly Trp Ser Ala Leu Pro Leu Ser Ala 290 295 300 Pro Ser Gly Asn Ala
Ser Gly Arg Pro Leu Ser Gln Leu Leu Asn Leu 305 310 315 320 Asp Leu
Ser Tyr Asn Glu Ile Glu Leu Ile Pro Asp Ser Phe Leu Glu 325 330 335
His Leu Thr Ser Leu Cys Phe Leu Asn Leu Ser Arg Asn Cys Leu Arg 340
345 350 Thr Phe Glu Ala Arg Arg Leu Gly Ser Leu Pro Cys Leu Met Leu
Leu 355 360 365 Asp Leu Ser His Asn Ala Leu Glu Thr Leu Glu Leu Gly
Ala Arg Ala 370 375 380 Leu Gly Ser Leu Arg Thr Leu Leu Leu Gln Gly
Asn Ala Leu Arg Asp 385 390 395 400 Leu Pro Pro Tyr Thr Phe Ala Asn
Leu Ala Ser Leu Gln Arg Leu Asn 405 410 415 Leu Gln Gly Asn Arg Val
Ser Pro Cys Gly Gly Pro Asp Glu Pro Gly 420 425 430 Pro Ser Gly Cys
Val Ala Phe Ser Gly Ile Thr Ser Leu Arg Ser Leu 435 440 445 Ser Leu
Val Asp Asn Glu Ile Glu Leu Leu Arg Ala Gly Ala Phe Leu 450 455 460
His Thr Pro Leu Thr Glu Leu Asp Leu Ser Ser Asn Pro Gly Leu Glu 465
470 475 480 Val Ala Thr Gly Ala Leu Gly Gly Leu Glu Ala Ser Leu Glu
Val Leu 485 490 495 Ala Leu Gln Gly Asn Gly Leu Met Val Leu Gln Val
Asp Leu Pro Cys 500 505 510 Phe Ile Cys Leu Lys Arg Leu Asn Leu Ala
Glu Asn Arg Leu Ser His 515 520 525 Leu Pro Ala Trp Thr Gln Ala Val
Ser Leu Glu Val Leu Asp Leu Arg 530 535 540 Asn Asn Ser Phe Ser Leu
Leu Pro Gly Ser Ala Met Gly Gly Leu Glu 545 550 555 560 Thr Ser Leu
Arg Arg Leu Tyr Leu Gln Gly Asn Pro Leu Ser Cys Cys 565 570 575 Gly
Asn Gly Trp Leu Ala Ala Gln Leu His Gln Gly Arg Val Asp Val 580 585
590 Asp Ala Thr Gln Asp Leu Ile Cys Arg Phe Ser Ser Gln Glu Glu Val
595 600 605 Ser Leu Ser His Val Arg Pro Glu Asp Cys Glu Lys Gly Gly
Leu Lys 610 615 620 Asn Ile Asn Leu Ile Ile Ile Leu Thr Phe Ile Leu
Val Ser Ala Ile 625 630 635 640 Leu Leu Thr Thr Leu Ala Ala Cys Cys
Cys Val Arg Arg Gln Lys Phe 645 650 655 Asn Gln Gln Tyr Lys Ala 660
210PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VH-CDR1 peptide 2Gly Phe Ser Leu Thr Gly Tyr Gly Ile Asn
1 5 10 316PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VH-CDR2 peptide 3Met Ile Trp Ser Asp Gly Ser Thr Asp Tyr
Asn Ser Val Leu Thr Ser 1 5 10 15 413PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VH-CDR3
peptide 4Asp Arg Asn Tyr Tyr Asp Tyr Asp Gly Ala Met Asp Tyr 1 5 10
511PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VL-CDR1 peptide 5Lys Ala Ser Asp His Ile Lys Asn Trp Leu
Ala 1 5 10 67PRTArtificial SequenceDescription of Artificial
Sequence Synthetic VL-CDR2 peptide 6Gly Ala Thr Ser Leu Glu Ala 1 5
79PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VL-CDR3 peptide 7Gln Gln Tyr Trp Ser Thr Pro Trp Thr 1 5
8140PRTArtificial SequenceDescription of Artificial Sequence
Synthetic heavy chain variable region polypeptide 8Met Ala Val Leu
Ala Leu Leu Phe Cys Leu Val Thr Phe Pro Ser Cys 1 5 10 15 Ile Leu
Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala 20 25 30
Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu 35
40 45 Thr Gly Tyr Gly Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly
Leu 50 55 60 Glu Trp Leu Gly Met Ile Trp Ser Asp Gly Ser Thr Asp
Tyr Asn Ser 65 70 75 80 Val Leu Thr Ser Arg Leu Arg Ile Ser Lys Asp
Asn Ser Asn Ser Gln 85 90 95 Val Phe Leu Lys Met Asn Ser Leu Gln
Val Asp Asp Thr Ala Arg Tyr 100 105 110 Tyr Cys Ala Arg Asp Arg Asn
Tyr Tyr Asp Tyr Asp Gly Ala Met Asp 115 120 125 Tyr Trp Gly Gln Gly
Thr Ser Val Thr Val Ser Ser 130 135 140 9127PRTArtificial
SequenceDescription of Artificial Sequence Synthetic light chain
variable region polypeptide 9Met Lys Phe Pro Ser Gln Leu Leu Leu
Phe Leu Leu Phe Arg Ile Thr 1 5 10 15 Gly Ile Ile Cys Asp Ile Gln
Val Thr Gln Ser Ser Ser Tyr Leu Ser 20 25 30 Val Ser Leu Gly Asp
Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His 35 40 45 Ile Lys Asn
Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro 50 55 60 Arg
Leu Leu Val Ser Gly Ala Thr Ser Leu Glu Ala Gly Val Pro Ser 65 70
75 80 Arg Phe Ser Gly Ser Gly Ser Gly Lys Asn Phe Thr Leu Ser Ile
Thr 85 90 95 Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln
Gln Tyr Trp 100 105 110 Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Thr
Leu Glu Ile Arg 115 120 125 10420DNAArtificial SequenceDescription
of Artificial Sequence Synthetic heavy chain variable region
polynucleotide 10atggctgtcc tggcattact cttctgcctg gtaacattcc
caagctgtat cctttcccag 60gtgcagctga aggagtcagg acctggcctg gtggcgccct
cacagagcct gtccatcaca 120tgcaccgtct cagggttctc attaaccggc
tatggtataa actgggttcg ccagcctcca 180ggaaagggtc tggagtggct
gggaatgata tggagtgatg gaagcacaga ctataattca 240gttctcacat
ccagactgag gatcagtaag gataattcca atagccaggt tttcttaaaa
300atgaacagtc tgcaagttga tgacacagcc aggtactatt gtgccagaga
tcgaaactac 360tatgattacg acggggctat ggactactgg ggtcaaggaa
cctcagtcac cgtctcctca 42011381DNAArtificial SequenceDescription of
Artificial Sequence Synthetic light chain variable region
polynucleotide 11atgaagtttc cttctcaact tctgctcttc ctgctgttca
gaatcacagg cataatatgt 60gacatccagg tgacacaatc ttcatcctac ttgtctgtat
ctctaggaga cagggtcacc 120attacttgca aggcaagtga ccacattaaa
aattggttag cctggtatca gcagaaacca 180ggaattgctc ctaggctctt
agtttctggt gcaaccagtt tggaagctgg ggttccttca 240agattcagtg
gcagtggatc tggaaagaat ttcactctca gcattaccag tcttcagact
300gaagatgttg ctacttatta ctgtcaacag tattggagta caccgtggac
gttcggtgga 360ggcaccactc tggagatcag a 3811241PRTArtificial
SequenceDescription of Artificial Sequence Synthetic conformational
epitope polypeptide 12His Leu Ser Leu Ala His Asn Arg Leu Ala Met
Ala Thr Ala Leu Ser 1 5 10 15 Ala Gly Gly Leu Gly Pro Leu Pro Arg
Val Thr Ser Leu Asp Leu Ser 20 25 30 Gly Asn Ser Leu Tyr Ser Gly
Leu Leu 35 40 135PRTArtificial SequenceDescription of Artificial
Sequence Synthetic VH-CDR1 LHG-10 peptide 13Ser Tyr Tyr Ile Asp 1 5
1417PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VH-CDR2 LHG-10 peptide 14Arg Ile Asp Pro Glu Asp Gly Gly
Thr Lys Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly 1517PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VH-CDR3 LHG-10
peptide 15Asn Glu Trp Glu Thr Val Val Val Gly Asp Leu Met Tyr Glu
Tyr Glu 1 5 10 15 Tyr 1611PRTArtificial SequenceDescription of
Artificial Sequence Synthetic VL-CDR1 LHG-10 peptide 16Gln Ala Ser
Gln Xaa Ile Xaa Ser Xaa Leu Ala 1 5 10 177PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR2 LHG-10
peptide 17Xaa Xaa Ser Xaa Xaa Xaa Thr 1 5 189PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR3 LHG-10
peptide 18Gln Gln Tyr Xaa Ser Xaa Pro Xaa Thr 1 5 1911PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR1 LHG-10
peptide 19Gln Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10
207PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VL-CDR2 LHG10 peptide 20Gly Ala Ser Arg Leu Gln Thr 1 5
219PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VL-CDR3 LHG10 peptide 21Gln Gln Tyr Asp Ser Leu Pro Val
Thr 1 5 2211PRTArtificial SequenceDescription of Artificial
Sequence Synthetic VL-CDR1 LHG10.3 peptide 22Gln Ala Ser Gln Ser
Ile Val Ser Tyr Leu Ala 1 5 10 237PRTArtificial SequenceDescription
of Artificial Sequence Synthetic VL-CDR2 LHG10.3 peptide 23Gly Ala
Ser Arg Leu Gln Thr 1 5 249PRTArtificial SequenceDescription of
Artificial Sequence Synthetic VL-CDR3 LHG10.3 peptide 24Gln Gln Tyr
Ala Ser Ala Pro Val Thr 1 5 2511PRTArtificial SequenceDescription
of Artificial Sequence Synthetic VL-CDR1 LHG10.4 peptide 25Gln Ala
Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 267PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR2
LHG10.4 peptide 26Gly Thr Ser Arg Leu Lys Thr 1 5 279PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR3
LHG10.4 peptide 27Gln Gln Tyr Tyr Ser Ala Pro Val Thr 1 5
2811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VL-CDR1 LHG10.5 peptide 28Gln Ala Ser Gln Thr Ile Ser Ser
Phe Leu Ala 1 5 10 297PRTArtificial SequenceDescription of
Artificial Sequence Synthetic VL-CDR2 LHG10.5 peptide 29Arg Ala Ser
Ile Pro Gln Thr 1 5 309PRTArtificial SequenceDescription of
Artificial Sequence Synthetic VL-CDR3 LHG10.5 peptide 30Gln Gln Tyr
Val Ser Ala Pro Pro Thr 1 5 3111PRTArtificial SequenceDescription
of Artificial Sequence Synthetic VL-CDR1 LHG10.6 peptide 31Gln Ala
Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 327PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR2
LHG10.6 peptide 32Gly Ala Ser Arg Leu Lys Thr 1 5 339PRTArtificial
SequenceDescription of Artificial Sequence Synthetic VL-CDR3
LHG10.6 peptide 33Gln Gln Tyr Ala Ser Val Pro Val Thr 1 5
34126PRTArtificial SequenceDescription of Artificial Sequence
Synthetic heavy chain variable region of sequence of LHG10
polypeptide 34Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Asn
Ser Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Arg Phe Thr Ser Tyr 20 25 30 Tyr Ile Asp Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Glu Asp
Gly Gly Thr Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr
Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Val Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala
Arg Asn Glu Trp Glu Thr Val Val Val Gly Asp Leu Met Tyr Glu 100 105
110 Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120
125 35107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic Light chain variable region of sequence LHG10 polypeptide
35Asp Ile Gln Met Thr Gln Ser Pro Thr Ser Leu Ser Ala Ser Leu Gly 1
5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser
Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Ser Phe Thr Leu
Thr Ile Ser Gly Leu Glu Ala 65 70 75 80 Glu Asp Ala Gly Thr Tyr Tyr
Cys Gln Gln Tyr Asp Ser Leu Pro Val 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Leu Lys 100 105 36107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic Light chain
variable region of sequence of LHG10.3 polypeptide 36Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp
Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Val Ser Tyr 20 25
30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile
35 40 45 Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60 Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser
Gly Leu Glu Ala 65 70 75 80 Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln
Tyr Ala Ser Ala Pro Val 85 90 95 Thr Phe Gly Gln Gly Thr Gly Val
Glu Leu Lys 100 105 37107PRTArtificial SequenceDescription of
Artificial Sequence Synthetic Light chain variable region of
sequence of LHG10.4 polypeptide 37Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr
Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly
Thr Ser Arg Leu Lys Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 65
70 75 80 Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Tyr
Ser Ala Pro Val 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Leu
Lys 100 105 38107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic Light chain variable region of sequence of
LHG10.5 polypeptide 38Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Pro Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala
Ser Gln Thr Ile Ser Ser Phe 20 25 30 Leu Ala Trp Tyr His Gln Lys
Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Arg Ala Ser Ile
Pro Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Ser Phe Thr Leu Thr Ile Gly Gly Leu Glu Ala 65 70 75 80 Glu
Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Val Ser Ala Pro Pro 85 90
95 Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 100 105
39107PRTArtificial SequenceDescription of Artificial Sequence
Synthetic Light chain variable region of sequence of LHG10.6
polypeptide 39Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln
Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Asn Ile Leu Ile 35 40 45 Tyr Gly Ala Ser Arg Leu Lys
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 65 70 75 80 Glu Asp Ala
Gly Thr Tyr Tyr Cys Gln Gln Tyr Ala Ser Val Pro Val 85 90 95 Thr
Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 100 105 4045PRTArtificial
SequenceDescription of Artificial Sequence Synthetic human GARP
truncated and tagged polypeptide 40Glu Ala Ala Glu Asn Leu Tyr Phe
Gln Gly Ala Ala Trp Ser His Pro 1 5 10 15 Gln Phe Glu Lys Gly Ala
Ala Trp Ser His Pro Gln Phe Glu Lys Gly 20 25 30 Ala Ala Trp Ser
His Pro Gln Phe Glu Lys Gly Ala Ala 35 40 45 414216DNAMacaca
fascicularispredicted cynomolgus GARP 41ggtggggcag ctgagtggcc
tgcgcctcct cgggccgtga ccccggggtc tggcgcgggg 60tgggacccgg gggcgggttt
gcgcaaaatg tgccgagact gcccgggaga ggaactgcgg 120ccgcgctgag
ccagagccat gagcccccag atcctgctgc tcctggccct gctgacccta
180ggcctggctg cacaacacca agacaaagtg gcatgtaaga tggtggacaa
gaaggtctcg 240tgccagggtc tgggcctgct ccaggtcccc ttggtgctcc
cgccggacac tgagaccctt 300gatctctctg ggaaccagct gcggagtatc
ctggcctcac ccctgggctt ctacacggca 360cttcgtcacc tggacctgag
caccaatgag atcaacttcc tccagccagg agccttccag 420gccctgaccc
acctggagca cctcagcctg gctcacaacc ggctggcgat ggccactgcg
480ctgagtgccg gtggtctggg ccccctgcca cgtgtgacct ccctggacct
gtctgggaac 540agcctgtaca gcggcctgct ggagcggctg ctaggggagg
cacccagcct gcataccctc 600tcactggcgg agaacagtct gactcgcctc
acccgccaca ccttccggga catgcctgcg 660ctggagcagc ttgacctgca
tagcaacgtg ctgatggaca tcgaggatgg cgccttcgag 720ggcctgcccc
acctgaccca tctcaacctt tccaggaatt ccctcacctg catctccgac
780ttcagccttc agcagctgcg ggtgctggac ctgagctgca acagcattga
ggcctttcag 840acggcctccc agccccaggc cgagttccag ctcacctggc
ttgacctgcg ggagaacaaa 900ctgctccatt tccccgacct ggccgcgctc
ccgagactca tctacctgaa cttgtccaac 960aacctcatcc ggctccccac
agggccaccc caggacagca agggcatcca cgcgccttcc 1020gagggctggt
cagccctgcc cctctcaacc cccaatggga atgtcagtgc ccgccccctt
1080tcccagctct tgaatctgga tttgagctac aatgagattg aactcatccc
cgacagcttt 1140cttgagcacc tgacctccct gtgcttcctg aacctcagca
gaaactgctt gcggaccttt 1200gaggcccggc gctcaggctc cctgccctgc
ctgatgctcc ttgatttaag ccacaatgcc 1260ctggagacac tggaactggg
cgccagagcc ctggggtcct tgcggacact gctcctacag 1320ggcaatgccc
tgcgggacct gcctccatac acctttgcca acctggccag cctgcagcgg
1380ctcaacctgc aggggaaccg ggtcagcccc tgtggggggc cgaatgagcc
cggccccgcc 1440agctgtgtgg ccttctctgg catcgcctcc ctccgcagcc
tgagcctggt ggataatgag 1500atagagctgc tcagggcagg ggccttcctc
cataccccac tgactgagct ggacctttct 1560tccaaccctg ggctggaggt
ggccacaggg gccttgacag gcctggaggc ctccttggaa 1620gtcctggcac
tgcagggcaa tgggttgacg gtcctgcagg tggacctgcc ctgcttcatc
1680tgcctcaagc ggctcaatct tgccgagaac cgcctgagcc accttcccgc
ctggacacag 1740gctgtgtcac tggaggtgct ggacctgcga aacaacagct
tcagcctcct gccaggcagt 1800gccatgggtg gcctggagac cagcctccgg
cgcctctacc tgcaggggaa tccactcagc 1860tgctgtggca atggctggct
ggcagcccag ctgcaccagg gccgtgtgga cgtggacgcc 1920acccaggacc
tgatctgccg cttcagctcc caggaggagg tgtccctgag ccacgtgcgt
1980cccgaggact gtgagaaggg ggggctcaag aacatcaacc tcatcatcat
cctcaccttc 2040atactggtct ctgccatcct cctcaccacg ctggccacct
gctgctgtgt ccgccggcag 2100aagtttaacc aacagtataa agcctaaaga
agccgggaga cactctaggt caatggggga 2160gcctgaggta cagagaagag
tgaggactga ctcaaggtca cacagtgacc caggatccca 2220gaactctggt
ctccaaattg caacccggga cacctttctc tgccgcctgc tgcatcagcg
2280ggtgaccccc ttcccgggct gcactttggg tccagctgtg gaagccagaa
gttgggcggt 2340ttcagggaca gcagggaata atgttgacct atcagatcaa
caaatcttca ctgagcatct 2400actttgtgcc acactctgct ctgggcactg
ggaatgctgg gaaataagat acactcccgc 2460cctcaagaat ctcccagtct
ggtaggaggg agtgctacag agccgcgtgg tgaccacgca 2520gtgtgcttag
ggcctgaggt gtgaaagccc gggactccgg agctcggcag gccccgctgg
2580ttcgatgcga agagtcctgc cccagccatg ccagggtgag agagggccaa
gcctgggagg 2640atttgtctga gacatttcca agcagactgt ttgtcacatc
ttctgataat gactttcagt 2700ctctctgaaa atgaaaagct tatgaccgga
agagagaatt ggagccatac gagtgtgtct 2760tggatctggt gctgttaggc
gggccgcggc ggctccagca gggtctggtt aaggggtcca 2820gcccggcact
ggaccattcc gtctcctgct ctggacaggc cgtctccctg cctggcactc
2880tcatgttaca cagcctgatc ccagtactgc tctaagcgcc gtccctgccc
agcccttctc 2940catcgcagcc ccgccttggc tgctaagcca agagctaaaa
ccttagatat ctgattctgt 3000tttgcaccca gcttggcaga tgtggatgtg
aatccaagcc tgtgtctgcc cctatatgac 3060agcccttgga ggttggtatt
ttatccccat tttataaaag aggaaactga agttctacaa 3120atctccttcc
agggccccag ctaactaatg ccttaggtga gattcaaacc ctcatacttc
3180tgtctccagg gcctgatctt tgccactgca ggggctgcag gccgttaagt
ggacaggaag 3240tggctccaca tagcccgagc agggtctgga agtatcctgt
gctatgcata cctgctctct 3300cctctctccc aggcaggcag ctgcaggcgc
tctcctcctc ctctgcctta gtttccctcc 3360ttccatcctt tccaccctgg
tgtgggttct cctgttctct ctgtgctctt gcatgctctc 3420attccctttt
cctctattga gcagagcctg gagtttgaga ctattgaatc caacctcccc
3480attgcacaga tggggaaact gaggcttagg aagagaatga aacttgtgga
gagctataca 3540gagcctctgg ggaaaaaaaa gagagcccta tttggggatg
agattagggg ttggaccata 3600gtgatgtcct ctcttggctg tcacatcaca
agataatgct ggctccaaac ttcctttctg 3660tgcctcctca tgcaggattt
tttttttccc tcttggaaaa ataggtagaa aggctcaccc 3720agataacccc
ctatccctca tagcatggag tcatgagctg tctgggaaga atggacacgc
3780tgggaccaac tcaagacctt gtgttgctgt cttcatcatc ttacctgtgc
ttggcccaca 3840gtctggctca tgatgtgggc tcagtaatgt gcaagaaaat
gaaaatgcca ctctctccac 3900cccattttac agaggagaac accgaggccc
agaggaagtt aagggagagt caatgggcag 3960agccagggct aggccctggt
gatgtgtgga gcacccaggc agacccagtc ctggttggga 4020tcacaaccac
aggtgctact gcacgtgaca ctcttcctta ggcctggagg ccaaggtgtg
4080ggtcctcacg cctgatcttt gaaaacacta cacaatgctg ctgtcagttc
ccaggaccca 4140ggccgcagcc caggcctcgg gaccaactct ttgtataacc
tacctgaatg tattaaaaac 4200taattttgga gaagca 4216422188DNAMacaca
fasciculariscynomolgus TGF beta-1 42ccgccgccct tcgcgccctg
ggccatctcc ctcccacctc cctccgcgga tcagccagac 60tgcgagggcc ccggccgggg
gcagggggga cgccccgtcc ggggcacccc cccggctctg 120agccgcccgc
ggggccggcc tcggcccgga gcggaggaag gagtcgccga ggagcagcct
180gaggccccag agtctgagac gagccgccgc cgcccccgcc actgcgggga
ggagggggag 240gaggagcggg aggagggacg agctggtcgg gagaagagga
aaaaaacttt tgagactttt 300ccgttgccgc tgggagccgg aggcgcgggg
acctcttggc gcgacgctgc cccgcgagga 360ggcaggactt ggggacccca
gaccgcctcc ctttgccgcc ggggacgctt gctccctccc 420tgccccctac
acggcgtccc tcaggcgccc ccattccgga ccagccctcg ggagtcgccg
480acccggcctc ccgcaaatac ttttccccag acctcgggcg caccccctgc
acgccgcctt 540catccccggc ctgtctcctg agcccccgcg catcctagac
cttttctcct ccaggagacg 600gatctctctc cgacctgcca cagatcccct
attcaagacc acccaccttc tggtaccaga 660tctcgcccat ctaggttatt
tccgtgggat actgagacac ccccggtcca agcctcccct 720ccaccactgc
gcccttctcc ctgaggacct caactttccc tcgaggccct cctacctttt
780cccgggagac ccccagcccc tgcaggggcg gggcctcccc accacgctag
ccctgttcgc 840cctctcggca gtgccggggg gcgccgcctc ccccatgccg
ccctccgggc tgcggctgct 900gccgctgctg ctaccgctgc tgtggctact
ggtgctgacg cctggccggc cggccgccgg 960actatccacc tgcaagacta
tcgacatgga gctggtgaag cggaagcgca tcgaggccat 1020ccgcggccag
atcctgtcca agctgcggct cgccagcccc ccgagccagg gggaggtgcc
1080gcccggcccg ctgcccgagg ccgtgctcgc cctgtacaac agcacccgcg
accgggtggc 1140cggggagagt gcggagccgg aacccgaacc ggaggccgac
tactacgcca aggaggtcac 1200ccgcgtgcta atggtggaaa cccacaacga
aatctatgac aagttcaagc agagcacaca 1260cagcatatat atgttcttca
acacatcaga gctccgagaa gcagtacctg aacctgtgtt 1320gctctcccgg
gcagagctgc gtctgctgag gctcaagtta aaagtggagc agcatgtgga
1380gctgtaccag aaatacagca acaattcctg gcgatacctc agcaaccggc
tgctggcgcc 1440cagcgactcg ccggagtggt tgtcttttga tgtcaccgga
gttgtgcggc agtggttgag 1500ccgcggaggg gaaattgagg gctttcgcct
tagcgcccac tgctcctgtg acagcaaaga 1560taacacactg caagtggaca
tcaacgcagg gttcactacc ggccgccgag gtgacctggc 1620caccattcat
ggcatgaacc ggcctttcct gcttctcatg gccaccccgc tggagagggc
1680ccaacatctg caaagctccc ggcaccgccg agccctggac accaactact
gcttcagctc 1740cacggagaag aactgctgcg tgcggcagct gtatattgac
ttccgcaagg acctcggctg 1800gaagtggatc cacgagccca agggctacca
tgccaacttc tgcctgggac cctgccccta 1860catttggagc ctggacacgc
agtacagcaa ggtcctggcc ctgtacaacc agcataaccc 1920gggcgcctcg
gcggcgccgt gctgcgtgcc gcaggcgctg gagccgctgc ccatcgtgta
1980ctacgtgggc cgcaagccca aggtggagca gctgtccaac atgatcgtgc
gctcctgcaa 2040atgcagctga ggccccgtcc cgccccgccc caccccggca
ggcccggccc cgccccgccc 2100cgcccccgct gccttgccct tgggggctgt
atttaaggac acccgtgccc caagcccacc 2160tggggcccca ttaaagatgg agagagga
21884323DNAArtificial SequenceDescription of Artificial Sequence
Synthetic cyno TGFB S1 primer 43cgcctccccc atgccgccct ccg
234420DNAArtificial SequenceDescription of Artificial Sequence
Synthetic cyno TGFB Sense 2 primer 44acaattcctg gcgatacctc
204520DNAArtificial SequenceDescription of Artificial Sequence
Synthetic cyno TGFB Anti-Sense 1 primer 45ctcaaccact gccgcacaac
204620DNAArtificial SequenceDescription of Artificial Sequence
Synthetic cyno TGFB Anti-Sense 2 primer 46tcagctgcat ttgcaggagc
2047231PRTArtificial SequenceDescription of Artificial Sequence
Synthetic human IgG1; Fc region of LHG-10 polypeptide 47Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 1 5 10 15 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 20 25
30 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
35 40 45 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 50 55 60 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 65 70 75 80 Asn Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp 85 90 95 Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu 100 105 110 Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 115 120 125 Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 130 135 140 Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 145 150 155
160 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
165 170 175 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
Tyr Ser 180 185 190 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser 195 200 205 Cys Ser Val Met His Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser 210 215 220 Leu Ser Leu Ser Pro Gly Lys 225
230 48330PRTArtificial SequenceDescription of Artificial Sequence
Synthetic Heavy chain constant domain of LHG-10 polypeptide 48Ala
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10
15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser
Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys
Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145
150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu 165 170 175 Glu Gln Tyr Xaa Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265
270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 325 330 49107PRTArtificial SequenceDescription of Artificial
Sequence Synthetic Light chain constant domain of LHG-10
polypeptide 49Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp
Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser
Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 50121PRTArtificial
SequenceDescription of Artificial Sequence Synthetic heavy chain
variable region polypeptide 50Gln Val Gln Leu Lys Glu Ser Gly Pro
Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr
Val Ser Gly Phe Ser Leu Thr Gly Tyr 20 25 30 Gly Ile Asn Trp Val
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Met Ile
Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ser Val Leu Thr 50 55 60 Ser
Arg Leu Arg Ile Ser Lys Asp Asn Ser Asn Ser Gln Val Phe Leu 65 70
75 80 Lys Met Asn Ser Leu Gln Val Asp Asp Thr Ala Arg Tyr Tyr Cys
Ala 85 90 95 Arg Asp Arg Asn Tyr Tyr Asp Tyr Asp Gly Ala Met Asp
Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120
51107PRTArtificial
SequenceDescription of Artificial Sequence Synthetic light chain
variable region polypeptide 51Asp Ile Gln Val Thr Gln Ser Ser Ser
Tyr Leu Ser Val Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Lys Ala Ser Asp His Ile Lys Asn Trp 20 25 30 Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Ile Ala Pro Arg Leu Leu Val 35 40 45 Ser Gly Ala
Thr Ser Leu Glu Ala Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Lys Asn Phe Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70
75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro
Trp 85 90 95 Thr Phe Gly Gly Gly Thr Thr Leu Glu Ile Arg 100 105
525PRTArtificial SequenceDescription of Artificial Sequence
Synthetic VH-CDR1 peptide 52Gly Tyr Gly Ile Asn 1 5 53390PRTHomo
sapiensTGF-beta1 amino acid sequence 53Met Pro Pro Ser Gly Leu Arg
Leu Leu Pro Leu Leu Leu Pro Leu Leu 1 5 10 15 Trp Leu Leu Val Leu
Thr Pro Gly Arg Pro Ala Ala Gly Leu Ser Thr 20 25 30 Cys Lys Thr
Ile Asp Met Glu Leu Val Lys Arg Lys Arg Ile Glu Ala 35 40 45 Ile
Arg Gly Gln Ile Leu Ser Lys Leu Arg Leu Ala Ser Pro Pro Ser 50 55
60 Gln Gly Glu Val Pro Pro Gly Pro Leu Pro Glu Ala Val Leu Ala Leu
65 70 75 80 Tyr Asn Ser Thr Arg Asp Arg Val Ala Gly Glu Ser Ala Glu
Pro Glu 85 90 95 Pro Glu Pro Glu Ala Asp Tyr Tyr Ala Lys Glu Val
Thr Arg Val Leu 100 105 110 Met Val Glu Thr His Asn Glu Ile Tyr Asp
Lys Phe Lys Gln Ser Thr 115 120 125 His Ser Ile Tyr Met Phe Phe Asn
Thr Ser Glu Leu Arg Glu Ala Val 130 135 140 Pro Glu Pro Val Leu Leu
Ser Arg Ala Glu Leu Arg Leu Leu Arg Leu 145 150 155 160 Lys Leu Lys
Val Glu Gln His Val Glu Leu Tyr Gln Lys Tyr Ser Asn 165 170 175 Asn
Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala Pro Ser Asp Ser 180 185
190 Pro Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val Arg Gln Trp Leu
195 200 205 Ser Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser Ala His
Cys Ser 210 215 220 Cys Asp Ser Arg Asp Asn Thr Leu Gln Val Asp Ile
Asn Gly Phe Thr 225 230 235 240 Thr Gly Arg Arg Gly Asp Leu Ala Thr
Ile His Gly Met Asn Arg Pro 245 250 255 Phe Leu Leu Leu Met Ala Thr
Pro Leu Glu Arg Ala Gln His Leu Gln 260 265 270 Ser Ser Arg His Arg
Arg Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser 275 280 285 Thr Glu Lys
Asn Cys Cys Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys 290 295 300 Asp
Leu Gly Trp Lys Trp Ile His Glu Pro Lys Gly Tyr His Ala Asn 305 310
315 320 Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr Gln
Tyr 325 330 335 Ser Lys Val Leu Ala Leu Tyr Asn Gln His Asn Pro Gly
Ala Ser Ala 340 345 350 Ala Pro Cys Cys Val Pro Gln Ala Leu Glu Pro
Leu Pro Ile Val Tyr 355 360 365 Tyr Val Gly Arg Lys Pro Lys Val Glu
Gln Leu Ser Asn Met Ile Val 370 375 380 Arg Ser Cys Lys Cys Ser 385
390 54249PRTHomo sapiensLAP amino acid sequence 54Leu Ser Thr Cys
Lys Thr Ile Asp Met Glu Leu Val Lys Arg Lys Arg 1 5 10 15 Ile Glu
Ala Ile Arg Gly Gln Ile Leu Ser Lys Leu Arg Leu Ala Ser 20 25 30
Pro Pro Ser Gln Gly Glu Val Pro Pro Gly Pro Leu Pro Glu Ala Val 35
40 45 Leu Ala Leu Tyr Asn Ser Thr Arg Asp Arg Val Ala Gly Glu Ser
Ala 50 55 60 Glu Pro Glu Pro Glu Pro Glu Ala Asp Tyr Tyr Ala Lys
Glu Val Thr 65 70 75 80 Arg Val Leu Met Val Glu Thr His Asn Glu Ile
Tyr Asp Lys Phe Lys 85 90 95 Gln Ser Thr His Ser Ile Tyr Met Phe
Phe Asn Thr Ser Glu Leu Arg 100 105 110 Glu Ala Val Pro Glu Pro Val
Leu Leu Ser Arg Ala Glu Leu Arg Leu 115 120 125 Leu Arg Leu Lys Leu
Lys Val Glu Gln His Val Glu Leu Tyr Gln Lys 130 135 140 Tyr Ser Asn
Asn Ser Trp Arg Tyr Leu Ser Asn Arg Leu Leu Ala Pro 145 150 155 160
Ser Asp Ser Pro Glu Trp Leu Ser Phe Asp Val Thr Gly Val Val Arg 165
170 175 Gln Trp Leu Ser Arg Gly Gly Glu Ile Glu Gly Phe Arg Leu Ser
Ala 180 185 190 His Cys Ser Cys Asp Ser Arg Asp Asn Thr Leu Gln Val
Asp Ile Asn 195 200 205 Gly Phe Thr Thr Gly Arg Arg Gly Asp Leu Ala
Thr Ile His Gly Met 210 215 220 Asn Arg Pro Phe Leu Leu Leu Met Ala
Thr Pro Leu Glu Arg Ala Gln 225 230 235 240 His Leu Gln Ser Ser Arg
His Arg Arg 245 55112PRTHomo sapiensmature TGF-beta1 amino acid
sequence 55Ala Leu Asp Thr Asn Tyr Cys Phe Ser Ser Thr Glu Lys Asn
Cys Cys 1 5 10 15 Val Arg Gln Leu Tyr Ile Asp Phe Arg Lys Asp Leu
Gly Trp Lys Trp 20 25 30 Ile His Glu Pro Lys Gly Tyr His Ala Asn
Phe Cys Leu Gly Pro Cys 35 40 45 Pro Tyr Ile Trp Ser Leu Asp Thr
Gln Tyr Ser Lys Val Leu Ala Leu 50 55 60 Tyr Asn Gln His Asn Pro
Gly Ala Ser Ala Ala Pro Cys Cys Val Pro 65 70 75 80 Gln Ala Leu Glu
Pro Leu Pro Ile Val Tyr Tyr Val Gly Arg Lys Pro 85 90 95 Lys Val
Glu Gln Leu Ser Asn Met Ile Val Arg Ser Cys Lys Cys Ser 100 105 110
5624DNAArtificial SequenceDescription of Artificial Sequence
Synthetic FOXP3i1 sense primer 56aaacctacta caaaacaaaa caac
245719DNAArtificial SequenceDescription of Artificial Sequence
Synthetic FOXP3i1 antisense primer 57ggaggaagag aagagggta
195825DNAArtificial SequenceDescription of Artificial Sequence
Synthetic FOXP3i1 probe primer 58cctataaaat aaaatatcta ccctc
255922DNAArtificial SequenceDescription of Artificial Sequence
Synthetic demethylated FOXP3i1 sense primer 59tctaccctct tctcttcctc
ca 226026DNAArtificial SequenceDescription of Artificial Sequence
Synthetic demethylated FOXP3i1 antisense primer 60gatttttttg
ttattgatgt tatggt 266120DNAArtificial SequenceDescription of
Artificial Sequence Synthetic demethylated FOXP3i1 probe primer
61aaacccaaca catccaacca 206241PRTHomo sapiens 62His Leu Ser Leu Ala
His Asn Arg Leu Ala Met Ala Thr Ala Leu Ser 1 5 10 15 Ala Gly Gly
Leu Gly Pro Leu Pro Arg Val Thr Ser Leu Asp Leu Ser 20 25 30 Gly
Asn Ser Leu Tyr Ser Gly Leu Leu 35 40 6341PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
63His Leu Ser Leu Ala His Asn Arg Leu Ala Thr Gly Met Ala Leu Ser 1
5 10 15 Ala Gly Gly Leu Gly Pro Leu Pro Arg Val Thr Ser Leu Asp Leu
Ser 20 25 30 Gly Asn Ser Leu Tyr Ser Gly Leu Leu 35 40
6441PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 64His Leu Ser Leu Ala His Asn Arg Leu Ala Met
Ala Thr Ala Leu Ser 1 5 10 15 Ala Gly Gly Leu Gly Pro Leu Pro Leu
Leu Val Ser Leu Asp Leu Ser 20 25 30 Gly Asn Ser Leu Tyr Ser Gly
Leu Leu 35 40 6541PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 65His Leu Ser Leu Ala His Asn Arg
Leu Ala Met Ala Thr Ala Leu Ser 1 5 10 15 Ala Gly Gly Leu Gly Pro
Leu Pro Arg Val Thr Ser Leu Asp Leu Ser 20 25 30 Gly Asn Ser Leu
His Gly Asn Leu Leu 35 40 6641PRTMus sp. 66His Leu Asn Leu Ala His
Asn Arg Leu Ala Thr Gly Met Ala Leu Asn 1 5 10 15 Ser Gly Gly Leu
Gly Arg Leu Pro Leu Leu Val Ser Leu Asp Leu Ser 20 25 30 Gly Asn
Ser Leu His Gly Asn Leu Val 35 40
* * * * *
References